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PRESENTATION	  AND	  OBJECTIVES	  

Obesity and associated metabolic diseases have reached epidemic proportions, 
affecting not only high-income countries but also low- and middle-income ones. 
In this context, the search for therapeutic approaches to treat obesity is 
becoming a priority worldwide. 
In this regard, the metabolic hormone fibroblast growth factor 21 (FGF21) has 
been identified as a potential candidate for the treatment of obesity and 
metabolic syndrome. Previous work by our group described that FGF21 is 
highly induced in liver in response to leucine deprivation and that the 
transcription factor ATF4 mediates this induction. The present work is the 
follow-up of this initial observation. To better expose our observations, some 
results from the thesis of Dr De Sousa-Coelho titled “Metabolic signalling during 
nutrient deprivation” (2012) are included. When this is the case, they are 
accurately labelled. 
This manuscript has been divided in three sections: the role of Rev-Erbα in the 
induction of Fgf21 upon leucine deprivation, the role of FGF21 in the metabolic 
response to leucine deprivation, and the role of FGF21 in the metabolic 
response to protein restriction. Accordingly, the current study has three general 
objectives: 
• To extend our understanding of the molecular mechanisms that regulate
Fgf21 expression during amino acid deprivation.
• To determine whether FGF21 mediates the metabolic response
observed under amino acid deprivation.
• To study the effects of a low protein diet on Fgf21 expression and its
mediated effects on target tissues.
Presentation and Objectives
1

INTRODUCTION	  

1 FGF21	  AS	  A	  THERAPEUTIC	  AGENT	  FOR	  METABOLIC	  DISEASES.	  
Obesity is a worldwide health problem mainly due to its associated 
comorbidities, such as non-alcoholic fatty liver disease (NAFLD), certain 
cancers, insulin resistance, and type 2 diabetes (DMT2), which all reduce life 
expectancy and life quality. 
FGF21 is an atypical member of fibroblast growth factors (FGFs) family that 
function as a hormone involved in metabolic homeostasis in healthy individuals 
and considered a promising therapeutic candidate for the treatment of obesity. 
Since it was described in 2005 as an unexpected regulator of metabolism, 
extensive investigation has situated FGF21 as a key component of the complex 
metabolic networks. 
Fibroblast Growth Factor 21 (FGF21) increases energy expenditure (EE). It thus 
has beneficial effects on glucose/lipid homeostasis and on body weight control. 
In rodent and primate models of metabolic diseases, FGF21 has the capacity to 
restore glycaemia and lipid profile, and to improve insulin resistance 
(Kharitonenkov & Shanafelt 2009; Kharitonenkov et al. 2005) 
Given the patently beneficial pharmacology of FGF21 in multiple animal 
models, the prospect of FGF21 emerging as a drug has steadily progressed 
through the past decade. 
It is widely accepted that FGF21 participates in metabolic homeostasis in health 
but its action takes on greater relevance in metabolic diseases. 
To date, the pharmacological use of FGF21 is limited due to its half-life of 
around 1-2 h. In order to improve the pharmacokinetics, selectivity, and potency 
of FGF21, several laboratories have focused on designing FGF21 analogs. Two 
such analogs (LY2405319 and PF05231023) are currently being tested in 
clinical trials and have yielded similar results: benign toxicology, decreased 
plasma TGs and LDL cholesterol, increased HDL cholesterol, modest weight 
loss, elevated adiponectin, reduced insulin levels, and elevated plasma 
ketones. Surprisingly, no glucose-lowering effect was registered in any trial. 
This is a major setback since both compounds were assessed mainly as anti-
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diabetic drugs. However, the results of these two trials highlight the capacity of 
FGF21 to ameliorate lipid and cholesterol metabolism (Gaich et al. 2013; Weng 
et al. 2015; Talukdar, Zhou, et al. 2016). 
Given the complex pharmacokinetics properties of FGF21, other approaches 
such as increasing FGF21 endogenous levels and sensitizing target tissues are 
being considered.  
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2 FGF21	  SIGNALLING	  MACHINERY	  
FGF21 acts as a hormone-like peptide and its signalling pathway requires 
FGF21 binding to a fibroblast growth factor receptor (FGFR). FGFRs are 
tyrosine kinase receptors, and seven isoforms have been described (1b, 1c, 2b, 
2c, 3b, 3c and 4).  
FGFR1c has been defined as the main mediator of FGF21 response in vivo 
(Yang et al. 2012) through an obligate dimerization with the co-receptor β-
Klotho (KLB) (Ding et al. 2012). The C-terminus of FGF21 binds with high 
affinity to KLB (Yie et al. 2012), which enables its interaction with the FGFR. 
The co-expression of these two receptors determines the sensitivity of a tissue 
or organ to FGF21 signalling. 
Figure	  I	  1	  FGFR1c-­‐FGF21-­‐KLB	  complex	  signalling	  transduction	  
Regarding the signal transduction pathway, the binding of FGF21 to the FGFR-
KLB dimer stimulates the dimerization of FGFR and the autophosphorylation of 
tyrosines. This action facilitates binding and activation of FGFR substrate 2α 
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(FRS2α), which transduces the signal to MAPK signalling cascades via the 
recruitment of several adaptor molecules. The activation of extracellular signal-
regulated kinase 1/2 (ERK1/2) and PI3K is critical to induce transcription of 
early response genes, including c-fos and early growth response 1 (EGR1) 
resulting in numerous changes in gene expression (Fisher & Maratos-Flier 
2016). 
However, inhibiting ERK signalling does not always attenuate FGF21 effects, 
and thus, novel signalling pathways are being studied (Ge et al. 2011). 
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3 FGF21	  REGULATION	  
3.1 PEROXISOME	   PROLIFERATOR-­‐ACTIVATED	   RECEPTOR	   (PPAR)	   α ,	   CAMP-­‐
RESPONSIVE	  ELEMENT-­‐BINDING	  PROTEIN	  H	  (CREBH)	  AND	  MANY	  OTHERS	  
FGF21 was initially described as a protein induced in the liver to regulate 
metabolic adaptation to long periods of starvation. This mRNA induction is 
orchestrated through PPARα (Badman et al. 2007; Inagaki et al. 2007; 
Lundåsen et al. 2007) and CREBH (Kim et al. 2014; Lee et al. 2011). Later, 
several studies showed that FGF21 expression is regulated not only by fasting 
but also by other nutritional states. Reviewed in (Pérez-Martí et al. 2016) 
(Annex 3). 
In addition to PPARα and CREBH, FGF21 expression responds positively or 
negatively to a broad set of factors: the retinoic acid (RA) receptor β (RARβ) (Li 
et al. 2013), the RA receptor-related orphan receptor α (RORα) (Wang et al. 
2010), the glucocorticoid receptor (GR)(Patel et al. 2015), the thyroid hormone 
receptor β (TRβ) (Adams et al. 2010), the activating transcription factor-4 
(ATF4) (De Sousa‑Coelho et al. 2012), Rev-erbα (Estall et al. 2009), the 
farnesoid X receptor (FXR) (Cyphert et al. 2012), the liver X receptor (LXR) 
(Archer et al. 2012) and the carbohydrate responsive element binding protein 
(ChREBP) (Iizuka et al. 2009).  
Given the complexity and variety of mechanisms that control FGF21 
expression, the following sections will focus on its regulation by the two factors 
of interest in this work, namely ATF4 and Rev-erbα. 
3.2 ATF4	  
3.2.1 Amino	  Acid	  Response	  
Amino acid homeostasis is achieved through the sensing of amino acid and 
trough the activation of proper signalling pathways. While the mTOR signalling 
pathway monitors amino acid sufficiency and promotes protein translation and 
cell growth, among many other processes (Laplante & Sabatini 2013), depletion 
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of amino acids is sensed by the GCN2/ATF4 pathway, which activates the 
Amino Acid Response (AAR). 
GCN2 kinase is a direct sensor of amino acid supply via the binding of 
deacylated tRNAs (Qiu et al. 2001). When levels of an indispensable amino 
acid fall below a threshold, its tRNA becomes deacylated (i.e uncharged). When 
activated by uncharged tRNAs, GCN2 increases eiF2α phosphorylation 
(Anthony et al. 2004; Hao et al. 2005) which results in the slowing or stalling of 
the initiation step of mRNA translation. Hence, phospho-eiF2α reduces general 
protein synthesis rates.  
Paradoxically, the delay in the reinitiation rate promotes an increase in the 
translation of discrete mRNAs that contain alternative upstream open reading 
frames in the 5`-UTR region; including that coding for ATF4. Once induced, 
ATF4 directly or indirectly triggers the transcription of a subset of specific target 
genes in order to adapt to dietary stress (Harding et al. 2003; Shan et al. 2009).  
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Figure	  I	  2	  The	  AAR	  pathway.	  Adapted	  from	  (Kilberg	  et	  al.	  2009)	  
 ATF4 is expressed by enhanced translation from pre-existing mRNA in 
response to a variety of stress conditions (Vattem et al. 2004). GCN2 is one of 
four known eIF2α kinases that collectively respond to a wide array of cellular 
stress. Other members include the protein kinase-like endoplasmic reticulum 
(ER)-resident kinase (PERK), the heme-regulated kinase (heme-controlled 
inhibitor, HRI) and the interferon-inducible, double-stranded RNA-activated 
protein kinase (PKR). Indeed, ER stress (Harding et al. 2000), the presence of 
dsDNA (Zhang et al. 2001), and heme deficiency (Zhan et al. 2002) each lead 
to eIF2α phosphorylation that, in turn, promotes increased ATF4 translation. 
ATF4 triggers increased transcription by binding to CCAAT-enhancer binding 
protein-activating transcription factor (C/EBP-ATF) response elements 
(CAREs). CAREs are composed of a half-site for the C/EBP family and a half-
site for the ATF family of transcription factors, also called amino acid response 
elements (AARE) (Fawcett et al. 1999). Among the known ATF4-activated 
genes are the transcription factors C/EBPβ (Thiaville et al. 2008), ATF3 (Pan et 
al. 2007) and C/EBP homology protein (CHOP) (Cherasse et al. 2007), which 
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then act as ATF4 counter regulatory signals. The numerous dimerization and 
interacting partners of ATF4 determine its diverse functions (Ameri and Harris, 
2008). 
Figure	   I	   3	   Genomic	   C/EBP-­‐ATF	   composite	   sites	   that	   serve	   as	   ATF4-­‐responsive	   elements	   for	   the	  
induction	  of	  well-­‐established	  ATF4	  target	  genes	   in	   response	  to	  amino	  acid	  starvation.	  Adapted	  from	  
(Chaveroux	  et	  al.	  2010)	  
3.2.2 ATF4	  regulation	  of	  FGF21	  
In 2012, our laboratory identified human FGF21 gene as a target gene for ATF4 
and localized two evolutionarily conserved ATF4-binding sequences in the 5’ 
regulatory region of the gene. These sequences are responsible for the ATF4-
dependent transcriptional activation of FGF21 (De Sousa-Coelho et al. 2012). 
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Figure	   I	  4	  Alignment	  of	  FGF21	  promoter	  sequences	  of	  different	  mammals.	  Two	  conserved	  AAREs	  are	  
boxed	  and	  asterisks	   indicate	   the	   sequence	   identity.	  Consensus	   sequence	   is	   shown	  at	   the	  bottom.	   (De	  
Sousa-­‐Coelho	  et	  al.	  2012).	  
Consequently, FGF21 is induced by amino acid deprivation both in mice and in 
cultured HepG2 cells. This induction occurs in liver but not in other FGF21-
expressing tissues such as white adipose tissue (WAT) and brown adipose 
tissue (BAT). 
Later studies confirmed that ER stress inducers, such as tunicamycin (Schaap 
et al. 2013) and thapsigargin (Wan et al. 2014), as well as methionine restriction 
(Lees et al. 2014), trigger FGF21 expression through ATF4 activation. In 
addition, mitochondrial dysfunction leads to ATF4-dependent induction of 
FGF21 in liver (Kim, Jeong, Kim, et al. 2013) and also in muscle (Kim, Jeong, 
Oh, et al. 2013; Keipert et al. 2014). 
Many lines of data support the notion that FGF21 regulation by ATF4 is a 
common feature of the response to intracellular stresses. Consequently, other 
intracellular stress signalling pathways that converge at eIF2α/ATF4, may 
regulate FGF21 expression. 
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3.3 REV-­‐ERBα 	  [NUCLEAR	  RECEPTOR	  SUBFAMILY	  1	  GROUP	  D	  MEMBER	  1	  (NR1D1)]	  
3.3.1 Linking	  circadian	  rhythms	  to	  metabolism	  
Circadian rhythmicity is present in almost all physiological processes, including 
the sleep-wake cycle, the rest-activity cycle, blood pressure, hormone secretion 
and metabolism. The rhythmicity is driven by the cellular clock machinery, which 
is comprised of transcription factors that act on one another to generate near-24 
hours oscillations. CLOCK and BMAL1 initiate the transcription of their target 
genes, including Per and Cry (Schibler & Sassone-Corsi 2002). PER and CRY 
form heterodimers that translocate to the nucleus to repress their own 
expression by repressing CLOCK/BMAL1 complex (Kume et al. 1999). This 
feedback loop takes approximately 24 hours to complete a cycle and 
constitutes a circadian oscillation of the molecular clock.  
Circadian clocks and metabolism are tightly connected, and the nuclear 
receptor Rev-erbα, which functions both as a core repressive component of the 
cell autonomous clock and as a regulator of metabolic genes, is central to 
complex interactions between circadian rhythms and metabolism. 
Rev-erbα is a core clock component but it also has tissue-specific functions. 
Interestingly, different mechanisms have been proposed for circadian regulation 
and tissue-specific actions.  
Rev-erbα represses transcription by recruiting the histone deacetylase 3 
(HDAC3) and nuclear receptor corepressor (NcoR) (Yin & Lazar 2005). The 
cofactor heme is a natural Rev-erbα ligand that potentiates the recruitment of 
NcoR, thereby enhancing the transcriptional repression of its target genes (Yin 
et al. 2007; Raghuram et al. 2007). Furthermore, overexpression of Delta-
aminolevulinate synthase 1 (Alas-1), the rate-limiting enzyme of hepatic heme 
biosynthesis, also enhances the recruitment of NcoR and HDAC3 (Estall et al. 
2009). 
The regulation of the clock requires Rev-erbα to bind directly to its classical 
canonical binding sequences, namely ROREs and RevDR2 (Harding & Lazar 
Introduction
14
1995; Giguere et al. 1994), where it competes with activating ROR transcription 
factors. 
In contrast, it has recently been described that Rev-erbα regulates metabolic 
genes primarily by recruiting the HDAC3 corepressor to sites to which it is 
tethered by cell type-specific transcription factors. (Zhang et al. 2015) 
Therefore, competition between Rev-erbα and RORs provides a universal 
mechanism for molecular clock regulation across all tissues, whereas Rev-erbα 
uses tissue-specific lineage-determining factors to direct metabolism in 
circadian cycles in function of the specific needs of that tissue.  
Figure	  I	  5	  Most	  significantly	  enriched	  motifs	  by	  ChIP	  seq	  in	  different	  tissues.	  (Zhang	  et	  al.	  2015)	  
In the liver, hepatocyte nuclear factor 6 (HNF6) and hepatocyte nuclear factor 4 
(HNF4) are the main Rev-erb α tethering factors. However, many other 
transcription factors, such as CEBP, NFY, PPAR and ATF4, can also tether 
Rev-erb α to chromatine (Zhang et al. 2016). 
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Figure	  I	  6	  Model	  of	  different	  mechanisms	  of	  Rev-­‐erbα	  function	  
3.3.2 Rev-­‐erbα	  regulation	  of	  FGF21	  
Since Rev-erb aplha connects the circadian clock to liver metabolism (Zhang et 
al. 2016) and Fgf21 presents a marked circadian expression pattern, it is 
feasible that these two molecules are linked. In this regard, FGF21 levels 
inversely correlate to the expression pattern of Rev-erbα and ALAS-1 in liver 
(Kaasik & Lee 2004; Oishi et al. 2008). 
In fact, peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-
1α) negatively regulates Fgf21 hepatic expression modulating the heme/Rev-
erbα axis (Estall et al. 2009). PGC-1α not only directly modulates the 
expression of Rev-erb α but also increases heme levels in response to 
hormonal cues. Furthermore, heme feeds back to inhibit PGC-1α expression 
through the activation of Rev-erbα (Wu et al. 2009).  
The mechanism proposed for Rev-erbα repression of Fgf21 consists of a 
repressor complex that includes LXRβ, RORα, Rev-erb α and HDAC3 onto the 
proximal Fgf21 promoter region, although the direct binding sites have yet to be 
determined (Archer et al. 2012). 
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Figure	  I	  7	  Model	  of	  the	  repressor	  complex	  onto	  the	  FGF21	  promoter.	  Adapted	  from(Archer	  et	  al.	  2012)	  
Interestingly, and in disagreement with this model, ChIP-seq results from 
Mitchell Lazar’s lab (GSE67973) point to Rev-erbα binding to DNA regions that 
contain the described AARE1 and AARE 2 of the Fgf21 promoter (De Sousa-
Coelho et al. 2012). 
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4 FGF21	  IN	  LIVER	  
4.1 LIVER	  IS	  THE	  PRINCIPAL	  FGF21	  PRODUCER	  
FGF21 is expressed and produced by multiple tissues. However, under normal 
physiological conditions, all circulating protein appears to derive from the liver 
(Markan et al. 2014). In liver, FGF21 expression is induced in response to 
stress. FGF21 was initially described as a fasting-adaptation hormone, since its 
hepatic production coupled to plasma levels is dramatically increased during 
prolonged fasting (Inagaki et al. 2007; Potthoff et al. 2009).  
It is now known that hepatic FGF21 expression is also induced in other liver-
stress circumstances such as in obesity, specific nutritional conditions, liver 
injury, viral infection, chemical insult, hepatosteatosis, steatohepatitis, NAFLD, 
cirrhosis, and liver cancer (Dushay et al. 2010; Dasarathy et al. 2011; Domingo 
et al. 2010; Zhang et al. 2008; Yang et al. 2013). 
4.2 AUTOCRINE	  EFFECTS	  
Hepatic overexpression of FGF21 triggers ketogenesis, gluconeogenesis, and 
FA oxidation (FAO) and suppresses lipogenesis in the liver (Dasarathy et al. 
2011; Fisher et al. 2011). However, the autocrine effects of FGF21 on this 
organ are still under debate. FGFR4 is the predominant isoform in the liver, but 
the FGFR4-KLB complex cannot activate the FGF21 transduction pathway 
(Yang et al. 2012). In contrast, hepatic FGFR1 levels are low, and it is unclear 
whether they are enough to ensure FGF21 signalling. 
Later studies reported contradictory results regarding the role of FGF21 in 
ketogenesis, thereby suggesting that the physiological effects of this molecule 
may differ from the pharmacological ones (Hotta et al. 2009).  
4.3 FGF21	  AS	  A	  HEPATOKINE	  
FGF21, as well as FGF19 and FGF23, lacks heparin binding domain. This detail 
allows FGF21 to be secreted and act as a hormone. 
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As a hepatokine, FGF21 affects WAT and BAT, tissues in which it regulates 
lipid metabolism—mainly by inducing lipolysis and browning and by increasing 
thermogenic capacity (De Sousa-Coelho et al. 2013; Hotta et al. 2009). FGF21 
also exerts action in the brain, where it is able to reduce physical activity, 
induce torpor, and regulate circadian behaviour (Bookout et al. 2013; Ishida 
2009). In conclusion, all data indicate that FGF21 is produced and secreted by 
the liver when the function of this organ is compromised by stress and that it is 
responsible for restoring and maintaining metabolic homeostasis.  
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5 FGF21	  IN	  ADIPOSE	  TISSUE	  
5.1 SHADES	  OF	  FAT:	  WHITE,	  BEIGE,	  BROWN	  
WAT comprises unilocular adipocytes and its principal function is to store lipids, 
which prevents their lipotoxic accumulation in other organs. Additionally, WAT 
can act as an endocrine organ by signalling to other tissues through the so-
called adipokines. The lipid storage capacity of WAT is adaptable, but when its 
maximum capacity is exceeded, it cannot properly store these fats or act as an 
endocrine organ. This impairment of WAT function can result in the 
accumulation of lipids in peripheral tissues and can contribute to insulin 
resistance and dyslipidemia (Virtue & Vidal-Puig 2010).  
The primary function of BAT is to produce heat in order to maintain core body 
temperature in response to cold stress. Multilocular brown adipocytes contain 
large numbers of mitochondria enriched in uncoupling protein 1 (UCP1), which 
uncouples substrate oxidation from ATP, thereby producing heat. Hence, BAT 
has potent machinery for oxidising metabolic substrates, and accordingly, 
efficient mechanisms for lipid and glucose uptake and catabolism. 
Persistent thermogenic activation (e.g. cold stress) causes the upregulation of 
the genes encoding UCP1, mitochondrial oxidative machinery, and lipid 
catabolism and uptake. Moreover, long-term thermogenic induction leads to the 
enlargement of BAT mass through hyperplasia and hypertrophy. 
As part of the same response, the so-called beige or “brite” (brown in white) 
cells are recruited in WAT in a process known as browning of WAT (Young et 
al. 1984). Beige adipose tissue (BeAT) is composed of UCP1-expressing 
adipocytes with great capacity for thermogenic stimulation, UCP1 expression 
induction and uncoupled respiration. Thus, stimulated beige adipocytes 
resemble brown adipocytes in terms of uncoupled respiration and UCP1 
expression (Wu et al. 2012).  
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Thermogenic activation leads BAT/BeAT to increase EE and act as a lipid and 
glucose sink, with a significant impact on whole body glucose homeostasis and 
body weight.  
Figure	   I	   8	   BAT	   and	   BeAT	   localization.	   iBAT,	   interscapular	   BAT.	   scWAT,	   subcutaneous	  WAT.	   scBeAT,	  
subcutaneous	  BeAT.	  	  supBAT,	  supraclavicular	  BAT.	  Adapted	  from	  (Peirce	  et	  al.	  2014)	  
5.2 TARGETING	  BAT	  FOR	  THE	  TREATMENT	  OF	  METABOLIC	  DISEASES	  
The recent discovery that adult humans have BAT (Hany et al. 2002; 
Nedergaard et al. 2007; Virtanen et al. 2009; van Marken Lichtenbelt et al. 
2009; Cypess et al. 2009) has paved the way for new therapeutic strategies and 
placed BAT in the spotlight of the research into metabolic diseases. 
Thermogenesis is an extremely high energy-consuming process. Consequently, 
significant attention has been directed toward the activation of BAT as a 
potential strategy for promoting EE and protecting against obesity (Cereijo et al. 
2015; Hankir et al. 2016; Peirce et al. 2014). 
Given the roles of BAT in the regulation of circulating lipids and glucose, it has 
been argued that this tissue is also a target for the treatment of diabetes 
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mellitus II, independently of weight loss. (Peirce & Vidal-Puig 2013; Kajimura et 
al. 2015) 
5.2.1 BAT/BeAT	  activators	  
Thermogenic activation is mediated mainly by the activation of the sympathetic 
nervous system (SNS). The release of norepineprhine by sympathetic nerve 
endings activates β-adrenergic receptors, therby inducing the thermogenic 
response. 
Pharmacological activators of the SNS have succeeded in inducing weight loss 
but their strong cardiovascular side effects outweigh their benefits. Thus, the 
lack of sensitivity shown by sympathomimetics drugs, make them unsuitable as 
a treatment option. The identification of new BAT/BeAT activators that act 
independently or in association with the SNS may provide more specific ways to 
activate BAT and bypass the cardiovascular effects. 
In addition to the SNS, the thyroid system is the other major player in BAT 
activation. Triiodothyronine (T3) is converted to thyroxine (T4) in BAT by type II 
thyroxine 5’-deionidase (Dio2), which activates the thermogenic programme 
and upregulates UCP1. The SNS and thyroid system are complexly linked in a 
complex manner since Dio2 is controlled by norepinephrine and, T3 stimulates 
sympathetic outflow in the hypothalamus (Lopez et al. 2010). 
Figure	  I	  9	  Sympathetic	  nervous	  system	  (SNS)	  and	  thyroid	  system	  crosstalk.	  TRH:	  thyrotropin-­‐releasing	  
hormone,	   TSH: thyroid-­‐stimulating	   hormone,	   NA:	   noradrenaline,	   BAT:	   brown	   adipose	   tissue,	   UCP1:	  
uncoupling	  protein	  1,	  DIO2:	  type	  II	  thyroxine	  5’-­‐deionidase	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The hypothalamic–pituitary–adrenal axis (HPA), which regulates processes in 
response to stress, is also involved in thermogenesis activation. The 
paraventricular nucleus of the hypothalamus synthesises and secretes the 
neuropeptide corticotropin releasing factor (CRF) which acts on pituitary cells to 
stimulate the secretion of adrenocorticotropic hormone (ACTH). The i.c.v 
administration of CRF elicits sustained increases in BAT sympathetic nerve 
activity, BAT temperature, expired CO2, and heart rate (Cerri & Morrison 2006). 
In addition to the SNS, the HPA axis and the thyroid system, several new 
players act as BAT activators. Vitamin A, and more specifically, its metabolites 
retinal and retinoic acid, are modulators of BAT thermogenesis (Kiefer et al. 
2012). 
Figure	   I	   10	   Hypothalamic–Pituitary–Adrenal	   axis	   (HPA)	   and	   Sympathetic	   Nervous	   System	   (SNS)	  
crosstalk.	  CRF:	   corticotropin	   releasing	   factor,	  ACTH:	  adrenocorticotropic	  hormone,	  NA:	  noradrenaline,	  
BAT:	  brown	  adipose	  tissue,	  UCP1:	  uncoupling	  protein	  1,	  DIO2:	  type	  II	  thyroxine	  5’-­‐deionidase	  
Liver and BAT activity are tightly connected. Bile acids released after meals 
induce Dio2 in BAT leading to a local increase in T3, which in turn induces Ucp1 
expression (Watanabe et al. 2006).  FGF21 is another key hepatic factor that 
regulates BAT activity. The mechanisms by which FGF21 exerts this function 
are discussed in section 5.4 of the introduction. 
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Exercise increases BAT activity and the release of myokines such as irisin, thus 
indicating a connection between muscle and BAT. In addition, irisin is a potent 
stimulator of browning of WAT (Bostrom et al. 2012).  
The heart is also a source of BAT activators, namely atrial natriuretic peptide 
(ANP), ventricular natriuretic peptide (VNP) and cardiotrophin-1, which all 
enhance BAT thermogenesis, as well as browning of WAT (Bordicchia et al. 
2012; Moreno-Aliaga et al. 2011).  
Unexpectedly, recent findings report that immune cells are BAT activators. 
Activated macrophages regulate BAT thermogenesis via the local release of 
cathecolamines (Nguyen et al. 2011), and the adipose-resident invariant natural 
killer T cells release FGF21, thus causing browning of WAT (Lynch et al. 2016).  
Several thermogenesis regulators act both in the hypothalamus and directly in 
BAT. As an example, bone morphogenic protein-8b sensitises BAT to SNS 
stimulation but also modulates sympathetic outflow (Whittle et al. 2012).  
Finally, ion channels such as transient receptor potential melastin 8 (TRPM8) 
and transient receptor potential vainilloid-4 (TRVP-4), participate in the 
regulation of BAT activation. TRPM8 agonist (e.g., menthol) induces BAT 
activity and pharmacological inhibition of TRVP leads to browning of WAT(Ma et 
al. 2012; Ye et al. 2012) .  
5.3 FGF21	  IN	  WAT	  
Adipose tissue is the main target tissue of FGF21 and the major mediator of its 
beneficial effects. While the physiological effects of FGF21 during fasting 
remain elusive, most data on its signalling in WAT derive from studies in which 
it was pharmacologically administered or overexpressed in obese mice. 
Nevertheless, FGF21 shows paradoxical actions on WAT depending on its 
source. Fgf21-overexpressing mice show induced lipolysis (Inagaki et al. 2007; 
Li et al. 2009). In contrast, Fgf21-knockout mice present enhanced lipolysis in 
late fasting (Hotta et al. 2009). In addition, while FGF21 suppresses lipolysis in 
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mouse and human adipocytes (Arner et al. 2008), it is induced by peroxisome 
proliferator activating receptor g (PPARg) in WAT upon feeding, thus stimulating 
adipogenesis (Dutchak et al. 2012; Muise et al. 2008).  
Regarding glucose metabolism, FGF21 induces glucose uptake in 3T3L1 
adipocytes by increasing glucose transporter 1 (GLUT1) independently of 
insulin action (Kharitonenkov et al. 2005; Ge et al. 2011). Moreover, later 
studies showed increased glucose uptake in both WAT and BAT of lean mice 
infused with FGF21 and fed a chow diet (Camporez et al. 2013). 
In summary, in WAT, FGF21 induces genes involved in glucose uptake, 
lipogenesis and lipolysis, depending on the metabolic state of the adipocytes. 
This apparently contradictory effects may be due to compensatory effects of 
genetic modifications in mice, different nutritional status and different FGF21 
concentrations reached between pharmacological administration and 
physiological secretion.  
WAT is not only a FGF21 target tissue but also a mediator of the effects of this 
growth factor. In this regard, the glucose- and insulin-sensitizing effects of 
FGF21 require the production and secretion of adiponectin from WAT. 
Accordingly, FGF21 stimulates this mechanism in rodents, and adiponectin-
knockout mice fail to reproduce the sensitizing effects of FGF21 (Lin et al. 
2013). Similarly, FGF21 also reduces the levels of the sphingolipid ceramide. 
Sphingolipid ceramides have been associated with insulin resistance caused by 
lipotoxicity. By inducing adiponectin secretion, FGF21 diminishes the 
accumulation of ceramides in obese animals (Holland et al. 2013). Overall, 
despite some contradictory effects of FGF21 in adipose fat depots, adipose 
tissue is considered indispensable for the physiological and pharmacological 
effects of FGF21.  
Finally, FGF21 induces the expression of Ucp1, thus producing browning of 
WAT in an autocrine, paracrine or endocrine fashion (De Sousa-Coelho et al. 
2013; Fisher et al. 2012). 
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5.4 FGF21	  IN	  BAT	  
BAT is a FGF21 target tissue since it expresses FGFR1 and KLB; however, it is 
also a source of FGF21. In BAT, FGF21 stimulates glucose uptake and 
thermogenesis through the induction of UCP1 in the interscapular depot in an 
autocrine and paracrine fashion (Hondares et al. 2011). Upon cold exposure, 
FGF21 expression is increased in BAT and other cold-sensitive fat depots in the 
β-adrenergic/ATF2-dependent pathway (Fisher et al. 2012; Hondares et al. 
2011; Chartoumpekis et al. 2011). In this regard, Fgf21-deficient mice respond 
poorly to cold exposure and show greater shivering (Fisher et al. 2012). The 
mechanisms underlying the action of FGF21 on BAT/WAT are still not well 
understood. Part of the FGF21-induced activation of the thermogenic program 
is driven by PGC-1α, as FGF21 increases the protein levels of this molecule. 
Similarly, Pgc-1α-knockout mice show an impaired response to FGF21 (Fisher 
et al. 2012).  
Furthermore, hepatic FGF21-mediated thermogenesis has also been described 
in response to maternal milk consumption in neonatal pups (Hondares et al. 
2010), and also in situations of metabolic stress, for example, as described in 
this thesis, upon amino acid restriction (De Sousa-Coelho et al. 2013). These 
observations suggest that the hepatic FGF21-mediated increase in thermogenic 
capacity is an adaptive response to metabolic stress.  
It has been proposed that the effect of FGF21 on EE and weight loss may be 
due to an increased thermogenic capacity of BAT and WAT (browning). 
However, recent experiments in Ucp1–null mice and interscapular BAT-excised 
mice show that when FGF21 is administered pharmacologically, UCP1 is not 
required for the improvement of the glucose, cholesterol, and free FA profile. 
Nonetheless, the increment in metabolic rate associated with the administration 
of FGF21 is diminished in these mice (Samms et al. 2015; Véniant et al. 2015; 
Bernardo et al. 2015). These data suggest that the metabolic benefits of FGF21 
are partly UCP1-independent. 
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6 FGF21	  IN	  OTHER	  TISSUES	  
6.1 FGF21	  IN	  SKELETAL	  MUSCLE	  
FGF21 expression in muscle was first described in Akt1 transgenic mice in 
which the mRNA and serum levels of FGF21 were induced (Izumiya et al. 
2008). In normal conditions, basal expression of FGF21 in skeletal muscle is 
low but its expression is increased by insulin (Izumiya et al. 2008; Hojman et al. 
2009), exercise (Kim, Kim, et al. 2013), mitochondrial myopathies (Tyynismaa 
et al. 2010), impaired mitochondrial FAO (Vandanmagsar et al. 2016), muscle-
specific autophagy deficiency (Kim, Jeong, Oh, et al. 2013) and transgenic 
overexpression of Akt1, perilipin-5 (Harris et al. 2015) or Ucp1 (Keipert et al. 
2014) in skeletal muscle. The induction of FGF21 in muscle due to a metabolic 
dysfunction is driven by the transcription factor ATF4, which is activated by 
endoplasmic reticulum (ER) stress. The AMPK and PI3K/Akt1 signalling 
pathways are also able to increase FGF21 expression (Vandanmagsar et al. 
2016). 
The impact of FGF21 on skeletal muscle is not clear, as the expression levels of 
KLB do not seem to be sufficient to respond to FGF21. Several studies suggest 
that FGF21 administration can improve glucose uptake in vitro (Lee et al. 2012; 
Mashili et al. 2011), and a model of impaired mitochondrial FAO has recently 
shown the same in vivo (Vandanmagsar et al. 2016). 
In contrast, the role of FGF21 as a myokine is more evident. In the 
abovementioned conditions where FGF21 is overexpressed in muscle, the 
plasma levels of this growth factor also increase. The metabolic effects of this 
increase include the reduction of fat content in liver, increased FAO, resistance 
to a HFD and browning of WAT. These results show that FGF21 can act as a 
myokine when secreted in response to muscle stress and that it exerts its 
effects on metabolism in an endocrine fashion. 
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6.2 FGF21	  IN	  HEART	  
Initially, the heart was discarded as a target tissue or source of FGF21 due to 
the low levels of FGF21 and KLB mRNA detected in this organ. However, later 
studies showed that FGF21 is expressed and secreted by cardiac cells in 
response to various stress conditions, including obesity, type 1 diabetes, 
fasting, ER stress, inflammation, infarct or hypertrophy, and some 
cardiovascular diseases (Brahma et al. 2014; Planavila et al. 2015). In the 
heart, FGFR1 and KLB have been detected in cardiac cells, where FGF21 
exerts protective effects in an autocrine and endocrine fashion. The mRNA 
expression of FGF21 in these cells is driven by the transcriptional activation of 
Sirtuin1 (Sirt1) – PPARα (Planavila et al. 2015) in response to cardiac insults; 
however, it can also be regulated by ATF4, especially when FGF21 induction is 
caused by ER or oxidative stress (Brahma et al. 2014; Dogan et al. 2014). 
It is now well established that FGF21 plays a key role in cardiac remodelling 
and pathophysiology. FGF21 protects cardiomyocytes from hypertrophy 
through a mechanism that involves the activation of the cAMP Responsive 
Element Binding protein (CREB), the induction of PGC-1α expression, and the 
reduction of the NF-kB pro-inflammatory pathway (Planavila et al. 2015). 
Cardiac FGF21 also induces the expression of anti-oxidant genes such as Ucp3 
and superoxide dismutase (Sod2), thus preventing the production of reactive 
oxygen species (ROS) in cardiac cells and oxidative stress in the heart 
(Planavila et al. 2014). In an autocrine fashion, FGF21 modulates cardiac lipid 
homeostasis (Brahma et al. 2014) and protects against diabetes-induced 
cardiomyopathy by activating the ERK-p38MAPK-AMPK pathway (Planavila et 
al. 2015). Finally, as an endocrine peptide, FGF21 can also inhibit 
cardiomyocyte apoptosis, thus reducing damage to the heart (Liu et al. 2013; 
Joki et al. 2015).  
6.3 FGF21	  IN	  THE	  CENTRAL	  NERVOUS	  SYSTEM	  
FGF21 has the potential to act in the central nervous system (CNS) since 
FGFRs are widely expressed in this tissue and KLB is specifically expressed in 
the suprachiasmatic nucleus, the dorsal vagal complex of the hindbrain, the 
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area postrema, the nucleus tractus solitari, the nodose ganglia, and the 
paraventricular nucleus (Fon Tacer et al. 2010; Bookout et al. 2013; Liang et al. 
2014). Immunoblotting experiments have revealed that FGF21 is expressed in 
several regions of the brain, such as the substantia nigra, striatum, 
hippocampus, and cortex (Makela et al. 2014); however, this growth factor also 
crosses the blood brain barrier and is present in the cerebrospinal fluid in a 
linear relationship with serum levels (Tan et al. 2011). FGF21 modulates 
circadian rhythm and fertility (Bookout et al. 2013; Owen et al. 2013), but 
current data point to the CNS as a mediator of the effects of FGF21 on EE and 
browning (Douris et al. 2015a). However, in all cases, the presence of KLB 
appears to be required for FGF21 to exert its effects. This observation thus 
indicates that this growth factor is an endocrine signal. Regarding the effects of 
FGF21 on EE and browning, experiments with diet-induced obese (DIO) mice 
show that the lack of KLB in the CNS abrogates all the effects of FGF21 on 
body weight, insulin sensitivity, metabolic regulation in liver, WAT, and BAT. 
These data suggest that direct signalling in the CNS causes an increase in the 
sympathetic outflow.  
In the hypothalamus, FGF21 affects the expression of CRF. 
Intracerebroventricular injection of FGF21 in Fgf21-KO mice restores the 
metabolic effects of FGF21 essentially through the CRF and the activation of 
CREB, which finally enhances hepatic gluconeogenesis and sympathetic nerve 
activity in BAT (Liang et al. 2014; Owen et al. 2014; Arase et al. 1988). 
According to that, lack of KLB in the brain blunts these effects (Liang et al. 
2014; Owen et al. 2014; Douris et al. 2015a). Finally, treatment with the b-
blocker propranolol diminishes the effects of FGF21 when it is centrally 
administered but not when delivered peripherally (Douris et al. 2015b).  
Given the wide range of biological processes regulated by the CNS and the 
capacity of FGF21 to act in the brain, it is likely that future studies will reveal 
new actions of FGF21 signalling through the CNS. 
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6.4 FGF21	  IN	  PANCREAS	  
FGF21 is highly expressed in the pancreas and has protective effects against 
cerulein-induced pancreatitis (Johnson et al. 2009). Supporting data show that 
FGF21-deficient mice are more susceptible to damage, and FGF21-
overexpressing mice are partly protected. In addition, FGF21 may be involved 
in enhancing islet engraftment (Uonaga et al. 2010) and in the preservation of 
b-cell function and survival (Wente et al. 2006). Another point is that KLB
expression is critical for these beneficial effects, but the expression of KLB is
reduced when islets are treated with high glucose concentrations (So et al.
2013). In the pancreas, FGF21 increases insulin content and glucose-
dependent secretion and inhibits glucagon release in isolated islets (Wente et
al. 2006).
Figure	  I	  11	  Metabolic	  effects	  of	  exogenous	  FGF21.	  (Gimeno	  &	  Moller	  2014)	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7 OTHER	  EFFECTS	  OF	  FGF21	  
In addition, and consistent with its metabolic benefits, FGF21 transgenic 
overexpression extends lifespan in mice. The authors of that study proposed 
that inhibition of the GH/IGF-1 signalling pathway would explain life extension in 
Fgf21 transgenic mice. Furthermore, microarray analysis showed that FGF21 
modulates gene expression in the liver in a similar manner to caloric restriction 
(which is known to extend lifespan in mammals). These data suggest that 
FGF21 extends lifespan by acting as a selective caloric restriction mimetic in 
the liver (Zhang et al. 2012).  
Interestingly, FGF21 appears to be not only a metabolic regulator but also a 
nutrient intake and taste regulator. Both pharmacologic administration and 
hepatic secretion of FGF21 produce a satiety signal that suppresses the intake 
of "sweets" (von Holstein-Rathlou et al. 2016; Talukdar, Owen, et al. 2016). In 
addition, two genome-wide meta-analyses associated genetic variations in a 
locus including Fgf21 with significant differences in macronutrient intake 
(Tanaka et al. 2013; Chu et al. 2013).  
While FGF21 boasts numerous beneficial effects, a major adverse effect is a 
decrease in bone mass. Both, genetic overexpression of Fgf21, and 
pharmacological administration of this molecule lead to the inhibition of 
osteoblastogenesis and the stimulation of adipogenesis. In contrast, the 
absence of Fgf21 leads to a high bone mass phenotype. The mechanism 
underlying bone mass loss is the potentiation of PPARγ activity (Wei et al. 
2012). Although this non-desirable effect has been described only in rodents, it 
has to be taken into account when considering FGF21 as a potential drug 
candidate. 
Introduction
31
8 NUTRITIONAL	  REGULATION	  OF	  FGF21	  
Nutritional signals play an important role in controlling gene expression in 
mammals. Macronutrients (carbohydrates, fatty acids (FAs), proteins), 
micronutrients (minerals and vitamins), and some bioactive dietary compounds 
have the capacity to regulate gene expression and thus metabolic homeostasis. 
In this context, it has been described that endogenous FGF21 levels are 
regulated by various nutritional challenges. 
Carbohydrates ingestion modulates FGF21 expression. A dextrose enriched 
diet induce hepatic FGF21 expression in mice (Hao et al. 2016), and human 
FGF21 promoter responds to xylitol and fructose through ChREBP. In addition, 
humans and rodents ingestion of fructose but not glucose leads to increased 
FGF21 serum levels after an acute load (Dushay et al. 2015) . 
High-fat diets (HFDs) induce FGF21 resistance (Fisher et al. 2010) although 
there is still some controversy due to the variety of fatty acids included in the 
diet. In vitro, oleate, linolate and trans-10, cis-12 conjugated linoleic induce 
FGF21 expression and secretion (Yu et al. 2011; Mai et al. 2009). Moreover, in 
neonatal mice, initiation of suckling induces hepatic FGF21 expression mainly 
due to high FA content of maternal milk (Hondares et al. 2010). PPARα and 
CREBH are the mediators of FGF21 induction in response to fatty acids.  
Amino acid-deficient and low protein diets (LPD) diminish aminoacidemia and 
trigger AAR, thereby resulting in elevated FGF21. This will be the focus of the 
results and discussion of the present work. 
Finally, bioactive dietary compounds such as polyphenols induce FGF21 
expression in liver and improve its signalling. Nevertheless, mechanisms driving 
these effects need further studies (Monika & Geetha 2015; Yu et al. 2013) 
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Figure	   I	  12	  FGF21	   is	  regulated	  by	  different	  nutritional	   impacts	  to	  adapt	  the	  metabolic	  profile.(Pérez-­‐
Martí	  et	  al.	  2016)	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9 AMINO	  ACID	  DEFICIENCY	  
In eukaryotic cells, amino acids are the building blocks for the synthesis of 
proteins and other biomolecules. Furthermore, amino acids are required as 
energy supply and also as signalling molecules. 
Multicellular organisms are unable to synthesise all amino acids. In this regard, 
nine essential amino acids (valine, isoleucine, leucine, lysine, methionine, 
phenylalanine, threonine, histidine and tryptophan) cannot be synthesised de 
novo or at least not in sufficient amounts to meet cellular needs. Furthermore, 
under certain conditions, non-essential amino acids may become indispensable 
(the so-called conditionally essential amino acids). All essential amino acids 
must be supplied by diet. Moreover, there is no dispensable amino acid store in 
mammals. Thus, when necessary, the organism has to hydrolyse muscle 
protein to produce free amino acids. 
In mammals, the blood concentration of amino acids can be affected by 
nutritional or pathological situations.  Protein undernutrition caused by a low 
protein diet or imbalanced diets (which are common in mammals confronted 
with deficient sources of selected amino acids like legumes, grains or corn) 
strongly affects aminoacidemia (Placko & Graham 1974; Grimble & Whitehead 
1970). In addition, pathological situations involving various forms of stress such 
as trauma, thermal burn, sepsis and fever, can lead to a negative nitrogen 
balance. 
At the cellular level, the size of the pool of each amino acid is the result of a 
balance between inputs and outputs. The metabolic outputs for amino acids are 
protein synthesis and amino acid degradation, whereas the inputs are de novo 
synthesis (for non-essential amino acids), protein breakdown and dietary 
supply. 
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Figure	  I	  13	  Biochemical	  systems	  involved	  in	  the	  homeostasis	  of	  proteins	  and	  amino	  acids.	  
Dietary amino acid availability alters metabolic pathways beyond protein 
homeostasis since there is a link between dietary amino acids and lipid 
metabolism. 
Leucine deprivation causes dramatic changes in lipid metabolism. In liver, 
leucine deprivation inhibits fatty acid synthase activity, decreases the 
expression of lipogenic genes, and increases the mobilisation of lipid stores. In 
WAT, it decreases fatty acid synthase activity and the expression of lipogenic 
genes, while it increases the expression of β-oxidation genes. Finally, in BAT, 
increased expression of UCP1 is observed (Cheng et al. 2010; Cheng et al. 
2009) 
The aforementioned effects of leucine deprivation on lipid metabolism match 
the effects of FGF21 on liver, WAT and BAT. This observation, in addition to our 
previous results indicating that leucine deprivation increases FGF21 hepatic 
expression and serum levels (De Sousa-Coelho et al. 2012), led us to 
hypothesise that FGF21 mediates the leucine deprivation effects on lipid 
metabolism. 
Introduction
35
Figure	  I	  14	  Overlapping	  metabolic	  effects	  of	  FGF21	  and	  leucine	  deprivation	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MATHERIALS	  AND	  METHODS	  

1 CELL	  CULTRE	  –	  MAMMALIAN	  CELL	  LINES	  
1.1 HepG2	  -­‐	  human	  liver	  carcinoma	  cell	  line	  (ATCC	  No.	  HB-­‐8065).	  
HepG2 are adherent, epithelial-like cells growing as monolayers and in small 
aggregates. HepG2 cell line was derived from the liver tissue of fifteen-year-old 
male with differentiated hepatocellular carcinoma. Cells were cultured in Eagle's 
Minimum Essential Medium (MEM) supplemented to contain 1x nonessential 
amino acids, 4 mM glutamine, 100 µg/ml streptomycin sulfate, 100 units/ml 
penicillin G, and 10% (v/v) fetal bovine serum (FBS). Cells were incubated at 
37ºC in humidified atmosphere with 5% CO2. Culture medium was discarded 
and changed every 2-3 days. To passage cells, cells were briefly rinsed with 1x 
PBS twice and 0.05% Trypsin-EDTA solution was added. Once cell layer was 
dispersed (3-4 min at 37ºC), trypsin was deactivated by adding complete growth 
medium. Cells were splited 1:2 dilution twice a week or counted and plated 
according the final experiment. 
1.2 AML12-­‐	  transgenic	  mouse	  liver	  cell	  line	  (ATCC	  No.	  CRL-­‐2254)	  	  
AML12 (alpha mouse liver 12) are adherent, epithelial-like cells growing as 
monolayers. AML12 cell line was established from hepatocytes from a mouse 
(CD1 strain, line MT42) transgenic for human TGF alpha. These cells exhibit 
typical hepatocyte features such as peroxisomes and bile canalicular like 
structure. Expression of liver specific proteins decreases with time in culture, 
but is reactivated by growing the cells in serum free medium. Cells were 
cultured in A 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's 
F12 medium with 0.005 mg/ml insulin, 0.005 mg/ml transferrin, 5 ng/ml 
selenium, and 40 ng/ml dexamethasone, 4 mM glutamine, 100 µg/ml 
streptomycin sulfate, 100 units/ml penicillin G, and 10% (v/v) fetal bovine serum 
(FBS). Cells were incubated at 37ºC in humidified atmosphere with 5% CO2. 
Culture medium was discarded and changed every 2-3 days. To passage cells, 
cells were briefly rinsed with 1x PBS twice and 0.05% Trypsin-EDTA solution 
was added. Once cell layer was dispersed (1-2 min at 37ºC), trypsin was 
deactivated by adding complete growth medium. Cells were splited 1:10 dilution 
twice a week or counted and plated according the final experiment. 
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1.3 3T3-­‐L1	  	  Mus	  musculus	  embryo	  cell	  line	  (ATCC	  No.	  CL-­‐173)	  
3T3-L1 is a cell line derived from mouse 3T3 (Swiss albino) cells developed 
through clonal isolation. 3T3-L1 cells have a fibroblast-like morphology, but, 
under appropriate conditions, the cells differentiate into an adipocyte-like 
phenotype (Diaz-Delfin et al. 2012). The cells undergo a pre-adipose to adipose 
like conversion as they progress from a rapidly dividing to a confluent and 
contact inhibited state. High serum content in the medium enhances fat 
accumulation. 
Cells were cultured in Dubelcco’s Modified Eagle's Medium (DMEM) 
supplemented to contain 4 mM glutamine, 100 µg/ml streptomycin sulfate, 100 
units/ml penicillin G, and 10% (v/v) calf serum (CS). Cells were incubated at 
37ºC in humidified atmosphere with 5% CO2. Culture medium was discarded 
and changed every 2-3 days. To passage cells, cells were briefly rinsed with 
1xPBS twice and 0.05% Trypsin-EDTA solution was added. Once cell layer was 
dispersed (1-2 min at 37ºC), trypsin was deactivated by adding complete growth 
medium. Cells were splited 1:5 dilution twice a week or counted and plated 
according the final experiment. 
1.4 Reagents	  used	  in	  cell	  culture	  maintainance	  
Reagent Company Ref 
Minimum Essential Media (MEM) GIBCO 61100-087 
Dubelcco’s Modified Eagle's Medium (DMEM) GIBCO 12100-061 
DMEM (Dulbecco's Modified Eagle Medium) /F-12 GIBCO 11320074 
Fetal Bovine Serum (FBS) GIBCO 10270-106 
Calf Serum GIBCO 12100-061 
L-Glutamine 200mM GIBCO 25030-024 
Pen Strep (Penicillin-Streptomycin) GIBCO 15140-122 
Sodium bicarbonate solution 7.5% Sigma-Aldrich S8761 
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1.5 Reagents	  used	  in	  cell	  culture	  transfection	  
1.6 Reagents	  used	  in	  cell	  culture	  specific	  treatments	  
MEM Non Essential Amino Acids (NEAA) 100x GIBCO 11140-035 
Tripsin-EDTA 10X GIBCO 15400-054 
Insulin-Transferrin-Sodium Selenite Supplement GIBCO 11074547001 
Dexamethasone Sigma-Aldrich D2915 
Reagent Company Ref 
OPTI-MEM GIBCO 31985-047 
Lipofectamine LTX Reagent Invitrogen 15338-100 
Plus Reagent Invitrogen 11514015 
Reagent Company Ref Description Treatment conditions 
L-histidinol
(HisOH) Sigma-Aldrich H6647 
Reversible inhibitor of protein 
synthesis. Dissolved in water 
to 50mg/mL. 
2mM / 8h 
SR8278 Sigma-Aldrich S9576 
Nuclear Heme Receptor REV-
ERB antagonist. Dissolved in 
DMSO to 1mM 
10µM / 24h 
Hemin Sigma-Aldrich H9039 
Heme is a small molecule 
present either free or bound to 
hemoglobin in the bloodstream 
of mammals. It is the natural 
ligand of REV-ERB. Dissolved 
in 1.4M NaOH to 30mM 
30µM / 24h 
PD98059 ThermoFisher Scientific PHZ1164 
PD98059 is a potent and 
selective cell permeable 
inhibitor of MAP kinase kinase 
30µM /16h 
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Following reconstitution stock solutions aliquots were stored at -20°C. 
2 PLASMID	  CONTRUCTS	  
All plasmid constructs were generated by PCR from human or mouse genomic 
DNA (HepG2 cells or C57BL/6 mouse strain), using Taq polymerase (Biotools) 
and primers introducing restriction sites when needed (see primer sequences 
below). The PCR products were cloned in the vector pGEM-T (Promega) and 
sequenced. The plasmids were digested with the corresponding restriction 
enzymes and subcloned into pGL3b vector (Promega), forming pGL3b-hFGF21 
wt, pGL3b-mFgf21 wt and pGL3b-mRev-erbα wt. (For more information of the 
cloning strategies see Annex 2) 
The sequences and orientations of the constructions were verified by 
sequencing (Macrogen sequencing service). 
2.1 Reporter	  constructions	  
(MEK). It selectively blocks the 
activation of MEK, thereby 
inhibiting the phosphorylation 
and the activation of MAP 
kinase. Dissolved in DMSO. 
Construction Insert Clonning targets Primers 
pGL3b-hFGF21 wt -768/+115 Kpn I / Sac I DH1309 / DH1310 
pGL3b-mFgf211 wt -1497/+5 Sma I / Xho I DH1195 / DH1196B 
pGL3b-mRev-erbα -393/+629 Mlu I / Xho I DH1415/DH1416 
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List of primers (restriction sites italicized and bolded) 
DH1195 5’- AGTCCCCGGGATTAATTAATCGCATGGAGT-3’ 
DH1196b 5’- GCAATCTCGAGGCTGTCTGGTGAACGCAGA-3’ 
DH1309 5’- GGTACCAGCCAACCTGTCTTCCCTCT-3’ 
DH1310 5’-CTCTGGCCCACACTCACTTT- 3’ 
DH1415 5’-AAACGCGTAATCTCTCCTCCCAGCTTGT-3’ 
DH1416 5’-AACTCGAGGTCTTCACCAGCTGAAAGCG-3’ 
2.2 Expression	  constructions	  
*N.A.  Not Available
3 DNA	  OLIGONUCLEOTIDE	  (PRIMERS	  AND	  PROBES)	  
All DNA oligos were synthesized by Sigma-Aldrich with technology ultra-high 
base coupling efficiency, combined with optimized cartridge purification and 
100% quality control by mass spectrometry.  
Construction Clonning targets Inserts species Origin 
pRK-ATF4 Sal I / Not I Human Addgene ( ref. 26114) 
pSG-Egr-1 EcoR I Rat CSIC 
pSG5-
hReverbα N.A Human Dr J.C. Rodríguez 
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4 TRANSIENT	  TRANSFECTION	  AND	  LUCIFERASE	  ASSAY	  
HepG2 cells (1 x 105 cells/well) or AML12 cells (0.6 x 105) were seeded on 24-
well plates 18–24h before transfection with Lipofectamine® LTX reagent 
(Invitrogen) at a ratio of 2 µl of Lipofectamine® and 0.5 µl of  PlusTM reagent to 
1µg of DNA. For each transfection, 0.2µg of the reporter plasmid was used 
along with 0.01µg of Renilla (pRL-CMV), as an internal control, and the 
indicated amounts of the transcription factor expression plasmids (in general 
0.25µg). The total amount of transfected DNA was kept constant among 
experimental groups by the addition of empty pcDNA3 plasmid. 24h following 
transfection, cells were transferred to fresh complete MEM medium and treated 
with Hemin or SR8278 when indicated. In this work every transfection with 
pSG5-hReverbα was treated with hemin. At approximately 48h following 
transfection, cellular extracts were prepared for analysis of luciferase activity. 
Cells were washed twice with PBS, and harvested in 100µl of 1x Passive lysis 
buffer (Promega). The lysates were collected and a 10µl aliquot was used for 
Firefly luciferase assays using the Dual-Luciferase Reporter Assay System 
(Promega). Relative luciferase activity was given as the ratio of relative 
luciferase unit / relative renilla unit.  
5 PROTEIN	  EXTRACTION	  
Whole-cell lysates from HepG2 cells were isolated using NP40 lysis buffer. 
Cells plated in MW6 were washed twice with ice-cold PBS, harvested with a 
rubber policeman, and centrifuged for 10min at 1000 x g at 4°C. The resulting 
pellet of cells was lysed with 50-100µL of NP40 lysis buffer with agitation for 15-
20min at 4°C, and centrifuged for 5-10min at 12000 x g at 4°C. The supernatant 
corresponding to the proteins extract was collected, frozen, and stored at -80°C. 
Nuclear extracts were prepared from HepG2 cells plated in 100-mm-diameter 
dishes (p100). Cells were washed twice with ice-cold PBS, harvested with a 
rubber policeman in 1mL PBS, and centrifuged for 5min at 800 x g at 4°C. Cell 
pellets were resuspended in 1mL of HB buffer, centrifuged at 800 x g for 5min. 
To obtain liver nuclear extracts, frozen liver was first triturated within a mortar in 
liquid nitrogen and immediately homogenized with a Dounce homogenizer in 
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1mL of HB buffer, and centrifuged at 800 x g for 5min. From here the protocol 
was the same for both cultured cells and tissues. The resulting pellet was 
resuspended in 100µL of HB buffer supplemented with 0.05% Triton X-100 
(Sigma), and centrifuged for 1 min at 1000 x g. Nuclear pellets were washed 
with 1mL of HB buffer supplemented with 0.05% Triton X-100 and 1mL of HB 
buffer. Nuclei were incubated on ice for 30min in 50µL of HB buffer containing 
36mM KCl and centrifuged for 5min at 10000 x g. The supernatant 
corresponding to the nuclear extract was collected, frozen, and stored at -80°C. 
To obtain total extracts from epididimal White Adipose Tissue (eWAT), Brown 
Adipose Tissue (BAT) or Liver, tissue was homogenized in RIPA (Radio-
Immunoprecipitation Assay) buffer and centrifuged at 12000 x g for 15min at 
4°C. The supernatant was collected and frozen at -80°C until analysis. 
All of the buffers were supplemented with a mixture of protease inhibitors 
(Sigma Aldrich), 0.1mM phenylmethylsulfonyl fluoride (PMSF), and a 
phosphatase inhibitor cocktail (IPC3, Sigma Aldrich). Protein concentration was 
estimated by using the Bio-Rad protein assay with bovine serum albumin (BSA) 
as standard. 
6 	  WESTERN	  BLOTTING	  ANALYSIS	  
Protein extracts were resolved by 8-10% SDS-polyacrylamide gel 
electrophoresis and transferred onto a PVDF membrane (Millipore) at 200mA 
for 2-3h or with iBlot 2 Dry Blotting System (ThermoFisher Scientific) 
programme 0  (20V 1 minute, 23V 4 minutes, 25V 5 minutes). Generally, 
membranes were blocked for 1 h at room temperature and the blots were then 
incubated with primary antibody in blocking solution overnight at 4ºC. In 
NP40	  lysis	  buffer RIPA	  buffer HB	  buffer
Tris-­‐HCl	  50mM	  pH	  8 Tris	  HCl	  10mM	  pH	  7 Tris-­‐HCl	  15mM	  pH	  8
NaCl	  150mM Triton	  X-­‐100	  1% NaCl	  15mM
NP40	  1%	   NaCl	  150mM KCl	  60mM
EDTA	  5mM EDTA	  0.5mM
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general, antibodies were diluted according to the manufacturer’s instructions. 
Specific blocking solutions and antibody dilutions are described above.  
Antibody Blocking solution Dilution 2ari antibody 
ACC1 TBS, 0.5%Tween, 5%Milk 1:500 Rabbit 
ACTIN PBS, 1%Tween, 5% Milk 1:1000 Rabbit 
ATF4 TN, 0.1%Tween, 5%Milk 1:200 Rabbit 
ERK1/2 TBS, 0.1%Tween, 5%BSA 1:1000 Rabbit 
FASN TBS, 0.5%Tween, 5%Milk 1:20000 Rabbit 
HSL TBS, 0.1%Tween, 5%Milk 1:1000 Rabbit 
p38α/βMAPK TBS, 0.1%Tween, 5%Milk 1:1000 Mouse 
phospho-HSL TBS, 1%Tween, 5%Milk 1:1000 Rabbit 
phospho-ACC1 TBS, 0.5%Tween, 5%Milk 1:500 Rabbit 
phospho-ERK1/2 TBS, 0.1%Tween, 5%BSA 1:1000 Rabbit 
phospho-p38MAPK TBS, 0.1%Tween, 5%BSA 1:1000 Rabbit 
SREBP1c TBS, 0.5%Tween, 5%Milk 1:500 Rabbit 
TUBULIN PBS, 0.1% Tween, 5%Milk 1:5000 Mouse 
TBS 
25 mM Tris 
150 mM NaCl 
2mM KCl 
pH 7.4 
PBS 
NaCl 137mM 
KCl 2.7mM 
Na2HPO4 10mM 
KH2PO4 1.76mM 
pH 7.5 
TN 
50mM Tris-HCl pH 8.0 
150mM NaCl 
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The blots were washed three times for 10min and incubated with horseradish 
peroxidase-conjugated secondary antibody in blocking buffer for 2 h at room 
temperature. After three washes, the blots were developed using the EZ-ECL 
Chemiluminescence Detection Kit for HRP (Biological Industries). Briefly, after 
the final washings, membranes were incubated with substrate for peroxidase 
and chemiluminescence’s enhancer for 1 minute and immediately exposed to 
ImageQuant LAS 4000 (GE Healthcare Lifesciences). Quantification was 
performed by densitometry using Image J software. 
7 ANTIBODIES	  
7.1 Primary	  antibodies	  
Antibody Company Ref 
HSL Cell Signaling Technology #4107 
phospho HSL Cell Signaling Technology #4126 
ERK1/2 Cell Signaling Technology #4695 
phospho-ERK1/2 Cell Signaling Technology #4370 
phospho-p38 Cell Signaling Technology #9211 
ATF4 Santa Cruz Biotechnology sc-200 
p38α/β Santa Cruz Biotechnology A-12, sc-7972
SREBP1c Santa Cruz Biotechnology C-20. sc-36
FASN Abcam ab128870 
ACC1 Millipore 04-322
phospho-ACC1 Millipore 07-303
ACTIN Sigma-Aldrich A2066 
TUBULIN Calbiochem #CP06 
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7.2 Secondary	  antibodies	  
Antibody Company Ref 
Donkey anti-rabbit IgG, whole Ab ECL 
antibody, horseradish peroxidase 
(HRP) conjugated 
Amersham Biosciences NA934V 
Sheep anti-mouse IgG, HRP-Linked 
whole Ab (from sheep) 
Amersham Biosciences NA931V 
8 ISOLATION	  OF	  TOTAL	  RNA	  
Total RNA was extracted from HepG2 cells or from frozen tissues using TRI 
Reagent Solution (Ambion) following the manufacter’s instructions. RNA was 
pretreated with DNase I (Ambion) to eliminate genomic DNA contamination. 
Frozen tissues were chopped in liquid nitrogen and then crushed in TRI 
Reagent solution with the help of a politron. RNA was dissolved in DNase, 
RNase, protease free water (Sigma-Aldrich) and the concentration and purity of 
each sample was obtained from A260/A280 measurements in a micro-volume 
spectrophotometer NanoDrop-1000 (NanoDrop Technologies, Inc. Thermo 
Scientific) 
9 ANALYSIS	  OF	  MRNA	  EXPRESSION	  
To measure the relative mRNA levels, quantitative (q)RT-PCR was performed 
using SYBR Green or TaqMan reagents. cDNA was synthesized from 1 µg of 
total RNA by MLV reverse transcriptase (Invitrogen, Thermo Fisher Scientific) 
with random hexamers (Roche Diagnostics), following the manufacturer's 
instructions. The TaqMan Gene Expression Master Mix (and SYBR® Green 
PCR Master Mix, supplied by Applied Biosystems (ThermoFisher Scientific), 
were used for the PCR step.  Amplification and detection were performed using 
the Step-One Plus Real-Time PCR System (Applied Biosystems, ThermoFisher 
Scientific). Each mRNA from a single sample was measured in duplicate, using 
18S, Beta-Actin, and 36b4 as housekeeping genes. The primer sequences are 
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shown above. Results were obtained by the Relative Standard Curve Method 
and expressed as fold increase versus the experimental control. 
Gene Sequence/Ref 
SYBR Green 18S 
F- 5’-CGGCTACCACATCCAAGGAA-3’
R- 5’-GCTGGAATTACCGCGGCT-3’
SYBR Green 36b4 
F- 5’-AGATGCAGCAGATCCGCAT-3’
R- 5’-GTTCTTGCCCATCAGCACC-3’
SYBR Green Alas-1 
F- 5’-GCCAGGCTGTGAAATTTACT-3’
R- 5’-CTGTTGCGAATCCCTTGGAT-3’
SYBR Green beta-Actin 
F- 5’-GCTCTGGCTCCTAGCACCAT-3’
R- 5’-GCCACCGATCCACACAGAGT-3’
SYBR Green Cebp-beta 
F- 5’-GGGTTGTTGATGTTTTTGGTTT-3’
R- 5´-GAAACGGAAAAGGTTCTCAAAA-3’
SYBR Green Dio2 
F- 5’-TGCGCTGTGTCTGGAACAG-3’
R- 5’-CTGGAATTGGGAGCATCTTCA-3’
SYBR Green Glut1 
F-5’-GCCCCCAGAAGGTTATTGA-3’
R-5’-CGTGGTGAGTGTGGTGGAT-3’
SYBR Green Pgc1-alpha 
F- 5’-AACCACACCCACAGGATCAGA-3’
R- 5’-CTCTTCGCTTTATTGCTCCATGA-3’
SYBR Green Ppar-gamma 
F- 5’-GCATCAGGCTTCCACTATGGA-3’
R- 5’-AATCGGATGGTTCTTCGGAAA-3’
SYBR Green Prdm16 
F- 5’-CAGCACGGTGAAGCCATT-3’
R- 5’-GCGTGCATCCGCTTGTG-3’
SYBR Green Rev-erb alpha 
F- 5’-TTACCAAGCTGAATGGCATGGTGC-3’
R- 5’- ATATTCTGTTGGATGCTCCGGCGA-3’
Taqman Acadm Mm01323360_g1 
Taqman Acadl Mm00599660_m1 
Taqman Acaca (Acc1) Mm01304257_m1 
Taqman Acox Mm01246834_m1 
Taqman Adrb3 Mm02601819_g1 
Taqman Atf4 Mm00515325_g1 
Taqman Atgl (Pnpla2) Mm00503040_m1 
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Taqman 
ASNS 
Asns 
Hs04186194_m1 
Mm00803785_m1 
Taqman Cd36 Mm00432403_m1 
Taqman Cpt1a Mm01231183_m1 
Taqman Cidea Mm00432554_m1 
Taqman Dio2 Mm00515664_m1 
Taqman Fabp4 Mm00445878_m1 
Taqman Fasn Mm00662319_m1 
Taqman 
Fgf21 
FGF21 
Mm00840165_g1 
Hs00173927_m1 
Taqman Fgfr1 Mm00438930_m1 
Taqman Hsl (Lipe) Mm00495359_m1 
Taqman Klb Mm00473122_m1 
Taqman Lpl Mm00434764_m1 
Taqman Ppargamma Mm00440940_m1 
Taqman Pgc-1alpha Mm01208835_m1 
Taqman Plin1 Mm00558672_m1 
Taqman Srebp1c (Srebf1) Mm00550338_m1 
Taqman Ucp1 Mm01244861_m1 
ANIMAL	  EXPERIMENTATION	  
1 MICE	  HOUSING	  
Mice were housed at the Animal Facility of the School of Pharmacy of the 
University of Barcelona. Mice were kept in a temperature-controlled room 
(22±1°C) on a 12/12 h light/dark cycle and were provided free access to 
commercial rodent chow and tap water prior to the experiments.  
All procedures were performed with male mice aged two to three months. 
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2 MOUSE	  STRAINS	  
The following mouse strains were used. 
Mouse Nomenclature Origin 
Wild type C57Bl/6J Harlan-Animals 
FGF21-KO 
B6N;129S5-
Fgf21tm1Lex/ 
Mmcd 
Dr Villaroya 
Laboratory 
Fgf21loxP B6.129S6(SJL)-Fgf21tm1.2Djm/J 
The Jackson 
Laboratory 
Ob/Ob B6.V-Lepob/JRj Janvier Labs 
Albumin-cre FVB(Cg)-Tg(Alb1-cre)1Dlr/J 
Dr. Zorzano 
Laboratory 
LFgf21KO FGF21fl/fl;Albumin-Cre Dr Haro and Dr Marrero Laboratory 
3 ANIMAL	  EXPERIMENTATION	  ETHICS	  COMMITTEE	  APPROVAL	  
All of the experimental protocols with mice were performed with the approval of 
the animal experimentation ethics committee of the University of Barcelona. All 
experiments were performed following the below approved procedures.  
Title CEEA Register 
Acceptance 
date 
Estudi de l'expressió d'FGF21 en ratolins alimentats amb una dieta 
deficient en leucina i els efectes de la deprivació d'aminoàcids en el 
metabolisme 
389/11 
593/13 04/10/2011 
Estudi de l'efecte de l'FGF21 hepàtic sobre el metabolisme lipídic i 
la homeòstasi energètica en ratolins alimentats amb una dieta amb 
baix contingut proteic 
48/15 16/12/2014 
Estudi de l'efecte de l'FGF21 a través del sistema nerviós simpàtic 
sobre el metabolisme lipídic i la homeòstasi energètica en ratolins 
alimentats amb una dieta amb baix contingut proteic 
328/16 16/12/2016 
Colònia de ratolí C-0086 13/11/2014 
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4 FGF21	  LIVER	  SPECIFIC	  KNOCKOUT	  MOUSE	  COLONY	  MANAGEMENT	  
To generate the Fgf21 liver specific knockout mice (LFgf21KO), Fgf21loxP mice 
(Fgf21tm1.2Djm/J) that have Fgf21 flanked by two loxP sites (Jackson Laboratory) 
were crossed with Albumin-cre (Tg(Alb1-cre)1Dlr/J) mice (kindly provided by Dr. 
A. Zorzano). The latter express the CRE recombinase enzyme under control of
albumin promoter/enhancer elements, thus allowing liver-specific gene
deletions. Fgf21LoxP mice were used as controls.
4.1 Genomic	  DNA	  extraction	  from	  tails	  
To extract genomic DNA (gDNA) from mice tail, the last 2mm of the tail were 
snipped and placed into 1.5mL microcentrifuge tube (eppendorf). At his point 
tails can be directly frozen at -20ºC and stored until use. 500 µl of Tail buffer 
(supplemented with proteinase K to a final concentration of 100 µg/mL) were 
added to each tube. Snipped tails were incubated at 55ºC with constant mixing 
for at least 4h in a water bath with agitation at 55ºC. Samples were occasionally 
vortexed until tissue was degraded. Once tails were dissolved, they were 
centrifuged at 1400rpm for 10 min at RT. The supernatant was transferred to a 
new tube and 500 µL of isopropanol and 2µl of GlycoBlue (Ambion) were 
added. Tubes were mixed without vortexing and centrifuged at 14000rpm for 5 
min at 4ºC. Supernatant was discarded, the pellet washed with 500 µl of cold 
70% ethanol and centrifuge at 14000 rpm for 5 min at 4ºC. Next, pellet was air-
dried and resuspended with 50µl of TE pH8. Samples were incubated for 5-10 
min in a 65ºC bath. Finally, to check out integrity of the DNA in the sample, an 
aliquot can be loaded in a 0.8-1% agarose gel and a single band in the top of 
the gel should be visualized. 
Tail buffer 
Tris-HCl 20 mM pH 8 
EDTA 5mM pH 8 
SDS 0.5% 
NaCl 200mM 
TE pH 8 
Tris-HCl 10mM pH 8 
EDTA 1mM 
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4.2 PCR	  Detection	  of	  Cre	  
Detection of Cre recombinase was performed by PCR using genomic DNA from 
mice tails.  H2O instead of gDNA was used as a negative control, and when 
possible, a positive control was used. 
PCR reaction 
dNTPs (10mM each)             1µL 
Buffer (10x)       2.5µL 
Primer Cre-Fw (10µM)          1uL 
Primer Cre-Rv (10µM)         1uL 
Taq polymerase                 0.5µL 
H2O 14µL 
gDNA ( ~ 25 ng/µL)               5µL 
PCR programme 
Step 1: 95ºC    5min 
Step 2: 94ºC    1sec 
Step 3: 50ºC    1min 
Step 4: 72ºC    1 min 
Step 5: Go to step 2 for 30 times 
Step 6: 72ºC     7 min 
Step 7: STOP 
PCR product will be around 100bp, so it should be loaded in a 2% agarose gel. 
4.3 PCR	  Detection	  of	  LoxP	  
Detection of LoxP sites was performed by PCR using genomic DNA from mice 
tails. H2O instead of gDNA was used as a negative control, and when possible, 
a positive control was used. 
Materials and Methods
53
PCR reaction 
dNTPs (10mM each)             1µL 
Buffer (10x)       2.5µL 
Primer LoxP-Fw (10µM)         1uL 
Primer LoxP-Rv (10µM)         1uL 
Taq polymerase                 0.5µL 
H2O 14µL 
gDNA ( ~ 25 ng/µL) 5µL 
PCR programme 
Step 1: 95ºC    5min 
Step 2: 94ºC    30sec 
Step 3: 60ºC    1min 
Step 4: 72ºC    1 min 
Step 5: Go to step 2 for 32 times 
Step 6: 72ºC     10 min 
Step 7: STOP 
PCR product will present a single 450bp band for homozygous mutants, single 
319bp band for wild type and both bands for heterozygous mutants. Thus, it 
should be loaded in a 2% agarose gel. 
5 DIETARY	  MANIPULATIONS	  
5.1 Leucine-­‐deficient	  diet	  
Control (Ctl) (nutritionally complete amino acid) and leucine-deficient ((-)leu)  
diets were obtained from Research Diets, Inc. All diets were isocaloric and 
compositionally the same in terms of carbohydrate and lipid components 
(detailed composition shown in Annex 1). At the beginning of the feeding 
experiment, twelve- to fifteen-week old male mice were first acclimated to the 
control diet for 7 days, and then randomly assigned to either the control diet 
group, with continued free access to the nutritionally complete diet, or the (- )leu 
diet group, with free access to the diet devoid of the essential amino acid 
leucine for 7 days. Food intake and body weight were recorded at least every 
two days 
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5.2 Low	  protein	  diet	  
The Control Diet (CD) and Low Protein Diet (LPD) were obtained from 
Research Diets, Inc. Both diets were isocaloric. They had the following 
composition (in percentage of mass): 20% protein, 66% carbohydrates and 5% 
fat for the CD, and 5% protein, 81% carbohydrates and 5% fat for the LPD 
(detailed composition shown in Annex 1). For the feeding experiment, 8-week-
old male mice were first fed the CD for 7 days and then randomly assigned to 
either the CD or LPD group with free access to food and water for 7 days. Food 
intake and body weight were recorded daily. 
5.3 Pair-­‐feeding	  
To compensate the reduction in food intake caused by leucine-deficient diet, in 
some experiments, a control pair-fed group was included. Food intake of mice 
on leucine-deficient diet was measured every day. Control pair-fed group was 
caged individually and administered the exact amount of food that leucine-
deprived mice ingested the previous day. 
5.4 Fasting	  
Animals were fasted for 15 hours. At 20:00h (Zeitgeber Time 12) mice were 
moved to new cages and food was removed while water was maintained at 
libitum. At 11:00 (Zeitgeber Time 3) mice were euthanized, tissues were 
isolated and immediately snap-frozen and stored at −80°C for future analysis. 
5.5 Food	  intake	  measurement	  
Animals were distributed in 2-3 mice per cage. Food was daily weighted with a 
tabletop scale measured to the closest 0.1 g and restocked during 7 days. Food 
intake was assumed to be the same for every mouse in the cage.  
6 GLUCOSE	  TOLERANCE	  TEST	  (GTT)	  PROTOCOL	  
GTT was carried out on Fgf21 liver specific knockout or Fgf21loxP mice, aged 8 
weeks and maintained for 7 days on either CD or LPD. 
To perform the GTT the following protocol was performed: 
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Material 
• filter-sterilized glucose solution 10%(w/v)
• glucometer and strips Ascencia Elite XL (Bayer)
• razor blades
• timer
• glucose solution 10% (w/v)
Preparation 
Mice were fasted for 6h [from 08:00h (Zeitgeber Time 0) to 14:00h (Zeitgeber 
Time 6)]. Mice were transferred to clean cages with new clean bottles of water 
but not food. Before starting the fast, each mouse was weighted (weight 
determines the amount of glucose to inject) and their tails marked in the order 
of injection. Glucose solution was freshly prepared before the beginning of the 
procedure. 
Glucose solution 10%(w/v):  9mL H2O + 1g D-glucose (then add H2O 
to have 10mL). 
Mice were located at the experimentation room at least 30 minutes before the 
beginning of the protocol. 
Method 
To obtain baseline blood glucose, the tail was nicked with a fresh razor blade by 
a horizontal cut of the very end, and measured using a glucometer. Each 
mouse was injected intraperitoneally (ip) with a filter-sterilized solution of D-
glucose, with the size of the bolus determined by animal weight (1.5 mg 
glucose/g body weight). At 30. 60. 90 and 120 min blood glucose was sampled 
from the tail of each mouse by gently massaging a small drop of blood onto the 
glucometer strip. Glucose injections and blood glucose sampling were timed to 
take approximately the same amount of time per animal, so that the samples 
time were accurate for each animal. The data were plotted as blood glucose 
concentration (mg/dL) over time (min) and as the area under the curve (AUC) of 
the % of basal glucose calculated by the trapezoidal rule. 
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7 INSULIN	  TOLERANCE	  TEST	  (ITT)	  PROTOCOL	  
ITT was carried out on Fgf21 liver specific knockout or Fgf21loxP mice, aged 8 
weeks and maintained for 10 days on either CD or LPD. 
To perform the ITT the following protocol was performed: 
Material 
• Filter-sterilized insulin solution 0.05 I.U/ml
• Glucometer and strips Ascencia Elite XL (Bayer)
• Razor blades
• Timer
Preparation 
Mice were fasted for 6h [from 08:00h (Zeitgeber Time 0) to 14:00h (Zeitgeber 
Time 6)]. Mice were transferred to clean cages with new clean bottles of water 
but not food. Before starting the fast, each mouse was weighted (weight 
determines the amount of insulin to inject) and their tails marked in the order of 
injection. Insulin solution was freshly prepared before the beginning of the 
procedure. 
Mice were located at the experimentation room at least 30 minutes before the 
beginning of the protocol. 
Method 
To obtain baseline blood glucose, the tail was nicked with a fresh razor blade by 
a horizontal cut of the very end, and measured using a glucometer. Each 
mouse was injected intraperitoneally (ip) with a filter-sterilized insulin solution, 
with the size of the bolus determined by animal weight (0.75 I.U insulin/kg body 
weight). At 30. 60 and 90 minutes blood glucose was sampled from the tail of 
each mouse by gently massaging a small drop of blood onto the glucometer 
strip. Insulin injections and blood glucose sampling were timed to take 
approximately the same amount of time per animal, so that the samples time 
were accurate for each animal. The data were plotted as blood glucose 
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concentration (mg/dL) over time (min) and as the inverted area under the curve 
below baseline glucose calculated by the trapezoidal rule.  
8 β-­‐ADRENOCEPTOR	  ANTAGONISM	  (PROPRANOLOL	  TREATMENT)	  
For the β-adrenergic blockade experiment, 8-week-old male mice were first 
daily i.p. injected with saline solution and fed the CD for 7 days. Then, mice 
were randomly assigned to either the CD or LPD group and given daily ip 
injections with ((s)-(-) propranolol hydrochloride; Sigma) at 5 mg/kg·d or saline 
vehicle alone for 7 more days. Food intake and body weight were recorded 
daily. 
9 TISSUES	  HARVESTING	  
Animals were anesthetized by isoflurane inhalation (4% for induction and 2% for 
maintenance), the thoracic cavity was opened and blood was collected from 
heart by intracardiac puncture. Then, blood was prepared for serum or plasma 
extraction. After sacrifice, tissues were isolated and immediately snap frozen 
and stored at -80ºC for future analysis. 
9.1 Serum	  extraction	  
Mouse serum was obtained by clotting whole blood (30 min, RT) and posterior 
centrifugation (1500G, 15 min, 4ºC). Serums were stored at -80°C for posterior 
analysis. 
9.2 Plasma	  extraction	  
Mouse plasma samples were obtained by centrifuging (1500G, 15 min, 4ºC) 
whole blood collected in EDTA-treated tube. The plasma was stored at −80°C 
for posterior analysis. 
10 PLASMA/SERUM	  MEASUREMENTS	  
10.1 Plasma	  free	  fatty	  acids	  (FFA)	  measurement	  
Free fatty acids (non-esterified fatty acids, NEFA) were determined in mice 
serum by an enzymatic colorimetric assay. The Free fatty acids, Half-micro test 
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was obtained from Roche. The measure was performed according to the 
manufactures’ instructions. Briefly, Free fatty acids are converted to Acyl-
Coenzyme A, AMP and pyrophosphate in the presence of acyl-CoA synthetase. 
Acyl-CoA reacts with oxigen in the presence of acyl-CoA oxidase to form 2,3-
enoyl-coenzyme A. The resulting hydrogen peroxide converts TBHB and 4-AA 
to a red dye in the presence of peroxidase. The dye is measured in the visible 
wavelenght range at 546nm.  
10.2 FGF21	  analysis	  
Mouse FGF21 enzyme-linked immunosorbent assay (ELISA) kit was obtained 
from Millipore for the quantification of FGF21 in mice serum. The assay was 
conducted according to the manufacturer's protocol.  
Briefly, FGF-21 molecules from samples were captured to the wells of a 
microtiter plate coated with a polyclonal goat anti-FGF-21 antibody, a second 
biotinylated polyclonal goat anti-FGF-21 antibody bound to the captured 
molecules. After washing, streptavidin-horseradish peroxidase conjugate bound 
to the immobilized biotinylated antibodies. After washing the excess of free 
enzyme conjugates, quantification of immobilized antibody-enzyme conjugates 
was performed by monitoring horseradish peroxidase activities in the presence 
of the substrate 3,3’,5,5’-tetramethylbenzidine. A calibration curve was 
constructed by plotting the difference of absorbance values at 450 and 590nm 
versus the FGF21 concentrations of the calibrators, and concentrations of 
unknown samples (performed in duplicate) were determined by using this 
calibration curve. 
10.3 Adiponectine	  measurement	  
Mouse adiponectine enzyme-linked immunosorbent assay (ELISA) kit was 
obtained from Millipore for the quantification of adiponectine in mice serum. The 
assay was conducted according to the manufacturer's protocol. The principle of 
procedure is the same as the abovementioned FGF21 ELISA kit.  
Briefly, a calibration curve was constructed by plotting the difference of 
absorbance values at 450 and 590nm versus the adiponectine concentrations 
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of the calibrators, and concentrations of unknown samples (performed in 
duplicate) were determined by using this calibration curve. 
10.4 Free	  T3	  measurement	  
Free T3 ELISA kit was obtained from Abnova for the quantification of free T3 in 
mice plasma. The assay was conducted according to the manufacturer's 
protocol.  
Tested specimen is placed into the microwells coated by specific rabbit 
polyclonal to T3-antibodies simultaneously with conjugated fT3-peroxidase. fT3 
from the specimen competes with the conjugated fT3 for coating antibodies. 
After washing procedure, the remaining enzymatic activity bound to the 
microwell surface is detected and quantified by addition of chromogen-substrate 
mixture, stop solution and photometry at 450 nm. Optical density in the 
microwell is inversely related to the quantity of the measured analyte in the 
specimen. A calibration curve was constructed by plotting the absorbance 
values at 450nm versus the free T3 concentrations of the calibrators. 
Concentrations of unknown samples (performed in duplicate) were determined 
by using this calibration curve. 
10.5 ACTH	  measurement	  
The ACTH (Mouse/Rat) ELISA Kit was obtained from Abnova for the 
quantification of ACTH in mice plasma. It is a two-site lumELISA for the 
measurement of the biologically active 39 amino acid chain of ACTH. A goat 
polyclonal antibody to ACTH, and a mouse monoclonal antibody to ACTH are 
specific for well-defined regions on the ACTH molecule. One antibody is 
prepared to bind only the C-terminal ACTH 34-39 and this antibody is 
biotinylated. The other antibody is prepared to bind only the mid-region and N-
terminal ACTH 1-24 and this antibody is labeled with horseradish peroxidase for 
detection. Calibrators, controls, or samples are simultaneously incubated with 
the enzyme labeled antibody and a biotin coupled antibody in a streptavidin-
coated microplate well. At the end of the assay incubation, the microwell is 
washed to remove unbound components. Upon the addition of the luminol 
substrate, the enzyme activity in the enzyme-bound fraction is directly 
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proportional to the concentration of the ACTH in the sample. A calibration curve 
was constructed by plotting the relative light units (RLU) after 10 seconds of 
integration versus the ACTH concentrations of the calibrators. Concentrations of 
unknown samples (performed in duplicate) were determined by using this 
calibration curve. 
10.6 Noradrenaline	  measurement	  
Epinephrine/Norepinephrine ELISA kit was obtained from Abnova for the 
quantification of norepinephrine in mice plasma. Noradrenaline (norepinephrine) 
is extracted by using a cis-diol-specific affinity gel, then acylated and then 
converted enzymatically. 
The competitive ELISA kit uses the microtiter plate format. The antigen 
(coverted noradrenaline) is bound to the solid phase of the microtiter plate. The 
solid phase bound analytes compete for a fixed number of antibody binding 
sites. After the system is in equilibrium, free antigen and free antigen-antibody 
complexes are removed by washing. The antibody bound to the solid phase is 
detected by an anti-rabbit IgG-peroxidase conjugate using TMB as a substrate.  
A calibration curve is constructed by plotting the absorbance values at 450nm 
versus the noradrenaline concentrations of the calibrators. Concentrations of 
unknown samples and controls (performed in duplicate) were determined by 
using this calibration curve. 
11 HISTOLOGICAL	  EXAMINATIONS	  
For the histological analysis, a little piece of each fresh tissue (liver and 
epididymal WAT) was cut and fixed in 10% formalin (Sigma-Aldrich) at 4°C o/n 
and processed for embedding in paraffin. Subsequent processing was 
performed by the Pathology Department of the Hospital Clinic of Barcelona. 
Four-micrometer-thick sections were obtained and stained with hematoxylin and 
eosin (H&E) and examined at 20X magnification. Images of adipose tissue were 
analyzed to establish cell size, and of liver to determine fat accumulation. At 
least 10 random and independent fields were acquired from each individual 
mouse tissue staining, using a Leica CTR 4000 microscope with the Leica 
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Application Suite Version 2.7.OR1 software. Quantitative data were obtained 
using the IMAT program developed in the Science and Technology Center of 
the University of Barcelona (CCIT-UB). The selection of the test objects has 
been performed according to color and choosing the same limits for binarization 
for all images. 
OTHER	  
1 HUMAN	  SAMPLES	  
We used plasma samples from 78 participants randomly selected from the 
nodes of the Hospital Clinic (Barcelona) and Reus (Tarragona) and included in 
the PREDIMED trial. This was a 5-year randomized clinical trial to compare the 
effects of either a Mediterranean diet supplemented with extra virgin olive oil or 
nuts versus a low-fat control diet. A total of 7447 asymptomatic men but at high 
cardiovascular risk (aged 55–80 years) and women (aged 60–80 years) were 
recruited. All participants had type 2 diabetes or three or more cardiovascular 
risk factors. Details of the recruitment method and study design have been 
described elsewhere (Estruch et al. 2013) and are also available at 
www.predimed.es. In addition to the plasma samples, we also gathered 
information from these 78 individuals, including a 137-item semi-quantitative 
food frequency questionnaire (FFQ), and a general questionnaire that provided 
data on lifestyle habits, concurrent diseases, anthropometry, and medication 
use. Total energy intake and nutrient intake were calculated on the basis of 
Spanish food composition tables (Mataix Verdú 2003). The study protocol was 
approved by the institutional review boards of the participating centers 
(ISRCTN35739639).  
2 STATISTICAL	  ANALYSIS	  
For human samples, baseline characteristics are presented as means ± 
standard error of the mean (SEM) for continuous variables, frequencies and 
percentages for categorical variables across quartiles of protein intake at 
baseline. Differences between quartiles were tested by a 1-factor ANOVA test 
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for continuous variables and by the chi-square test for the categorical ones. We 
performed multiple linear regressions to evaluate the relationship between 
protein intake (exposure variable) and FGF21 hormone levels (dependent 
variable). Protein intake was previously adjusted for calories using the residual 
method. Regression analyses were unadjusted (model 1) or adjusted by body 
mass index (BMI) and total energy intake (model 2) 
All statistical analyses were conducted using SAS software, version 9.3 (SAS 
Institute, Inc.). All t tests were 2-sided and P values below 0.05 were considered 
statistically significant. 
3 INFORMATION	  TECHNOLOGIC	  TOOLS	  
Entrez-Pubmed, National Center for Biotechnology Information (NCBI, USA) -
http://www.ncbi.nlm.nih.gov/pubmed/  
Basic Local Alignment Search Tool (BLAST), National Center for Biotechnology 
Information (NCBI, USA) - http://blast.ncbi.nlm.nih.gov/Blast.cgi 
Webcutter 2.0 - http://bio.lundberg.gu.se/cutter2/ 
Primer3 (v. 0.4.0) - http://frodo.wi.mit.edu/primer3/ 
PROMO (ver 8.3) - 
http://alggen.lsi.upc.es/cgibin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3 
UCSC Genome Browser - https://genome.ucsc.edu 
4 ADDITIONAL	  INFORMATION	  
Any missing information regarding the experimental procedures, which also cannot be 
found in the ANNEX, means that the procedure was performed according to the 
detailed information given by “Molecular Cloning, a Laboratory Manual” (Sambrook, 
Fritsch and Maniatis) and/or “Current Protocols in Molecular Biology” (Ausubel, Bent, 
Kingston, Moore, Seidman, Smith and Struhl), or following the protocols provided in the 
instructions of the commercial kits used. 
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RESULTS	  

THE	   ROLE	   OF	   REV-­‐ERBα 	   IN	   THE	   INDUCTION	   OF	   FGF21	   UPON	  
LEUCINE	  DEPRIVATION
Rev-erbα is a core component of the molecular clock and a transcriptional 
repressor (Harding & Lazar 1995). It is highly expressed in the liver, skeletal 
muscle, adipose tissue, and brain, repressing many genes in order to regulate 
metabolism in a circadian rhythm. 
Given that Rev-erbα links the circadian clock to liver metabolism (Zhang et al. 
2016), that FGF21 levels inversely correlate with the expression pattern of REV-
ERBα and ALAS-1 in liver (Kaasik & Lee 2004; Oishi et al. 2008) and that PGC-
1α negatively regulates hepatic Fgf21 expression by modulating the heme/Rev-
erbα axis (Estall et al. 2009), we hypothesised that Rev-erbα participates in the 
regulation of Fgf21 during amino acid deprivation. 
Moreover, the analysis of the ChIP-seq results from Mitchell Lazar’s group 
(Figure R0) points to an indirect binding of Rev-erbα to DNA regions containing 
AARE1 and AARE 2 of the Fgf21 promoter, thus presenting the interesting idea 
of competition between the activator ATF4 and the repressor Rev-erbα for the 
occupancy of this promoter. The putative tethering factor CEBPβ (Zhang et al. 
2015) also binds to the DNA region enriched by Rev-erbα immunoprecipitation. 
Figure	   R	   0	   Analysis	   of	   ChIP-­‐seq	   results	   from	   Mitchell	   Lazar’s	   group	   (GSM1659686).	   Sequences	  
enrichment	   after	   immunoprecipitation	   of	   Rev-­‐erbα	   is	   shown	   in	   green.	  WT:	   liver	   of	   C57BL/6J	   mouse.	  
129mice:	   liver	  of	  129S1/SvlmJ	  mouse.	  DBDmut:	   liver	  of	  C57BL/6J	  Rev-­‐erbα	  DNA	  binding	  domain	  (DBD)	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mutant	   mouse.	   Fgf21	   gene	   representation	   is	   shown	   in	   blue.	   Sequences	   enrichment	   after	  
immunoprecipitation	  of	  CEBPβ	  in	  C2C12	  cells	  is	  shown	  in	  brown	  (from	  Caltech	  TFBS	  database).	  
All together, these considerations led us to address the role of Rev-erbα in the 
regulation of Fgf21 during amino acid deprivation. 
1 Rev-­‐erbα	   and	   Fgf21	   expression	   is	   negatively	   correlated	   across	  
various	  nutritional	  states	  and	  different	  tissues	  
To address the contribution of Rev-erbα to the regulation of Fgf21, wild-type 
mice were challenged with nutritional conditions known to increase the 
expression of this gene, namely leucine deprivation (De Sousa-Coelho et al. 
2012), fasting (Lundåsen et al. 2007) or both. mRNA levels of Fgf21 and Rev-
erbα, as well as of other factors involved in the Heme/Rev-erbα axis, were 
analysed. 
1.1 Fgf21	  is	  repressed	  by	  fasting	  in	  mice	  fed	  a	  leucine-­‐deficient	  diet	  
First, we analysed FGF21 serum concentration of mice administered ad libitum 
a control diet (Ctl) or a leucine-deficient diet ((-)leu) for 7 days. Two other 
groups on the Ctl or (-)leu diet were fasted 15 h before sacrifice.  
Figure	  R	  1	  FGF21	  Expression	  under	  a	   leucine-­‐deficient	  diet	   is	  differentially	   induced	   in	  the	  fed	  and	   in	  
the	  fasted	  state.	  Serum	  FGF21	  protein	  concentrations	  were	  measured	  by	  ELISA	  (A).	  Fgf21	  mRNA	  in	  liver	  
was	   measured	   by	   qRT-­‐PCR	   (B).	   Error	   bars	   represent	   the	   mean	   ±	   standard	   error	   of	   the	   mean	   (SEM)	  
*p<0.05	  **p<0.01	  versus	  Ctl	  ad	  libitum;	  #p<0.05,	  #	  #	  p<0.01	  versus	  (-­‐)leu	  ad	  libitum	  (n=6/group).
As previously described, fasting caused an increase in FGF21 serum 
concentration (Inagaki et al. 2007) and leucine deprivation strikingly did it too 
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(De Sousa-Coelho et al. 2012). However, surprisingly, when leucine-deprived 
animals were fasted, FGF21 serum concentrations were significantly lower than 
in leucine-deprived animals fed ad libitum. The addition of two conditions known 
to increase Fgf21 expression, namely, leucine deprivation and fasting, did not 
increase FGF21 levels but rather decreased them (Figure R1A). Fgf21 mRNA 
levels in liver accurately paralleled FGF21 serum levels (Figure R1B). The 
weaker induction of Fgf21 in fasted leucine-deprived mice led us to study the 
role of the transcriptional repressor Rev-erbα in these conditions.   
1.2 mRNA	  levels	  of	  factors	  involved	  in	  the	  heme/Rev-­‐erbα	  axis	  in	  liver	  of	  leucine-­‐
deprived	  and	  fasted	  mice	  
To analyse the role of Rev-erbα during fasting and leucine deprivation, we 
measured the expression of Rev-erbα and the factors involved in its activity.  
Figure	  R	   2	  Rev-­‐erbα	   is	   downregulated	  by	   leucine	   deprivation	   and	  upregulated	  by	   fasting.	  Rev-­‐erbα,	  
Alas1,	  Cebpβ	  and	  Pgc-­‐1α	  mRNA	  in	  liver	  was	  measured	  by	  qRT-­‐PCR	  (B).	  Error	  bars	  represent	  the	  mean	  ±	  
standard	   error	   of	   the	   mean	   (SEM)	   *	   p<0.05,	   **	   p<0.01,	   ***p<0.001	   versus	   Ctl	   ad	   libitum;	   #,p<0.05;	  
#	  #	  p<0.01	  versus	  ,	  #	  #	  #	  p<0.001	  versus	  (-­‐)leu	  ad	  libitum	  (n=6/group).	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Analysis of hepatic mRNA levels showed that Rev-erbα expression was 
repressed by leucine deprivation and increased by fasting (Figure R2A). The 
expression of Alas1, (the rate-limiting enzyme of the biosynthesis of the Rev-
erbα ligand, heme) increased in response to fasting in both dietary groups 
(Figure R2B), while the expression of the putative tethering factor Cebpβ  
remained unchanged between conditions (Figure R2C). Finally, Pgc-1α, which 
positively regulates Rev-erbα and Alas1, was increased by fasting in mice on 
both diets, but the induction was much higher in leucine-deprived animals 
(Figure R2D).  
These results reveal a negative correlation between Fgf21 expression and the 
heme/Rev-erbα axis. In mouse liver, leucine deprivation causes the 
upregulation of Fgf21 and the downregulation of Rev-erbα. When leucine-
deprived mice were fasted, Rev-erbα and Alas1 increased, resulting in the 
blunted upregulation of Fgf21.  
1.3 Fgf21	   is	   downregulated	   and	   Rev-­‐erbα	   is	   upregulated	   in	   eWAT	   of	   leucine-­‐
deprived	  mice	  
We also checked whether the negative correlation between Fgf21 and Rev-erbα 
mRNA level observed under leucine deprivation was translatable to other 
Fgf21-expressing tissues such as eWAT. 
Figure	  R	  3	  Fgf21	  and	  Rev-­‐erbα	  expression	  in	  eWAT	  of	  leucine-­‐deprived	  mice.	  Rev-­‐erbα	  and	  Fgf21	  
mRNA	  in	  liver	  was	  measured	  by	  qRT-­‐PCR	  (B).	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  
mean	  (SEM)	  *	  p<0.05	  Ctl	  diet;	  (n=6/group).	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Contrary to liver, leucine deprivation caused a decrease in Fgf21 expression in 
eWAT. Consistent with its role as a repressor, Rev-erbα mRNA levels tended to 
increase (p= 0,17) in response to leucine deficiency. (Figure R3) 
These results, together with the abovementioned data (Figure R1, R2), show a 
consistent negative correlation between Fgf21 and Rev-erbα expression across 
tissues and nutritional states.  
2 Rev-­‐erbα	  represses	  Fgf21	  promoter	  activity	  
Given the negative correlation between expression patterns of Fgf21 and Rev-
erbα and the published data suggesting that Rev-erbα regulates Fgf21 (Estall et 
al. 2009; Archer et al. 2012), we studied the effect of Rev-erbα on the FGF21 
promoter. 
2.1 Inhibition	  of	  Rev-­‐erbα	  increases	  FGF21	  promoter	  activity	  
To imitate the leucine deprivation state in the liver, AML12 cells were transiently 
co-transfected with the reporter construction pGL3b-hFGF21 (-768/+115 of the 
human FGF21) and an ATF4 expression plasmid. Rev-erbα activity was 
inhibited by treating the cells with its synthetic antagonist SR8278. 
Figure	  R	  4	  Rev-­‐erbα 	   antagonism	  enhances	  ATF4	  activation	  of	   FGF21	  promoter.	  Luciferase	  activity	  of	  
the	  human	  FGF21	   promoter	   reporter	   construct	   co–transfected	  with	  an	  expression	  plasmid	   for	  human	  
ATF4	   in	   the	  presence	  or	   absence	  of	   the	  Rev-­‐erbα	   antagonist	   SR8278	   (10μM).	  Data	   are	  means	   ±	   SEM	  
from	   three	   independent	   experiments	   with	   two	   plates	   each.	   **p<0.01,	   ***p<0.001	   versus	   reporter	  
construction	   treated	   with	   vehicle.	   #	   p<0.05	   versus	   reporter	   construction	   cotransfected	   with	   ATF4	  
treated	  with	  vehicle.	  
As previously reported by our group (De Sousa-Coelho et al. 2012), the 
transcriptional activity of the FGF21 promoter increased in the presence of 
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ATF4. Remarkably, the inhibition of the endogenous Rev-erbα protein by 
SR8278 enhanced the activation induced by ATF4. This result is consistent with 
the analysis of the mRNA levels, suggesting that a decrease in Rev-erbα 
activity enhances the ATF4-mediated upregulation of Fgf21. 
2.2 CEBPβ 	  represses	  Fgf21	  promoter	  activity	  
We next co-transfected the Fgf21 promoter with expression plasmids for the 
activator ATF4, the repressor Rev-erbα and the tethering factor CEBPβ.  
Figure	   R	   5	   CEBPβ	   blocks	   ATF4	   activation	   of	   Fgf21	   promoter.	   Luciferase	   activity	   of	   the	  mouse	   Fgf21	  
promoter	  reporter	  constructs	  co–transfected	  with	  an	  expression	  plasmid	  for	  human	  ATF4,	  Rev-­‐erbα	  or	  
Cebpβ	  as	  indicated.	  Data	  are	  means	  ±	  SEM	  from	  three	  independent	  experiments	  with	  two	  plates	  each.	  
**p<0.01,	   versus	   reporter	   construction	   alone.	   #	   p<0.05,	   #	   #	   p<0.05	   versus	   reporter	   construction	  
cotransfected	  with	  ATF4.	  
The single addition of Rev-erbα did not alter the activation induced by ATF4. 
However, when Rev-erbα was cotransfected with Cebpβ, the activation of the 
promoter decreased dramatically. This effect occurred independently of the 
presence of Rev-erbα. A feasible explanation for this observation is that CEBPβ 
repress the promoter by thethering the endogenous Rev-erbα protein of the 
cells. 
3 EGR-­‐1	  represses	  Rev-­‐erbα	  promoter	  activity	  
Rev-erbα is downregulated in mouse liver during leucine deprivation, and this 
effect correlates with the upregulated expression of Fgf21 (Figures R1, R2). 
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During leucine deprivation, early growth response protein 1 (Egr-1) is highly 
induced in cultured cells in a partially Gcn2 dependent manner (Deval et al. 
2009), and this observation is consistent with our results showing an induction 
of Egr-1 in liver of leucine-deprived mice (Figure R6A). In addition, Egr-1 can 
act as a transcriptional repressor by competing with specific protein 1 (Sp1) for 
its binding elements. Consequently, we hypothesised that Egr-1 is responsible 
for the downregulation of Rev-erbα during amino acid deprivation. 
To study the possible effect of EGR-1 on Rev-erbα expression, we co-
transfected AML12 cells with a reporter plasmid containing 1022pb (-393/+629) 
of the mouse promoter and increasing amounts of an Egr-1 expression plasmid. 
Figure	  R	  6	  Egr-­‐1	   is	   induced	  by	   leucine	  deprivation	   in	   liver	  and	  EGR-­‐1	  diminishes	  Rev-­‐erbα 	  promoter	  
activity.	  Egr-­‐1	  mRNA	  in	   liver	  was	  measured	  by	  qRT-­‐PCR	  (A).	  Error	  bars	  represent	  the	  mean	  ±	  standard	  
error	  of	  the	  mean	  (SEM)	  *	  p<0.05	  versus	  Ctl	  diet;	  (n=6/group).	  Luciferase	  activity	  of	  the	  mouse	  Rev-­‐erbα	  
promoter	  reporter	  construct	  co–transfected	  with	  various	  amounts	  of	  an	  expression	  plasmid	  for	  rat	  Egr-­‐1	  
(B).	  Data	  are	  means	  ±	  SEM	  from	  three	  independent	  experiments	  with	  two	  plates	  each.	  *p<0.05,	  versus	  
reporter	  construction	  alone.	  
When the reporter construction was cotransfected with 250 or 500 ng of the 
Egr-1 expression plasmid, the activity of the promoter was significantly lower 
(Figure R6B). This finding proposes EGR-1 as a possible effector of the Rev-
erbα repression under leucine deprivation. 
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THE	  ROLE	  OF	  FGF21	   IN	  THE	  METABOLIC	  RESPONSE	  TO	   LEUCINE	  
DEPRIVATION
The coincidence between the metabolic response to essential amino acid 
deprivation and to FGF21, the induction of Fgf21 under amino acid deprivation 
(De Sousa-Coelho et al. 2012), together with the repression of the transcription 
and maturation of sterol regulatory element binding protein (SREBP) 1c induced 
by FGF21 in HepG2 cells (Zhang et al. 2011), led us to consider that FGF21 
could be an important mediator between amino acid deprivation and lipid 
metabolism in liver, WAT and BAT.  
To investigate this hypothesis, we examined the response of FGF21-deficient 
mice to deprivation of the essential amino acid leucine. 
1 FGF21	  gene	  expression	  is	  induced	  by	  leucine	  deprivation	  specifically	  
in	  liver	  but	  not	  BAT	  or	  WAT	  
Figure	  L	  1.	   	  FGF21	   is	  differently	   regulated	  by	   leucine	  deprivation	   in	   liver	  and	  adipose	  tissues.	  Serum	  
FGF21	   protein	   concentrations	  were	  measured	   by	   ELISA	   (A).	  Fgf21	  mRNA	   in	   BAT,	   eWAT	   and	   liver	  was	  
measured	  by	  qRT-­‐PCR	  (B).	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  mean	  (SEM)	  a,	  p<0.05	  
versus	  Ctl	  WT;	  b,	  p<0.05	  versus	  Ctl	  FGF21-­‐KO;	  c,	  p<0.05	  versus	  (-­‐)leu	  WT	  (n=6/group).	  
According to our previously reported results (De Sousa-Coelho et al. 2012), 
mice maintained on a leucine-deficient diet showed a dramatic increase in 
FGF21 circulating levels (Figure L1A). To check the origin of this circulating 
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FGF21 we analysed Fgf21 gene expression in several tissues. Consistent with 
the liver as the main site of FGF21 production and release into the blood, Fgf21 
mRNA levels in liver paralleled those in serum, whereas mRNA levels were 
unchanged in BAT and, unexpectedly, significantly decreased in epididymal (e) 
WAT in wild-type mice maintained on a (-)leu diet (Figure L1B). As expected, 
Fgf21 mRNA levels were undetectable in any analysed tissue in the FGF21-KO 
mice. According with previous reports (Badman et al. 2009), the circulating 
levels of FGF21 in knockout mice were below the threshold for correct 
quantification. 
2 FGF21	  deficiency	  significantly	  attenuates	  weight	  loss	  under	  leucine	  
deprivation	  
When fed a leucine-deprived diet, mice undergo rapid weight loss (Cheng et al. 
2009). The goal of the present study is to investigate whether this phenomenon 
is FGF21-dependent. For this purpose, wild-type and FGF21-KO mice were fed 
a control or leucine-deficient diet for 7 days. 
2.1 Total	  body	  weight	  after	  7	  days	  on	  a	  leucine-­‐deficient	  diet	  	  
Figure	  L	  2.	  FGF21	  is	  required	  for	  leucine-­‐deficient	  diet	  effects	  on	  body	  weight.	  Body	  weight	  of	  mice	  fed	  
with	  Ctl	   or	   (-­‐)leu	  diet	   (A).	   The	  weight	  on	   the	   first	  day	  was	   considered	  100%.	  Body	  weight	   change	   (%)	  
after	  7	  days	  of	  feeding	  the	  Ctl	  or	  (-­‐)leu	  diet	  (B).	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  
mean	   (SEM).	   a,	   p<0.05	   versus	   Ctl	   WT;	   b,	   p<0.05	   versus	   Ctl	   FGF21-­‐KO;	   c,	   p<0.05	   versus	   (-­‐)leu	   WT	  
(n=6/group).	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Accordingly to previous reports, mice on a leucine-deficient diet experienced a 
drastic weight loss. Fgf21 deficiency modestly reduced weight loss from 17% of 
total body weight to 11% indicating that FGF21 is partially responsible for the 
weight loss under leucine deprivation.  
2.2 Tissue	  weight	  after	  7	  days	  on	  a	  leucine-­‐deficient	  diet	  
To better understand the contribution of each tissue to the total body weight 
loss, BAT, eWAT, scWAT and liver weight were analysed. 
Figure	  L	  3.	  FGF21	  is	  required	  for	  leucine-­‐deficient	  diet	  effects	  on	  eWAT,	  scWAT	  and	  liver	  weight.	  BAT,	  
eWAT	  and	  scWAT	  weight	  of	  mice	  fed	  with	  Ctl	  or	  (-­‐)leu	  diet	  related	  to	  100	  mg	  of	  body	  weight	  (A).	  Liver	  
weight	  of	  mice	  fed	  with	  Ctl	  or	  (-­‐)leu	  diet	  related	  to	  100	  mg	  of	  body	  weight	  (B).	  Error	  bars	  represent	  the	  
mean	  ±	  standard	  error	  of	   the	  mean	  (SEM).	  a,	  p<0.05	  versus	  Ctl	  WT;	  b,	  p<0.05	  versus	  Ctl	  FGF21-­‐KO;	  c,	  
p<0.05	  versus	  (-­‐)leu	  WT	  (n=6/group).	  
Together with total body weight loss, mice fed a leucine-deprived diet 
underwent a fat mass loss, both epididymal and subcutaneous. Liver showed 
the same tendency although didn’t reach statistical significance (Figure L3). We 
found that these effects were partially blunted in FGF21-KO mice 
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2.3 Food	  intake	  of	  mice	  fed	  a	  leucine-­‐deficient	  diet	  
Figure	  L	  4.	  FGF21	  is	  not	  responsible	  for	  reduced	  food	  intake	  in	  leucine-­‐deprived	  mice.	  Food	  intake	  was	  
recorded	  daily	   for	   seven	  days.	   Error	  bars	   represent	   the	  mean	  ±	   standard	  error	  of	   the	  mean	   (SEM).	   a,	  
p<0.05	  versus	  Ctl	  WT;	  b,	  p<0.05	  versus	  Ctl	  FGF21-­‐KO;	  (n=6/group).	  
The reduction in food intake caused by leucine deprivation (~30%), which is 
partially responsible for the body weight loss, was unchanged between 
genotypes (Figure L4). This result suggests that Fgf21 is not involved in the 
food aversion caused by a leucine-deficient diet. 
3 FGF21	  deficiency	  prevents	  changes	  in	  WAT	  of	  leucine-­‐deprived	  mice	  
The reported observation that white adipocytes from FGF21 transgenic mice 
are substantially smaller than those from wild-type mice (Inagaki et al. 2007; 
Kharitonenkov et al. 2005), and that leucine deprivation decreases adipocyte 
volume (Cheng et al. 2009), together with the abovementioned partially FGF21-
dependent weight loss of WAT in mice fed a leucine-deficient diet (FigureL3), 
led us to examine whether this effect was mediated by FGF21. 
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3.1 FGF21	  mediates	  the	  reduction	  of	  adipocytes	  size	  upon	  leucine	  deficiency	  
Figure	   L	   5.	   Leucine-­‐deficient	   diet	   effects	   on	   adipocyte	   size	   are	   FGF21-­‐dependent.	   Representative	  
hematoxylin	  and	  eosin	  (H&E)-­‐stained	  eWAT	  sections	  from	  WT	  and	  FGF21-­‐KO	  mice	  (×20	  magnification).	  
Scale	  bar,	  50	  mM	  (A).	  Adipocyte	  size	  was	  measured	  by	  IMAT	  programme	  ,	  using	  at	  least	  three	  different	  
randomly	  chosen	  fields	  of	  eWAT	  sections	  from	  each	  mouse.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  
error	  of	  the	  mean	  (SEM).	  a,	  p<0.05	  versus	  Ctl	  WT;	  b,	  p<0.05	  versus	  Ctl	  FGF21-­‐KO;	  c,	  p<0.05	  versus	  (-­‐)leu	  
WT	  (n=6/group).	  
The histological analysis of eWAT showed that leucine deprivation resulted in a 
reduction in adipocyte volume compared with mice fed a control diet. By 
contrast, the adipocyte volume was only slightly reduced in (-)leu-fed FGF21-
KO animals and remained unchanged in FGF21-KO mice on the control diet 
(Figure L5A). We note that other groups reported increased (Hotta et al. 2009) 
or decreased (Dutchak et al. 2012) adipocyte size in FGF21-KO mice on regular 
diets. 
3.2 FGF21	  mediates	  increased	  lipolysis	  upon	  leucine	  deficiency	  
It has been previously described that leucine deprivation increases lipolysis in 
WAT (Cheng et al. 2010). It has also been suggested that FGF21 stimulates 
lipolysis in WAT during normal feeding, but inhibits it during fasting (Hotta et al. 
2009). Therefore, to examine the role of FGF21 in lipolysis, we evaluated the 
mRNA levels of adipose triglyceride lipase (Atgl), hormone-sensitive lipase 
(Hsl), and perilipin 1(Plin1), and the levels of phosphorylated HSL. 
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3.2.1 Leucine	  deficiency	  doesn’t	  change	  mRNA	  levels	  of	   lipolysis	  related	  genes	   in	  
eWAT.	  
Figure	   L	   6	   .	  mRNA	   levels	  of	   lipolysis-­‐related	  genes	   in	  eWAT.	  Atgl,	  Hsl	  and	  Plin1	  gene	  expression	  was	  
measured	   by	   qRT-­‐PCR	   in	   mice	   eWAT.	   Error	   bars	   represent	   the	   mean	   ±	   standard	   error	   of	   the	   mean	  
(SEM).	  a,	  p<0.05	  versus	  Ctl	  WT;	  b,	  p<0.05	  versus	  Ctl	  FGF21-­‐KO;	  (n=6/group).	  
The analysis of eWAT mRNA levels of Atgl, Hsl and Plin1 did not find any 
statistically significant changes upon leucine deprivation (Figure L6). However, 
HSL activity is mainly modulated by its phosphorylation by protein kinase A 
(PKA). Thus, we next analysed HSL phosphorylation by Western blot.  
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3.2.2 	  Increased	   phosphorylation	   of	   HSL	   under	   leucine	   deprivation	   is	   FGF21	  
dependent	  
Figure	   L	   7.	   FGF21-­‐dependent	   phosphorylation	   of	   HSL	   in	   mice	   fed	   a	   leucine-­‐deficient	   diet.	  
Phosphorylated	  and	  total	  HSL	  protein	   levels	  were	  measured	  in	  WT	  and	  FGF21-­‐KO	  eWAT	  homogenates	  
by	  Western	  blot	  analysis	  (A).	  The	  bottom	  panel	  shows	  quantification	  by	  densitometry	  of	  phosphorylated	  
HSL	  normalized	  to	  total	  HSL,	  using	  Image	  J	  software	  (B).	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  
of	  the	  mean	  (SEM).	  a,	  p<0.05	  versus	  Ctl	  WT;	  c,	  p<0.05	  versus	  (-­‐)leu	  WT	  (n=6/group).	  
Consistent with changes in body weight and adipocytes size, lack of FGF21 
significantly decreased levels of phosphorylated HSL in WAT under leucine 
deprivation (Figure L7), which suggests that lipolysis was impaired in these 
mice. Despite the evidence of increased lipolysis under leucine deprivation, 
levels of free fatty acids in serum were not significantly altered in the conditions 
analysed (Table1, Section 6). This observation suggests increased fatty acid 
utilization by other tissues. 
3.3 FGF21	   mediates	   the	   downregulation	   of	   lipogenesis-­‐related	   genes	   upon	  
leucine	  deficiency	  in	  eWAT	  
As lipogenic genes are downregulated in eWAT of leucine-deprived mice 
(Cheng et al. 2010), we speculated that FGF21 might regulate their expression. 
To investigate this possibility, we examined the expression of genes involved in 
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lipogenesis in eWAT of wild-type and FGF21-KO mice maintained either on Ctl 
or  (-)leu diet. 
Figure	   L	   8.	   mRNA	   levels	   of	   lipogenic	   genes	   in	   eWAT.	   Fasn,	   Srebp1c	   and	  Acc1	   gene	   expression	   was	  
measured	   by	   qRT-­‐PCR	   in	   mice	   eWAT.	   Error	   bars	   represent	   the	   mean	   ±	   standard	   error	   of	   the	   mean	  
(SEM).	  a,	  p<0.05	  versus	  Ctl	  WT;	  c,	  p<0.05	  versus	  (-­‐)leu	  WT	  (n=6/group).	  
As expected, gene expression analysis in eWAT revealed that the mRNA levels 
of the lipogenic genes fatty acid synthase (Fasn), sterol regulatory element-
binding protein 1c (Srebp1c) and acetyl CoA carboxylase 1 (Acc1) were lower in 
this tissue in mice maintained on the (-)leu diet. These changes were blunted in 
the FGF21-KO animals, particularly for Fasn (Figure L8). The analysis of FASN, 
protein abundance showed a good correlation with the gene expression data 
(Figure L9). All together, this data show that FGF21 mediates the impairment of 
lipogenesis in eWAT of leucine-deprived mice.  
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Figure	  L	  9.	  FASN	  protein	  levels	  are	  downregulated	  by	  FGF21	  in	  mice	  on	  a	  leucine-­‐deficient	  diet.	  	  FASN	  
protein	   levels	   were	   detected	   by	   western	   blot	   analysis	   in	   mice	   eWAT	   (A).	   The	   bottom	   panel	   shows	  
quantification	  by	  densitometry	  of	   the	   immunoblotted	  proteins,	  using	   Image	   J	   software	   (B).	   Error	  bars	  
represent	  the	  mean	  ±	  standard	  error	  of	  the	  mean	  (SEM),	  (n=6/group).	  
3.4 Leucine	  deficiency	  induces	  both	  Klb	  and	  Fgf21r1c	  in	  eWAT	  
Given the shocking effects of FGF21 on eWAT of leucine-deprived mice, we 
questioned whether additional mechanisms enhancing FGF21 were acting. 
Consequently, we analysed the expression of the FGF21-receptor Klb and 
Fgfr1.  
Figure	  L	  10	  FgfR1	  and	  Klb	  are	  upregulated	  in	  eWAT	  of	   leucineB deprived	  mice.	  FgfR1	  and	  βt Klotho	  
gene	  expression	  was	  measured	  by	  qRTt PCR	  in	  mice	  eWAT.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  
error	  of the  mean  (SEM).  a,  p<0.05  versus  Ctl  WT;  b,  p<0.05  versus  Ctl  FGF21---KO;  c,  p<0.05  
versus  (---)leu  WT  (n=6/group). 	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Figure	   L	   11.	   Regulation	   of	   lipid	  metabolism	   genes	   by	   FGF21	   in	   3T3L1	   adipocytes.	   The	  expression	  of	  
genes	   related	  with	   lipid	  metabolism	  pathways	  was	  measured	  by	  qRT-­‐PCR	   in	  3T3L1	  adipocytes	   treated	  
with	  recombinant	  FGF21	  (100nM)	  for	  24h.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  mean	  
(SEM).	  a,	  p<0.05	  versus	  Ctl	  (n=3).	  
Consistent with mice results, the expression of the lipogenic genes Fasn, 
Srebp1c, and Acc1 was repressed by FGF21 treatment. In addition, Atgl 
expression was also decreased.  (Figure L11).  
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Leucine deprivation increased Klb and Fgfr1 mRNA levels in both genotypes 
but only reached statistic significance in the FGF21-KO mice (Figures L10). A
compensative mechanism can explain this observation. The components of the 
receptor complex are overexpressed to compensate lack of FGF21 signalling in 
the FGF21-KO animals. 
3.5 Expression	  of	  lipogenic	  and	  lipolytic	  genes	  in	  3T3L1	  treated	  with	  FGF21	  
To further confirm the results obtained in mice, we analysed the expression of
lipid metabolism genes in 3T3L1 cells treated with FGF21.
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3.6 Increased	   FGF21	   expression	   under	   leucine	   deprivation	   do	   not	   affect	  
adiponectin	  circulating	  levels	  
Adipose tissue is not only the main target tissue of FGF21 but also a necessary 
mediator of its actions. Adiponectin secretion by adipocytes mediates the 
effects produced by the pharmacological administration of FGF21, including 
changes in EE, lower blood glucose levels and insulin sensitizing effects 
(Holland et al. 2013; Lin et al. 2013). Given the high levels of FGF21 reached in 
leucine-deprived mice we examined whether adiponectin serum levels were 
changed in this condition. 
Figure	   L	   12.	   Circulating	   Adiponectin	   is	   diminished	   in	   FGF21	   null	   mice.	   	   Serum	   adiponectin	   protein	  
concentrations	  were	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	   the	  mean	  
(SEM).	  c,	  p<0.05	  versus	  (-­‐)leu	  WT	  (n=6/group).	  
Leucine deprivation, and associated increased FGF21 blood levels, did not 
produce changes in adiponectin circulating levels. However, and consistent with 
the role of FGF21 in the regulation of adiponectin secretion, FGF21 deficiency 
decreased serum adiponectin concentration (Figure L12). 
4 FGF21	  deficiency	  prevents	  changes	  in	  liver	  of	  leucine-­‐deprived	  mice	  
4.1 FGF21	   mediates	   the	   downregulation	   of	   lipogenesis-­‐related	   genes	   upon	  
leucine	  deficiency	  in	  liver	  
A link between FGF21 and SREBP1c during lipogenesis in cultured 
hepatocytes has recently been proposed (Zhang et al. 2011). As lipogenic 
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genes are downregulated in liver of mice deprived of leucine (Guo & Cavener 
2007), we speculated that FGF21 might regulate their expression. 
Figure	   L	   13.	   FGF21	   regulation	   of	   of	   lipid	   metabolism	   genes	   in	   liver	   of	   leucine-­‐deprived	   mice.	  
Expression	   of	   genes	   related	   with	   lipid	   handling	   was	  measured	   by	   qRT-­‐PCR	   in	   mouse	   liver.	   a,	   p<0.05	  
versus	  Ctl	  WT;	  b,	  p<0.05	  versus	  Ctl	  FGF21-­‐KO;	  c,	  p<0.05	  versus	  (-­‐)leu	  WT	  (n=6/group).	  
As expected, levels of Fasn, Srebp1c and Acc1 mRNA were significantly 
decreased on the (-)leu diet. However, in mice lacking FGF21, the reduction of 
Fasn expression was statistically significantly blocked, and, although not 
statistically significant, Srebp1c and Acc1 showed both the same tendency 
(Figure L13). The expression of other genes involved in fatty acid uptake 
[cluster of diferentiation 36 (Cd36), fatty acid binding protein 4 (Fabp4)] or 
oxidation [carnitine palmytoiltransferase 1a (Cpt1a)] was decreased in the 
absence of Fgf21. 
The analysis of FASN, SREBP1c, and ACC1 protein abundance showed a 
good correlation with the gene mRNA levels (Figure L14). In addition, ACC1 
phosphorylation (which inhibits its activity) was decreased under leucine 
deprivation in both wild-type and FGF21-KO mice. 
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Figure	  L	  14.	  FGF21	   reduces	  abundance	  of	   lipogenesis	   related	  proteins	   in	   liver	  of	  mice	   fed	  a	   leucine-­‐
deficient	  diet.	  FASN,	  SREBP1c	  and	  p-­‐ACC1	  and	  total	  ACC1	  protein	  levels	  were	  detected	  by	  western	  blot	  
analysis	   in	   mouse	   liver	   (A).	   The	   bottom	   panels	   (B,C)	   show	   quantification	   by	   densitometry	   of	   the	  
immunoblotted	  proteins,	  using	  Image	  J	  software.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  
mean	   (SEM).	   a,	   p<0.05	   versus	   Ctl	   WT;	   b,	   p<0.05	   versus	   Ctl	   FGF21-­‐KO;	   c,	   p<0.05	   versus	   (-­‐)leu	   WT	  
(n=6/group).	  
4.2 FGF21	  deficiency	  abolish	   the	   reduction	   in	   lipid	  content	   in	   liver	  upon	   leucine	  
deficiency	  
Although liver triglyceride levels, measured by extraction and posterior 
quantification, did not reflect the expression pattern of the lipid synthesis genes, 
haematoxylin and eosin staining revealed it.  
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Figure	   L	   15.	   FGF21-­‐KO	   liver	   has	   impaired	   lipid	   accumulation	   in	   response	   to	   leucine	   deprivation.	  
Histological	  appearance	  and	  hepatic	  lipid	  accumulation	  of	  H&E	  liver	  staining	  of	  WT	  and	  FGF21-­‐KO	  mice	  
maintained	   either	   on	   a	   Ctl	   or	   a	   (-­‐)leu	   diet.	   Representative	   H&E-­‐stained	   hepatocytes	   are	   shown	   (×20	  
magnification)	  (A).	  Scale	  bar,	  50	  mM.	  Lipid	  accumulation	  (B)	  was	  measured	  by	  IMAT	  programme,	  using	  
at	  least	  three	  different	  randomly	  chosen	  fields	  of	  liver	  sections	  from	  each	  mouse.	  c,	  p<0.05	  versus	  (-­‐)leu	  
WT	  (n=6/group).	  
The staining and consequent quantification of lipid content suggested a 
decreased lipid accumulation under leucine deprivation in wild-type animals that 
does not seem to occur in the FGF21-KO mice (Figure L15). 
5 FGF21	  deficiency	  prevents	  BAT	  activation	  of	  leucine-­‐deprived	  mice	  
5.1 FGF21	  mediates	  the	  upregulation	  of	  Ucp1	  and	  Dio2	  upon	  leucine	  deficiency	  in	  
BAT	  
Thermogenesis in BAT is mediated by the upregulation of UCP1 (Matthias et al. 
2000). It has been proposed that the induction of FGF21 production by the liver 
mediates direct activation of brown fat thermogenesis during the fetal-to-
neonatal transition (Hondares et al. 2010). FGF21 also regulates PPAR gamma 
coactivator 1 (PGC1) α and browning of white adipose tissues in adaptive 
thermogenesis (Fisher et al. 2012). Therefore, in order to analyse the effect of 
high FGF21 circulating levels during leucine deprivation on thermogenesis, we 
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analysed the expression of several genes involved in thermogenesis in BAT of 
wild-type or FGF21 null mice fed a Ctl or (-)leu diet.  
Figure	   L	   16.	   FGF21	   is	   required	   for	   inducing	  BAT	  activation	  during	   amino	   acid	  deprivation.	  Ucp1	  and	  
Dio2	  gene	  expression	  was	  measured	  by	  qRT-­‐PCR	  in	  mice	  BAT.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  
error	  of	  the	  mean	  (SEM).	  a,	  p<0.05	  versus	  Ctl	  WT;	  b,	  p<0.05	  versus	  Ctl	  FGF21-­‐KO;	  c,	  p<0.05	  versus	  (-­‐	  )leu	  
WT	  (n=6/group).	  
Consistent with previous results (Cheng et al. 2009), leucine deprivation caused 
an increase of Ucp1 and Dio2 mRNAs in wild-type mice. These changes were 
blocked in FGF21-KO mice (Figure L16). Because Ucp1 expression is related to 
EE, the absence of induction of Ucp1 in FGF21-KO under leucine deprivation 
may contribute to the decrease in weight loss observed under these 
circumstances. 
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5.2 Leucine	  deprivation	  triggers	  expression	  of	  Pgc-­‐1α,	  Pparϒ	  and	  Adrb3	  in	  BAT	  
Figure	   L	   17. The	   role	   of	   FGF21	   in	   the	   expression	   of	   genes	   related	  with	   lipid	  metabolism	   in	   BAT	   of	  
leucine-­‐deprived	  mice.	  The	  expression	  of	  genes	   related	  with	   lipid	  metabolism	  was	  measured	  by	  qRT-­‐
PCR	  in	  mice	  BAT.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  mean	  (SEM).	  a,	  p<0.05	  versus	  Ctl	  
WT;	  b,	  p<0.05	  versus	  Ctl	  FGF21-­‐KO;	  c,	  p<0.05	  versus	  (-­‐	  )leu	  WT	  (n=6/group).	  
The analysis of other genes involved in thermogenesis and lipid metabolism 
revealed interesting data. mRNA levels of Pgc1α, which regulates the 
expression of UCP1 (Handschin & Spiegelman 2006), were increased by 
leucine deprivation. However, they did not differ between wild-type and FGF21-
KO mice under either control or (-)leu diet conditions. The same pattern as for 
peroxisome proliferator-activated receptor gamma (Pparγ) and Pgc1α, was 
observed for adrenoreceptor beta 3 (Adrb3) mRNA levels (Figure L17).  These 
data propose that part of the thermogenic programme is induced by leucine 
deficiency independently of FGF21.  
5.3 Upregulation	  of	  Ucp1	  is	  independent	  of	  the	  p38	  MAPK	  signalling	  
Given the upregulation of Adrb3 mRNA levels by leucine deficiency (FigureL17) 
and the well described role of p38MAPK in the regulation of Ucp1 (Cao et al. 
2001), we tested the possibility that the activation of p38 by the ADRB3 
participated in the induction of Ucp1 gene in BAT under this situation. 
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Figure	   L	   18.	   Phosphorylation	   of	   p38MAPK	   does	   not	   change	   upon	   leucine	   deprivation	   or	   FGF21	  
deficiency.	  Phosphorylated	  and	  total	  p38	  MAPK	  levels	  were	  measured	  in	  WT	  and	  FGF21-­‐KO	  mouse	  liver	  
extracts	   by	   Western	   blot	   analysis.	   The	   below	   panel	   (B)	   shows	   quantification	   by	   densitometry	   of	  
phosphorylated	  p38	  MAPK	  normalized	  to	  total	  p38	  MAPK,	  using	  Image	  J	  software.	  
However, phosphorylated p38 levels remained unchanged between diets and 
genotypes (Figure L18). This result discards p38MAPK pathway as the 
mediator of FGF21 effects on BAT during leucine deprivation.  
5.4 FGF21	   treatment	   represses	   Fasn	   and	   increases	   glycerol	   release	   in	   primary	  
brown	  adipocytes	  
To better understand the effect of FGF21 on BAT, and to characterize it as a 
direct effect, we analysed the expression of lipogenic and lipolytic genes and 
glycerol release in primary brown adipocytes treated with FGF21. 
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Figure	   L	   19	   Expression	   of	   genes	   related	   with	   lipid	   metabolism	   in	   FGF21-­‐treated	   primary	   brown	  
adipocytes.	  Fasn,	  Srebp1c,	  Atgl	  and	  Plin1	  gene	  expression	  was	  measured	  by	  qRT-­‐PCR	   in	  differentiated	  
primary	  BAT	  treated	  with	  FGF21	  (50nM)	  for	  24h.	  ).	  a,	  p<0.05	  versus	  Ctl	  (n=3)	  
This treatment decreased the expression of Fasn and increased glycerol 
release without significant changes in the expression of Atgl and Plin (Figure 
L19 and L20). Accordingly, mRNA levels of Hsl and Atgl as well as HSL 
phosphorylation did not change in BAT of Fgf21-deficient mice (Figures L17 
and L21). 
Figure	   L.	   20	   FGF21	   increases	   glycerol	   release	   in	   primary	   brown	   adipocytes.	   Glycerol	   release	   in	  
differentiated	  primary	  BAT	  treated	  with	  FGF21	  (5nM	  and	  50nM)	  for	  24h.	  a,	  p<0.05	  versus	  Ctl (n=3)	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Figure	   L	   21	   Phosphoryation	   of	   HSL	   do	   not	   change	   upon	   leucine	   deprivation	   or	   FGF21	   deficiency.	  
Phosphorylated	  and	  total	  HSL	  protein	  levels	  were	  measured	  in	  WT	  and	  FGF21-­‐KO	  BAT	  homogenates	  by	  
Western	  blot	  analysis.	  The	  bottom	  panel	  shows	  quantification	  by	  densitometry	  of	  phosphorylated	  HSL	  
normalized	  to	  total	  HSL,	  using	  Image	  J	  software.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  
mean	  (SEM.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  mean	  (SEM).	  (n=6/group).	  
6 Serum	  biochemical	  parameters	  of	  leucine-­‐deprived	  mice	  
Since leucine deprivation, via FGF21, caused striking metabolic changes in 
liver, WAT and BAT, we examined how this changes were affecting basic serum 
biochemical parameters. Thus, we measured non-esterified fatty acids 
(NEFAs), triglycerides, cholesterol, glucose, glycerol and insulin in wild-type and 
FGF21 null mice fed a complete diet or a leucine-deficient diet.  
Table	  1.	  Serum	  measurements	  in	  mice	  maintained	  on	  different	  diets	  
Ctl WT Ctl FGF21-KO (-)leu WT (-)leu FGF21-KO 
NEFA (nmol/l) 0,79±0,11 1,05±0,11 0,73±0.09 0,82±0.06 
Triglycerides (mg/dl) 95,79±7,18 153,73±11,62a 99,39±15,36 186,08±27,38a,c 
Cholesterol (mg/dl) 101,13±13,13 147,65±4,21a 96,40±7,69 122,55±3,08b,c 
Glucose (mg/dl) 209,43±10,45 212,90±7,88 185,53±14,87 187,02±9,55 
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Glycerol (µmol/l) 393,50±38,32 520,95±23,10a 313,93±26,56 372,16±19,99b 
Insulin (µg/l) 1,26±0,23 2,01±0,52 0,41±0.04a 1,21±2,20c 
All	  data	  are	  expressed	  as	  means	  ± 	  SEM.	  Significant	  differences	  were	  assessed	  by	  a	  two-­‐tailed	  Student’s	  t-­‐test.	  
P<0.05	  was	  considered	  statistically	  significant.	  N=6/group	  of	  mice.	  a	  P<0.05	  versus	  Ctl	  WT	  mice.	  b	  P<0.05	  versus
Ctl	  FGF21-­‐KO	  mice.	  c	  P<0.05	  versus	  (-­‐)leu	  WT	  mice
When pharmacologically administered, FGF21 reduces circulating glucose and 
NEFAs (Fisher et al. 2010) as well as triglycerides (Kharitonenkov et al. 2005) 
and cholesterol (Emanuelli et al. 2015). In addition, leucine deprivation 
decreases glycerol and NEFAs (Cheng et al. 2009).  
Among all parameters analysed, only insulin was modified by leucine 
deprivation. Insulin levels were significantly lower in leucine-deprived mice and 
lack of FGF21 reverted this effect. Although not significant, glycerol and NEFAs 
presented the same tendency of previously reported data. Finally, lack of 
FGF21 significantly increased triglycerides, cholesterol and glycerol levels, 
which agrees with the beneficial effects of pharmacological administration of 
FGF21 on these parameters. 
7 Leucine	  deprivation	  activates	  the	  mitogen	  activated	  protein	  kinase	  
ERK1/2	  signalling	  pathway	  in	  liver	  independently	  of	  FGF21.	  
As described, MAPK ERK1/2 signalling is required for the amino acid starvation 
response (Thiaville et al. 2008; Pan et al. 2007) and a downstream signal of 
FGF21 (Adams et al. 2012; Fisher et al. 2011). Thus, we next studied the role of 
ERK1/2 signalling in the FGF21-mediated response to amino acid starvation. 
7.1 Inhibition	   of	   ERK1/2	   phosphorylation	   blocks	   the	   amino	   acid	   deficiency	  
response	  mediated	  by	  ATF4	  	  
To study the relation between amino acid limitation and ERK1/2 signalling 
pathway, HepG2 cells were treated with the MEK inhibitor PD98 and histidinol, 
which blocks charging of histidine onto the corresponding tRNA, and thus 
mimics histidine deprivation, 
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Figure	  L	  22	  Histidinol	  induces	  ERK1/2	  phosphorylation.	  HepG2	  cells	  were	  incubated	  for	  8h	  with	  HisOH	  
(2mM)	  and	  the	  MEK	  inihibitor	  PD98	  (30μM),	  when	  indicated.	  Phosphorylation	  of	  ERK1/2	  was	  analyzed	  
by	  Western	  blot	  in	  HepG2	  extracts.	  	  
Histidinol treatment of HepG2 cells induced the phosphorylation of ERK1/2, 
which was reversed by PD98. (Figure L22). 
Figure	   L	  23.	   Increased	  expression	  of	  Fgf21	   is	   a	  downstream	  signal	  of	  ERK1/2	  phosphorylation.	  ATF4	  
protein	   levels	   (A)	  were	   analyzed	   by	  Western	   blot	   in	   nuclear	  HepG2	   extracts.	  mRNA	   levels	   for	  FGF21,	  
ASNS	  and	  FASN	  (B)	  were	  analyzed	  by	  qRT-­‐PCR.	  a,	  p<0.05	  versus	  DMSO;	  c,	  p<0.05	  versus	  HisOH	  (n=3).	  
In addition, histidinol treatment increased ATF4 protein levels (Figure L23A), as 
well as its target genes FGF21 and asparagine synthetase (ASNS) mRNA 
levels (Figure L23B). The MEK inhibitor considerably reduced these increases. 
In these cells, FASN expression is opposed to that of FGF21 (Figure L23B), 
mimicking what we observed in leucine-deprived wild-type (high FGF21) or 
Fgf21 null mice (Figure L13). 
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7.2 ERK1/2	   phosphorylation	   is	   induced	   in	   liver	   of	   leucine-­‐deprived	   mice	  
independently	  of	  FGF21	  	  
As it has been described that exogenous FGF21 is able to induce ERK1/2 
phosphorylation in the liver and WAT of acutely treated mice (Fisher et al. 
2011), we checked ERK1/2 phosphorylation in leucine-deprived wild-type and  
FGF21 null mice. 
Figure	  L	  24.	  Activation	  of	  the	  MEK/ERK	  pathway	  in	  the	  liver	  by	  leucine	  deprivation	  is	  independent	  of	  
FGF21.	   Phosphorylated	   and	   total	   ERK1/2	   levels	   were	   measured	   in	   WT	   mouse	   liver	   homogenates	   by	  
Western	   blot	   analysis.	   Error	   bars	   represent	   the	  mean	   ±	   standard	   error	   of	   the	  mean	   (SEM).	   a,	   p<0.05	  
versus	  Ctl	  WT;	  b,	  p<0.05	  versus	  Ctl	  FGF21-­‐KO	  (n=6/group).	  
ERK1/2 phosphorylation was induced in liver of leucine-deprived animals, 
although there were no differences between genotypes (Figure L24). 
Accordingly, the amino acid starvation response programme was correctly 
initiated in FGF21-KO mice, as shown by the increased levels of ATF4 protein 
and mRNA levels of Asns (Figure L25).  
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Figure	   L	   25	   Leucine	   deprivation	   increases	   ATF4	   protein	   levels	   and	   Asns	  mRNA	   synthesis	   in	   liver	   of	  
FGF21-­‐KO	  mice.	  Nuclear	  ATF4	  protein	   levels	  (A)	  and	  Asns	  and	  Atf4	  mRNA	  levels	  (B)	  were	  measured	  in	  
FGF21-­‐KO	  mouse	  liver	  by	  qRT-­‐PCR	  and	  Western	  blot,	  respectively.	  Actin	  was	  used	  as	  a	  loading	  control.	  A	  
representative	  blot	   is	   shown.	   Error	  bars	   represent	   the	  mean	  ±	   standard	  error	  of	   the	  mean	   (SEM).	   	   b,	  
p<0.05	  versus	  Ctl	  FGF21-­‐KO	  (n=6/group).	  
Moreover, despite the fact that FGF21 serum levels are highly increased in 
leucine-deprived mice (Figure L1A), ERK1/2 phosphorylation is not modified in 
WAT (Figure L26).  
Figure	   L	   26.	   ERK1/2	   phosphorylation	   is	   not	   modified	   by	   leucine	   deprivation	   in	   mice	   eWAT.	  
Phosphorylated	  and	  total	  ERK1/2	  levels	  (A)	  were	  measured	  in	  WT	  mice	  eWAT	  homogenates	  by	  Western	  
blot	   analysis.	   The	   right	   panel	   (B)	   shows	   quantification	   by	   densitometry	   of	   phosphorylated	   ERK1/2	  
normalized	  to	  total	  ERK1/2,	  using	  Image	  J	  software.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  
the	  mean	  (SEM).	  (n=6/group).	  
8 Obesity	  lessen	  leucine	  deprivation	  effects	  on	  energy	  expenditure	  
FGF21 mediates most of the beneficial metabolic effects of leucine deprivation 
(De Sousa-Coelho et al. 2013). In lean mice, leucine deprivation increases 
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Ucp1 expression increasing EE and drastically reduces body weight in an 
FGF21-dependent manner. To analyse the putative beneficial effects of leucine 
deprivation on pathological situations such obesity we maintained Ob/Ob mice 
under leucine deprivation for 7 days. 
8.1 Leucine	  deprivation	  reduces	  food	  intake	  in	  Ob/Ob	  mice	  
 In lean mice, leucine deficiency decreased daily food intake approximately 1g 
(Figure L4). Despite disrupted leptin signalling, in Ob/Ob mice, the decrease in 
food intake is maintained and even higher (1,5g) than in lean animals (Figure 
L27).   
Figure	  L	  27.	  Leptin	  is	  not	  involved	  in	  food	  aversion	  caused	  by	  leucine-­‐deficient	  diets.	  Ob/Ob	  mice	  were	  
maintained	  for	  7	  days	  on	  Ctl	  diet	  and	  7	  days	  on	  leucin	  deficient	  diet.	  Food	  intake	  was	  measured	  daily.	  
**,	  p<0.01	  (n=6/group)	  
8.2 Ob/Ob	  mice	  under	  leucine	  deprivation	  under	  go	  the	  same	  weight	  loss	  than	  a	  
pair	  pair-­‐fed	  Ob/Ob	  pair-­‐fed	  mice	  
To exclude the changes on caloric intake from the effect of the (-)leu diet on 
body weight, we pair-fed Ob/Ob mice with (-)leu and Ctl diets.  
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Figure	  L	  28.	  Leucine-­‐deficient	  diet	  causes	  same	  weight	  loss	  than	  	  control	  pair-­‐fed	  diet.	  Body	  weight	  of	  
Ob/Ob	  mice	  fed	  with	  (-­‐)leu	  diet	  or	  a	  control	  pair-­‐fed	  diet	  (A).	  The	  weight	  on	  the	  first	  day	  was	  considered	  
100%.	  Body	  weight	  change	  (g)	  after	  7	  days	  of	  feeding	  the	  Ctl	  or	  (-­‐)leu	  diet	  (B).	  Error	  bars	  represent	  the	  
mean	  ±	  standard	  error	  of	  the	  mean	  (SEM).	  (n=6/group).	  
Both groups, leucine-deprived and control pair-fed, lost weight in a similar way 
and no statistical differences were observed (Figure L28A-B). Hence, the 
reduced food intake is the major responsible for the weight loss in both groups.  
8.3 Leucine	  deprivation	  induces	  Ucp1	  expression	  in	  BAT	  of	  Ob/Ob	  mice	  
In leucine-deprived lean mice, triggered levels of Ucp1 in BAT increases 
thermogenesis and EE (Figure L16) (Cheng et al. 2010). To evaluate this 
observation in a context of obesity, we analysed Ucp1 mRNA levels in BAT of 
Ob/Ob mice fed a (-)leu diet or pair-fed with a Ctl diet.  
Figure	  L	  29.	  Ucp1	  expression	  is	  induced	  in	  BAT	  of	  Ob/Ob	  leucine-­‐deprived	  mice.	  Ucp1	  gene	  expression	  
was	  measured	  by	  qRT-­‐PCR	  in	  Ob/Ob	  mice	  BAT.	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  the	  
mean	  (SEM).	  *,	  p<0.05	  vs	  control	  pair-­‐fed	  (n=6/group).	  
Leucine-deprived Ob/Ob mice presented a modest but statistically significant 
Ucp1 induction. In these obese mice a 2 fold induction was observed (Figure 
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L29), while in lean animals the induction was much more higher and reached 
7,5 folds (Figure L16).  
8.4 Fgf21	  is	  slightly	  induced	  in	  liver	  of	  leucine-­‐deprived	  Ob/Ob	  mice	  
Given that FGF21 partially mediates the weight loss and Ucp1 induction upon 
leucine deprivation, we analysed FGF21 serum levels and Fgf21 hepatic 
expression in leucine-deprived and pair-fed Ob/Ob mice. 
Figure	  L	  30.	  Fgf21	  mRNA	  levels	  and	  serum	  concentration	  of	  Ob/Ob	  mice	  on	  a	   leucine-­‐deficient	  diet.	  
Fgf21	   in	   liver	  was	  measured	  by	  qRT-­‐PCR	   (A).	   Serum	  FGF21	  protein	   concentrations	  were	  measured	  by	  
ELISA	  (B).	  Asns	  in	  liver	  was	  measured	  by	  qRT-­‐PCR	  (C).	  Error	  bars	  represent	  the	  mean	  ±	  standard	  error	  of	  
the	  mean	  (SEM)	  **,	  p<0.01	  versus	  Ctl	  pair-­‐fed	  (n=6/group).	  	  
Fgf21 hepatic expression was slightly induced in leucine-deprived Ob/Ob mice 
and serum levels paralleled the expression pattern (Figure L30A-B). The 
induction of Fgf21 in Ob/Ob mice was much smaller than the induction 
observed in lean animals (Figure L1). Actually, it didn’t reach statistical 
significance (p=0,12). Remarkably, the pair-fed group presented elevated 
FGF21 serum levels. This observation is consistent with the notion that obesity 
is an FGF21-resistant state (Fisher et al. 2010).  
To evaluate the AAR in the liver of Ob/Ob mice, we analysed the mRNA levels 
of the ATF4 target gene Asns. Leucine deprivation normally induced Asns in the 
liver of Ob/Ob mice (Figure L30C). This result discards trunked AAR as the 
mechanism underlying the abnormally slight induction of Fgf21 in response to 
leucine deprivation.  
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THE	  ROLE	  OF	  FGF21	   IN	  THE	  METABOLIC	  RESPONSE	  TO	  PROTEIN	  
RESTRICTION
Given the unfeasibility to translate single amino acid deprivation to humans, we 
focussed on low-protein diets (LPDs) instead of amino acid-deficient diets as a 
more realistic approach. 
During the development of the present work, some other groups published data 
in the same direction that our results. Protein restriction brings about weight 
loss and an increase in both food intake and EE (Ozaki et al. 2015). Moreover, 
LPD induces thermogenic markers in BAT of obese rats (Pezeshki et al. 2016). 
Furthermore, serum concentrations of FGF21 in both rodents and humans 
increase upon exposure to a LPD, regardless of overall calorie intake. This 
observation thus reveals that FGF21 is involved in the metabolic response to 
protein-restricted diets (Laeger et al. 2014).  
Here we addressed whether a LPD exerts similar effects on lipid metabolism to 
those of a (-)leu diet and whether these effects are dependent on hepatic 
FGF21 production. To this end, we examined the metabolic response of wild-
type and Fgf21 liver-specific knockout mice (LFgf21KO) to a LPD (up to 5% of 
energy as protein). 
1 Generation	  and	  characterization	  of	  the	  Fgf21	  liver-­‐specific	  knockout	  
mice	  (LFgf21KO)	  
Although liver is well established as the main source of FGF21, autocrine and 
endocrine actions of FGF21 in different tissues still on debate. To elucidate the 
specific role of liver-derived FGF21 during protein restriction we generated the 
Fgf21 liver-specific knockout mice (LFgf21KO). 
To generate the LFgf21KO mice, Fgf21loxP mice that have Fgf21 loxP sites 
flanking exons 1-3 were crossed with Albumin-cre mice. The latter express the 
CRE recombinase enzyme under control of albumin promoter/enhancer 
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elements, thus allowing liver-specific gene deletions. After several generations, 
the homozygous mutant was obtained. Fgf21LoxP mice were used as controls. 
Mice were genotyped by PCR (Figure 0A) and the expression of Fgf21 was 
analysed in liver, BAT, eWAT and scWAT. 
Figure	   P	   0	   Genotyping	   and	   characterization	   of	   the	   LFgf21KO	  mice.	   PCR	   genotyping	   was	   performed	  
using	  50ng	  of	  genomic	  DNA	  (A).	  Fgf21	  mRNA	  levels	   in	  liver,	  BAT,	  eWAT	  and	  scWAT	  were	  measured	  by	  
qRT-­‐PCR	  (B).	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  ***p<0.001	  versus	  Fgf21LoxP	  mice	  (n=7–9/group).	  
As expected, Fgf21 mRNA levels were undetectable in liver while no 
compensatory effects were detected in adipose depots. 
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2 A	  LPD	  induces	  FGF21	  gene	  expression	  in	  the	  liver,	  but	  not	  in	  BAT	  or	  
WAT.	  
2.1 LPD	  increase	  plasma	  levels	  of	  FGF21	  in	  parallel	  with	  its	  hepatic	  expression	  
Figure	   P	   1	   FGF21	   is	   induced	   by	   a	   LPD	   in	   liver	   and	   this	   induction	   correlates	   positively	   with	   plasma	  
concentration	  in	  mice.	  Plasma	  protein	  concentration	  of	  FGF21	  was	  measured	  by	  ELISA	  (A).	  Fgf21	  mRNA	  
levels	   in	   liver	   (B)	   were	   measured	   by	   qRT-­‐PCR.	   Error	   bars	   represent	   the	   mean	   ±	   SEM.	   **	   p<0.01	  
***p<0.001	  versus	  Fgf21LoxP	  mice	  fed	  a	  CD	  (n=7–9/group).	  
The liver is the main site of FGF21 production and release into the blood. 
Accordingly, we observed a great induction of Fgf21 mRNA synthesis in the 
liver of mice on the LPD (Figure P1B). This increase correlated positively with 
plasma levels (Figure P1A). 
To determine the specific role of hepatic FGF21 in the metabolic response to a 
LPD, we fed LFgf21KO mice a LPD diet. As expected, Fgf21 mRNA levels were 
undetectable in the livers of these animals (Figure P1B), 
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2.2 LPD	  do	  not	  increase	  FGF21	  expression	  in	  BAT,	  eWAT	  or	  scWAT	  	  
Figure	  P	  2.	  FGF21	  is	  not	  induced	  by	  a	  LPD	  in	  in	  BAT	  or	  WAT.	  Fgf21	  mRNA	  levels	  were	  measured	  by	  qRT-­‐
PCR.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  (n=7–9/group).	  
In contrast to liver upregulation, Fgf21 expression did not increase in BAT, 
eWAT and scWAT of control mice on the LPD (Figure P2) while no statistically 
significant changes were detected in LFgf21KO mice when compared to the 
same tissues in control mice (Figure 2P). Interestingly, in the same direction as 
leucine deprivation, Fgf21 mRNA levels showed a decreasing tendency in 
eWAT of animals on a LPD. 
3 A	  LPD	  increases	  ATF4	  protein	  levels	  in	  mouse	  liver	  
The 5’ region of Fgf21 contains two evolutionarily conserved functional ATF4-
binding sequences responsible for its ATF4-dependent transcriptional activation 
(De Sousa-Coelho et al. 2012). To determine the effect of a LPD on ATF4 
expression, we analysed liver protein extracts of mice fed a LPD or a CD for 7 
days. 
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Figure	   P	   3.	   A	   LPD	   increases	   ATF4	   protein	   levels	   in	   liver.	   ATF4	   protein	   levels	   were	   determined	   by	  
Western	  blot	  analysis	  using	  hepatic	  nuclear	  extracts	  obtained	  from	  Fgf21LoxP	  mice	  administered	  a	  CD	  or	  
LPD.	  The	  experiment	  was	  normalized	  by	  actin	  protein	  levels	  as	  loading	  control	  and	  the	  intensity	  of	  the	  
bands	  were	  quantified	  by	  densitometry	  with	  the	  Image	  J	  software	  (B).	  Error	  bars	  represent	  the	  mean	  ±	  
SEM.	  **	  p<0.01	  versus	  CD.	  (n=3/group).	  
ATF4 expression was induced in liver in response to the LPD, as revealed by 
Western blot assays (Figure P2A-B). These results are consistent with previous 
published data reporting that ATF4 triggers the expression of FGF21 and that 
Gcn2 -/- mice show a partially blunted induction of FGF21 under protein 
restriction (Laeger et al. 2014). 
4 Fgf21	  deficiency	  significantly	  attenuates	  weight	  loss	  under	  a	  LPD	  
Mice fed a LPD present rapid weight loss. Here we addressed whether this 
phenomenon is dependent on hepatic FGF21. For this purpose, Fgf21LoxP and 
LFgf21KO mice were fed a CD or LPD for 7 days. 
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4.1 Total	  body	  weight	  after	  7	  days	  on	  a	  LPD	  
Figure	   P	   4.	   Hepatic	   FGF21	   expression	   is	   required	   for	   the	   weight	   loss	   caused	   by	   LPD.	   Body	   weight	  
progression	  of	  mice	  fed	  a	  CD	  or	  LPD	  expressed	  as	  percentage	  of	  the	  initial	  weight,	  which	  was	  considered	  
100%	  (A).	  Total	  body	  weight	  change	  (g)	  after	  7	  days	  on	  a	  CD	  or	  LPD	  (B).	  Error	  bars	  represent	  the	  mean	  ±	  
SEM.	  **	  p<0.01	  versus	  Fgf21LoxP	  mice	  fed	  a	  CD,	  #	  p<0.05	  versus	  LFgf21KO	  fed	  a	  CD;	  (n=7–9/group).	  
Our data show that weight loss caused by LPD was partially blunted in 
LFgf21KO mice (Figure P4A-B). Control mice fed a LPD underwent a 5,75% 
loss of their initial body weight while Fgf21KO animals weight loss reached 
1,21%. 
4.2 LPD	  reduces	  food	  intake	  
Figure	  P	  5.	  Hepatic	  FGF21	  does	  not	  affect	  food	  consumption.	  Daily	  food	  intake.	  Error	  bars	  represent	  the	  
mean	  ±	  SEM.	  *	  p<0.05	  versus	  Fgf21LoxP	  mice	  fed	  a	  CD,	  0.07	  represents	  p	  value	  versus	  LFgf21KO	  mice	  
fed	  a	  CD	  (n=7–9/group).	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The reduction in food intake observed under a LPD was unchanged between 
genotypes (Figure P5). It is remarkable that these results contradict previous 
publications describing either no change or an increase in food intake in 
response to protein restriction (Laeger et al. 2014). Nonetheless, the present 
results are consistent with the decreased food intake described in mice fed 
leucine-deficient diets (FigureL4). 
4.3 Tissue	  weight	  after	  7	  days	  on	  a	  LPD	  
To determine the importance of each tissue in overall weight loss, we calculated 
the change in weight of individual tissues.  
Figure	  P	  6.	  Hepatic	  FGF21	  is	  required	  for	  the	  weight	   loss	  caused	  by	  a	  LPD.	  The	  weight	  of	  heart,	  liver,	  
eWAT,	  scWAT,	  BAT	  and	  gastrocnemius	  in	  mice	  fed	  a	  CD	  or	  LPD	  is	  presented	  as	  the	  mg	  of	  tissue	  per	  100	  
mg	  of	  total	  body	  weight.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  *	  p<0.05	  ***	  p<0.001	  versus	  Fgf21LoxP	  
mice	   fed	   a	  CD;	   #	  p<0.05	  ##	  p<0.01	   versus	   LFgf21KO	  mice	   fed	   a	  CD;	   0.06	   represents	   the	  p	   value	  with	  
respect	  to	  Fgf21LoxP	  mice	  fed	  a	  CD	  (n=7–9/group).	  
All tissues analysed tended to weigh less in mice on the LPD, reaching 
statistical significance in heart, liver, scWAT and p=0.06 in eWAT (Figure P6). 
Regarding the role of FGF21, our results show that the weight loss observed in 
scWAT and heart was dependent on hepatic FGF21 expression, as weight loss 
was blunted in LFgf21KO mice under the same diet. The effect of the LPD on 
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liver tissue weight was partially abolished by hepatic Fgf21 deficiency (Figure 
P6). 
5 FGF21	  induces	  thermogenic	  genes	  in	  response	  to	  LPD	  in	  scWAT,	  but	  
not	  in	  BAT	  or	  eWAT	  
Since hepatic FGF21 exerts its effects mainly in WAT and BAT through 
regulating lipid metabolism, the following experiments are focused on 
describing the role of LPD-induced FGF21 on the metabolic response of 
adipose depots. 
Thermogenesis in BAT is mediated by the upregulation of UCP1 (Matthias et al. 
2000) and FGF21 upregulates Ucp1 in BAT in response to leucine deficiency 
(De Sousa-Coelho et al. 2013). In addition, FGF21 induces browning of scWAT 
(Fisher et al. 2012). Consequently, we evaluated the expression of thermogenic 
genes in BAT, eWAT and scWAT of Fgf21LoxP and LFgf21KO mice on a CD or 
LPD. 
5.1 Thermogenic	  genes	  in	  BAT	  and	  eWAT	  of	  mice	  on	  a	  LPD	  
Figure	  P	  7.	  A	  LPD	  does	  not	  alter	   thermogenic	  genes	   in	  BAT	  or	  eWAT.	  Ucp1	  and	  Dio2	  expression	  was	  
measured	  by	  qRT-­‐PCR	  in	  mouse	  BAT	  and	  eWAT.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  *	  p<0.05	  versus	  
Fgf21LoxP	  mice	  fed	  a	  CD	  (n=7–9/group).	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Contrary to activation of the thermogenic programme reported under leucine 
deprivation, no statistically significant induction of Ucp1 or Dio2 mRNA levels 
were observed in BAT or eWAT of control mice under a LPD (Figure P7A-B). 
5.2 Thermogenic	  genes	  in	  scWAT	  of	  mice	  on	  LPD	  
Figure	  P	  8.	  Hepatic	  FGF21	   is	   required	  for	   inducing	  thermogenic	  gene	  expression	  during	  a	  LPD.	  Ucp1,	  
Dio2,	   Pgc1a,	   Pparg,	   Prmd16	  and	   Cidea	   expression	  was	  measured	   by	   qRT-­‐PCR	   in	  mouse	   scWAT.	   Error	  
bars	  represent	  the	  mean	  ±	  SEM.	  *	  p<0.05	  versus	  Fgf21LoxP	  mice	  fed	  a	  CD	  (n=7–9/group).	  
In contrast, the analysis of gene expression in scWAT revealed that the LPD 
induced the expression of Ucp1, Pgc1a, Cidea and PR domain containing 16 
(Prdm16), reaching a statistically significant value for Ucp1 and Pgc1a (Figure 
P8). This expression pattern was not detected in the LFgf21KO mice (Figure 
P8), thereby indicating the role of FGF21 in the metabolic adaptation of scWAT 
to protein restriction. 
6 FGF21	  signalling	  in	  the	  CNS	  of	  protein	  restricted	  mice	  
FGF21 has the potential to act in the central nervous system (CNS) since 
FGFRs are widely expressed in this tissue and KLB is specifically expressed in 
certain regions. (Fon Tacer et al. 2010; Bookout et al. 2013; Liang et al. 2014). 
In addition, FGF21 crosses the blood brain barrier and is present in the 
cerebrospinal fluid in a linear relationship with serum levels (Tan et al. 2011). 
Recent studies point to the CNS as a mediator of the effects of FGF21 on EE 
and browning of WAT (Douris et al. 2015; Owen et al. 2014). 
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Given the capacity of FGF21 to modulate signalling pathways in the CNS to 
increase BAT activation, we speculated whether weight loss and browning of 
scWAT observed under the LPD is mediated by FGF21 actions in the CNS. 
Therefore, we analysed the levels of T3, adrenocorticotropin hormone (ACTH) 
and noradrenaline in plasma of Fgf21loxP and LFgf21KO mice fed the CD or the 
LPD.  
6.1 Liver-­‐derived	  FGF21	  reduces	  plasmatic	  free	  T3	  levels	  upon	  protein	  restriction	  
FGF21 and thyroid hormone show mutual regulatory dependency 
(Domouzoglou et al. 2014) and leucine deficiency increases T3 serum levels 
(Cheng et al. 2010). As thyroid system is strictly linked with thermogenesis and 
EE we analysed free T3 plasmatic levels of Fgf21loxP and LFgf21KO mice fed a 
CD or a LPD. 
Figure	  P	  9	  Hepatic	  FGF21	  induced	  by	  a	  LPD	  reduces	  free	  T3	  circulating	  levels.	  Plasma	  concentration	  of	  
free	  T3	  was	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  **	  p<0.01	  versus	  Fgf21LoxP	  mice	  
fed	  a	  CD	  (n=7–9/group).	  
The LPD caused a significant decrease in circulating free T3 (Figure P9). 
Hence, the increase of FGF21 levels in plasma (Figure P1) inversely correlates 
with free T3. This result is consistent with previous data showing that 
pharmacologic administration of FGF21 decreases free T3 as well as T4 
(Coskun et al. 2008).  No variations in T3 levels were observed in the LFgf21KO 
mice on the CD or LPD (Figure P9) indicating an FGF21-mediated effect on 
circulating T3. 
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6.2 ACTH	  plasmatic	  levels	  in	  mice	  fed	  a	  LPD	  
Corticotropin-releasing factor (Crf) mRNA in hypothalamus and circulating 
corticosterone concentration are increased in Fgf21 transgenic mice (Bookout 
et al. 2013) and acute administration of FGF21 results in increased plasma 
levels of ACTH (Owen et al. 2014). Moreover, i.c.v. injection of CRF receptor 
antagonist completely blocks the effect of FGF21 on sympathetic nerve activity 
in BAT (Owen et al. 2014). 
This consistent data led us to hypothesize that FGF21 increase upon protein 
restriction modulates the hypothalamic–pituitary–adrenal axis. Therefore, we 
measured plasma ACTH of Fgf21loxP and LFgf21KO mice fed the CD or the 
LPD. 
Figure	  P	  10	  Hepatic	  FGF21	  deficiency	  increases	  ACTH	  circulating	  levels.	  Plasma	  concentration	  of	  ACTH	  
was	  measured	  by	  ELISA.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  #	  p<0.05	  	  versus	  LFgf21KO	  mice	  fed	  a	  CD	  
(n=7–9/group).	  
ACTH plasmatic levels presented high variability and no statistical differences 
could be registered. However, some tendencies may be appreciated, LPD 
increased ACTH plasmatic levels independently of the genotype and lack of 
hepatic Fgf21 rose the basal levels of ACTH. 
6.3 Protein	  restriction	  increases	  sympathetic	  outflow	  
Finally, we also analysed noradrenaline plasmatic levels in order to study the 
effect of liver-released FGF21 on the sympathetic tone. Several studies support 
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our hypothesis that FGF21 acts on the CNS increasing the sympathetic outflow 
to adipose depots. Centrally FGF21-treated mice present increased browning 
markers in scWAT and adrenergic blockade prevents the actions of central 
FGF21 (Douris et al. 2015). Moreover, the specific knockout of Klb in the 
hypothalamus and the dorsal-vagal complex abolishes the effects of the 
transgenic overexpression of Fgf21 on thermogenic genes in BAT and scWAT 
(Owen et al. 2014). 
Figure	  P	  11.	  LPD	   induces	  noradrenaline	  circulating	   levels.	  Plasma	  concentration	  of	  noradrenaline	  was	  
measured	  by	  ELISA.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  **	  p<0.01	   	  versus	  Fgf21LoxP	  mice	  fed	  a	  CD	  
(n=7–9/group).	  
LPD increased plasmatic levels of noradrenaline in both Fgf21loxP and 
LFgf21KO mice although the difference only reached statistical significance in 
the control animals. This result suggests that, beyond FGF21, protein restriction 
increases the sympathetic tone. 
6.4 Blockade	   of	   adrenergic	   receptors	   diminishes	   weight	   differences	   between	  
mice	  fed	  CD	  or	  LPD	  
In order to determine the role of enhanced adrenergic tone in the weight loss 
observed under a LPD, animals were injected intraperitoneally with the non-
selective β-blocker propranolol or the vehicle, and fed CD or LPD for 7 days. 
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Figure	  P	  12.	  Propranolol	  treatment	  decreased	  body	  gain	  by	  CD	  and	  body	  weight	  loss	  by	  LPD	  in	  mice.	  
Body	  weight	  progression	  of	  mice	   fed	  a	  CD	  or	  LPD,	   injected	  with	  propranolol	  5mg/kg/d	  or	   the	  vehicle,	  
expressed	  as	  percentage	  of	  the	  initial	  weight,	  which	  was	  considered	  100%	  (A).	  Total	  body	  weight	  change	  
(g) after	  7	  days	  on	  a	  CD	  or	  LPD	  (B).	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  **	  p<0.01,	  ***	  p<0.001	  versus
vehicle	  treated	  mice	  fed	  a	  CD,	  0.06	  represents	  the	  p	  value	  with	  respect	  to	  propranolol	  treated	  mice	  fed
a	  CD	  (n=6	  group).
As previously reported, mice on a LPD lost weight (Figure P12A-B). It is worth 
to mention that, in this experiment, weight loss registered in animals fed LPD 
during the first days of the time-course was partially recovered at the conclusion 
(Figure P12B). No statistical differences were found between propranolol and 
vehicle-injected mice fed a LPD (Figure P12B). Interestingly, propranolol 
treatment diminished weight gain in CD animals. This led us to analyse the 
effect of propranolol treatment on food intake. 
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Figure	  P	  13.	  Propranolol	  treatment	  decreased	  food	  intake.	  Daily	  food	  intake	  (g)	  (A).	  Weight	  difference	  
of	   vehicle	   or	   propranolol	   5mg/kg/d	   treated	  mice	   on	   LPD	   respect	   their	   control	   diet	   groups.	   Error	   bars	  
represent	  the	  mean	  ±	  SEM.	  ***	  p<0.001	  versus	  vehicle	  treated	  mice	  fed	  a	  CD	  (n=6	  group).	  
Propranolol treatment decreased daily food intake in both groups (Figure 
P13A), which explains blunted weigh gain in propranolol treated mice on CD. 
When comparing the effect of LPD to their respective control groups, the food 
intake difference registered in vehicle-treated mice was 1,15g/day, while it was 
0,3g/day in propranolol treated animals. 
6.5 Adrenergic	  receptors	  blockade	  do	  not	  prevent	  Ucp1	  upregulation	  in	  mice	  on	  a	  
LPD	  
The release of noradrenaline by sympathetic nerve activates β-adrenergic 
receptors inducing the thermogenic response. Since LPD increases plasma 
noradrenaline (Figure P11) and thermogenic gene expression in scWAT (Figure 
P8), we speculated that noradrenaline was participating in Ucp1 induction in 
scWAT. To determine the contribution of noradrenaline to Ucp1 induction, we 
analysed the mRNA levels of mice treated with propranolol or the vehicle, and 
fed a CD or a LPD. 
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Figure	  P	  14.	  Propranolol	  treatment	  do	  not	  block	  Ucp1	   induction	  during	  a	  LPD.	  Ucp1,	  Dio2	  and,	  Pparg	  
expression	  of	  mice	  fed	  a	  CD	  or	  LPD,	  injected	  with	  propranolol	  5mg/kg/d	  or	  the	  vehicle,	  was	  measured	  by	  
qRT-­‐PCR	  in	  mouse	  scWAT.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  *	  p<0.05	  versus	  vehicle	  treated	  mice	  
fed	  a	  CD.	  #p<0.05	  versus	  propranolol	  treated	  mice	  fed	  a	  CD	  0.06	  indicates	  p	  value	  versus	  vehicle	  treated	  
mice	  fed	  a	  CD	  (n=6	  group).	  
Propranolol treatment didn’t modified Ucp1 expression neither on CD nor LPD-
fed mice. However, other thermogenic genes were affected by the propranolol 
treatment. Propranolol downregulated Dio2 in both diets and blunted Pparγ 
increase caused by LPD. These results are consistent with published data 
reporting lack of effect of propranolol on Ucp1 expression when FGF21 is 
administered peripherally (Douris et al. 2015). The blockade of beta-adrenergic 
receptors did not interfere with the induction of Ucp1, discarding the increase of 
sympathetic tone in scWAT as the putative mechanism. 
7 Hepatic	  FGF21	  deficiency	  blunts	  improved	  glucose	  tolerance	  in	  mice	  
on	  LPD	  
FGF21 has been postulated as a potential treatment for diabetes mainly due to 
its beneficial metabolic effects on insulin sensitivity and glucose tolerance in 
animal models (Kharitonenkov et al. 2007; Xu et al. 2009). Additionally, leucine- 
and methionine-restricted mice are protected from insulin resistance (Xiao et al. 
2011; Ables et al. 2012). This led us to hypothesise that enhanced Fgf21 
expression upon protein restriction ameliorates glucose metabolism. 
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7.1 Intraperitoneal	  Glucose	  tolerance	  test	  (IPGTT)	  
To evaluate the effect of liver-derived FGF21 on glucose tolerance, Fgf21loxP 
and LFgf21KO mice were maintained on CD or LPD for 7 days and an 
intraperitoneal glucose tolerance test (IPGTT) was performed. 
Figure	  P	  15	   Intraperitoneal	  Glucose	  Tolerance	  Test	   (IPTGG)	   for	  Fgf21loxP	  mice	  fed	  a	  CD	  or	  a	  LPD	  (A)	  or	  
LFgf21KO	  fed	  a	  CD	  or	  LPD	  (B).	  Mice	  were	  fasted	  for	  6h	  and	  then	  injected	  with	  glucose	  (1,5g/kg	  ip).	  Blood	  
glucose	  concentrations	  were	  determined	  with	  a	  glucometer	  using	  blood	  taken	  from	  cut	  tail	  tips	  at	  the	  
indicate	  time	  points.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  (n=7	  group)	  
In control mice fed a LPD, blood glucose concentrations were noticeably lower 
following the intraperitoneal glucose injection (Figure P15A). To simplify the 
results and evaluate them despite different basal glucose concentrations, we 
calculated the AUC of the % of basal glucose (Figure P16).  
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Figure	  P	  16.	  Area	  Under	  the	  Curve	  of	  the	  percentage	  of	  basal	  glucose	  for	  the	  Intraperitoneal	  Glucose	  
Tolerance	   Test	   (IPTGG)	   .	   Fgf21loxP	   or	   LFgf21KO	   mice	   fed	   a	   CD	   or	   LPD.	   Area	   Under	   the	   Curve	   was	  
calculated	  by	  the	  trapezoidal	  method.	  Mice	  were	  fasted	  for	  6h	  and	  then	  injected	  with	  glucose	  (1,5g/kg	  
ip).	  Blood	  glucose	  concentrations	  were	  determined	  with	  a	  glucometer	  using	  blood	   taken	   from	  cut	   tail	  
tips	  at	  the	  indicate	  time	  points.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  *	  p<0.05	  versus	  Fgf21LoxP	  mice	  fed	  
a	  CD	  (n=7	  group)	  
Lack of hepatic Fgf21 blunted the improved glucose tolerance of mice on LPD 
(Figure P16). In addition, LFgf21KO mice showed a tendency to respond poorer 
to glucose injection. In agreement with the pharmacological effects of FGF21, 
liver-produced FGF21 in response to LPD improves whole body glucose 
tolerance. 
7.2 Intraperitoneal	  Insulin	  Tolerance	  Test	  (IPITT)	  
To further analyse the effect of LPD on glucose metabolism, we performed an 
IPITT in the same mice.   
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Figure	  P	  17	  Intraperitoneal	  Insulin	  Tolerance	  Test	  (IPTGG)	  for	  Fgf21loxP	  or	  LFgf21KO	  mice	  fed	  a	  CD	  or	  a	  
LPD	   (A).	   Inverse	  Area	  Under	   the	   Curve	   below	  baseline	   glucose	   calculated	   by	   the	   trapezoidal	  method.	  
Mice	  were	   fasted	   for	   6h	   and	   then	   injected	  with	   insulin	   (0,75	   IU/kg	   ip).	   Blood	   glucose	   concentrations	  
were	   determined	  with	   a	   glucometer	   using	   blood	   taken	   from	   cut	   tail	   tips	   at	   the	   indicate	   time	   points.	  
Error	  bars	  represent	  the	  mean	  ±	  SEM.	  (n=7	  group)	  
The differences in the basal glucose levels complicated the interpretation of the 
time-course results. When calculating the inverse AUC below baseline glucose, 
no statistical differences were found between groups.  
Regarding insulin sensitivity, the in vitro experiments done both in 3T3-L1 
adipocytes and human primary adipocytes show that FGF21 potently stimulates 
glucose uptake in an insulin-independent manner (Kharitonenkov et al. 2005). 
Our results agree with these previous data.  
7.3 Glut	  1	  expression	  does	  not	  change	  in	  adipose	  depots	  of	  mice	  on	  a	  LPD	  
Unlike insulin, FGF21 has no effect on plasma membrane translocation of the 
glucose transporter GLUT4, but induces the expression of GLUT1 through its 
transcriptional activation (Kharitonenkov et al. 2005). Thus, we analysed Glut 1 
expression in adipose depots of Fgf21loxP and LFgf21KO mice on CD or LPD. 
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Figure	  P	  18.	  LPD	  does	  not	  change	  Glut1	  expression	   in	   fat	  depots.	  Glut1	  expression	  was	  measured	  by	  
qRT-­‐PCR	  in	  mouse	  BAT,	  eWAT	  and	  scWAT.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  (n=7–9/group).	  
No statistical differences were observed in the mRNA levels of Glut1 between 
diets or genotypes in any of the tissues analysed. This result discards our 
hypothesis that FGF21 produced under LPD is improving glucose tolerance by 
upregulating Glut1 transporter in adipose depots. 
8 FGF21	   plasma	   levels	   correlate	   negatively	   with	   protein	   intake	   in	  
humans	  
To translate our results to humans, we evaluated the relationship between 
protein intake and circulating levels of FGF21 in 78 individuals randomly 
selected from the PREDIMED trial. 
Table	   2	   Multivariable	   regression	   analyses	   with	   FGF21	   (pg/mL)	   as	   dependent	   variable	   and	   energy-­‐
adjusted	  protein	  intake	  at	  baseline	  (g/day)	  as	  independent	  variable.	  
Q1 Q2 Q3 Q4 P valueb 
No subjects (78) 19 20 20 19 
Age (years) 67.1±5.9 65.7±4.8 67.0±6.4 65.3±4.0 0.30 
Sex (women) 6 (31) 10 (50) 9 (45) 15 (79) 0.03 
Body mass index (Kg/m2) 28.1±3.2 30.0±3.4 27.7±2.7 30.8±2.9 0.006 
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Energy intake (Kcal/d) 2370±350 2192±603 2227±433 2390±571 0.51 
Protein intake (g/day) 80±6 90±2 97±3 110±5 <0.0001 
FGF21 (pg/mL) 289±116 276±143 256±117 190±115 0.07 
aCategorical	  variables:	  subjects	  (percentage),	  continuous	  variables:	  mean	  ±	  SD	  
bOne-­‐way	  ANOVA	  tests	  (continuous	  variables)	  or	  chi-­‐squared	  tests	  (categorical	  variables).	  
Baseline data for these subjects are shown in Table 2. Protein intake was 
obtained from FFQs and was expressed as grams of protein per day (g/day). 
Table	   3	   Multivariable	   regression	   analyses	   with	   FGF21	   (pg/mL)	   as	   dependent	   variable	   and	   energy-­‐
adjusted	  protein	  intake	  at	  baseline	  (g/day)	  as	  independent	  variable.	  
βa P value 95% CI 
Protein intake (continuous variable) Model 1b -3.42 0.006 -5.83,-1.02
Model 2c -3.39 0.007 -5.86, -0.92
Quartiles of protein intake Model 1b -31.5 0.01 -56.5, -6.5
Model 2c -30.8 0.02 -56.5, -5.0
CI:	  Confidence	  Interval.	  
aParameter	  estimates.	  
bUnadjusted.	  
cAdjusted	  for	  body	  mass	  index	  (BMI)	  and	  total	  energy	  intake.	  
Results from the multiple linear regression analyses showed a significant 
inverse relationship between plasma FGF21 concentrations and dietary intake 
of protein. At baseline, FGF21 levels decreased by 3.39 pg/mL for each gram of 
protein ingested (Table 3). The participants with a high intake of protein showed 
statistically significant lower values of circulating FGF21.   
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Figure	   P	   19.	   Circulating	   FGF21	   levels	   correlate	   negatively	   with	   protein	   intake.	   Plasma	   FGF21	  
concentration	  divided	  into	  quartiles	  of	  protein	  intake	  adjusted	  for	  the	  calorie	  intake	  of	  78	  participants	  in	  
the	  PREDIMED	  trial.	  Error	  bars	  represent	  the	  mean	  ±	  SEM.	  *	  p<0.05	  from	  1st	  quartile;	  #	  p<0.05	  from	  the	  
2nd	  quartile.	  
We also performed regression analyses using quartiles of protein intake and 
obtained similar results. After adjustment for BMI and calories, FGF21 
decreased (-30.7 pg/mL) when moving from the lower to higher quartiles 
(p=0.015) (Figure 7).   
Similarly to the data from mice, these results indicate that the serum 
concentrations of FGF21 are inversely proportional to dietary protein intake. 
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DISCUSSION 

THE ROLE OF REV-ERBα IiN THE INDUCTION OF FGF21 UPON 
LEUCINE DEPRIVATION 
Previous work by our group characterised the ATF4-dependent regulation of 
FGF21 during amino acid deprivation, concretely during leucine deprivation, 
and also in response to ER stress inducers (De Sousa-Coelho et al. 2012). In 
that study, we localised two evolutionarily conserved ATF4-binding sequences 
in the 5’ regulatory region of human FGF21. Later studies validated that these 
binding sequences (Lees et al. 2014; Schaap et al. 2013; Wan et al. 2014). 
To delve deeper into the molecular mechanisms that regulate FGF21 
expression during leucine deprivation, we focused on the transcriptional 
repressor Rev-erbα, which functions both as a core repressive component of 
the cell autonomous clock and as a regulator of metabolic genes.  
Rev-erbα links the circadian clock to liver metabolism (Zhang et al. 2016) and 
FGF21 levels inversely correlate to the expression pattern of Rev-Erbα and 
ALAS-1 in liver (Kaasik & Lee 2004; Oishi et al. 2008). In addition, PGC-1α 
negatively regulates hepatic Fgf21 expression by modulating the heme/Rev-
erbα axis (Estall et al. 2009). These lines of evidence led us to consider that 
Rev-erbα participates in the regulation of Fgf21 during amino acid deprivation. 
To test this hypothesis, first we analysed the expression of Fgf21, Rev-erbα and 
factors involved in Rev-erbα activity in livers of wild-type mice fed Ctl or (-) leu 
diet. In addition, given that Rev-erbα is involved in Fgf21 regulation during 
fasting (Archer et al. 2012; Estall et al. 2009), we also examined the PGC-1α 
/Rev-erbα in the liver of mice on Ctl or (-)leu diet fasted for 15 h.  
According to the bibliography, fasting increased Fgf21 mRNA levels (Inagaki et 
al. 2007), and leucine deprivation strikingly did so too in a striking manner. (De 
Sousa-Coelho et al. 2012). Interestingly, when leucine-deprived mice were 
fasted, Fgf21 expression was lower than in leucine-deprived mice fed ad 
libitum. FGF21 serum concentrations paralleled mRNA levels.  
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Rev-erbα expression was repressed by leucine deprivation and increased by 
fasting. The increased expression of this repressor during fasting can explain 
the blunted induction of Fgf21 in leucine-deprived fasted mice. Thus, we 
hypothesise that, in this condition, ATF4 activation is counteracted by a 
corepressor complex recruited by Rev-erbα. In addition, the downregulation of 
Rev-erbα during leucine deprivation boosted ATF4-mediated induction of Fgf21. 
Along the same line, the expression of Alas1, greatly increased by fasting in 
animals on both diets. According to our hypothesis, the increase in Alas-1 
supplies Rev-erbα with its endogenous ligand heme, and thus enhancing the 
recruitment of the corepressor complex.  
Finally, Pgc-1α mRNA levels were also increased by fasting. This observation is 
consistent with the notion that PGC-1α regulates ALAS-1 expression through 
the coactivation of NRF-1 and FOXO1 (Handschin et al. 2005).   
These results reveal a consistent negative correlation between Fgf21 and the 
Pgc-1α/heme/Rev-erbα axis across various nutritional states. The negative 
correlation persisted in the eWAT of mice fed a leucine-deficient diet. This 
observation indicates that the proposed mechanism could be extended to other 
tissues.  
The abovementioned results, together with the analysis of the ChIP-seq 
findings by Mitchell Lazar’s group (Figure R0) that point to the binding of Rev-
erbα to the DNA regions containing AAREs of Fgf21 promoter, led us to 
propose a model whereby the activator ATF4 and the repressor Rev-erbα 
compete for occupancy of the Fgf21 promoter. 
ATF4 triggers increased transcription by binding to AAREs, which are 
composed of a half-site for the C/EBP family and a half site for the ATF family of 
transcription factors (Wolfgang et al. 1997; Fawcett et al. 1999). ATF4 binds to 
AAREs likely as a heterodimer with members of the C/EBP family although the 
identity and properties of these proposed heterodimers have not been widely 
studied. Among C/EBP family members, C/EBPβ has been shown to 
heterodimerize with ATF4 at AREE sites in vitro and in vivo (Siu et al. 2002; 
Lopez et al. 2007; Thiaville et al. 2008; Chen et al. 2004). 
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Differential mechanisms have been proposed for Rev-erbα to regulate 
transcription. The direct binding of Rev-erbα to DNA in competition with RORs 
provides a universal mechanism for the regulation of the molecular clock across 
all tissues types, whereas the tethering of Rev-erbα by tissue-specific lineage-
determining factors determines the expression of metabolic genes. In liver, the 
Rev-erbα-tethered binding sites are enriched in other transcription factors such 
as ATF4 and CEBP, among others (Zhang et al. 2016).  
In the model we propose, ATF4 and Rev-erbα compete for interaction with their 
shared partner C/EBPβ in order to exert their function (See Figure D1). 
Figure D 1 Proposed molecular mechanism for the activation of FGF21 promoter during leucine 
deprivation. 
To test this hypothesis we analysed the activity of the human FGF21 promoter 
in the presence of ATF4 with or without inhibiting Rev-erbα. The results from 
the reporter gene assay confirmed that a decrease in Rev-erbα activity 
enhances the ATF4-mediated upregulation of Fgf21. However, we cannot 
assume from these data that ATF4 and Rev-erbα compete for the same partner 
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and DNA binding site. Further studies including co-immunoprecipitation (Co-IP), 
chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay 
(EMSA) are needed to confirm the model. In this regard, ChIP is currently being 
set up with this purpose.  
Along the same line, the study of the mouse Fgf21 promoter activity in the 
presence of ATF4, C/EBPβ and Rev-erbα revealed that C/EBPβ blocks the 
ATF4-induced activation of the Fgf21 promoter. When transfected alone, Rev-
erbα did not produce any change in ATF4 activation. C/EBPβ interaction with 
ATF4 may seem paradoxical. Low levels of C/EBPβ are constitutively bound to 
AAREs to heterodimerize with ATF4, thus facilitating its activity; however, when 
levels of C/EBPβ increase after the initial response to amino acid deprivation (4-
6h), it antagonises ATF4 (Kilberg et al. 2009). How C/EBPβ antagonises ATF4 
actions is not well understood. A feasible explanation of the blockade produced 
by C/EBPβ is that it tethered endogenous Rev-erbα present in HepG2 cells. 
When transfected alone, Rev-erbα had no effect because its tethering to the 
promoter can only occur when C/EBPβ is present.  
Finally, we propose Egr-1 as a candidate for the downregulation of Rev-erbα 
during amino acid limitation. During leucine deprivation, Egr-1 is highly induced 
in cultured cells in a GCN2-partially dependent manner (Deval et al. 2009) and 
the adenoviral overexpression of EGR-1 in primary hepatocytes downregulates 
Rev-erbα (Tao et al. 2015). Along the same line, our results showed that Egr-1 
was upregulated in liver of leucine-deprived mice and that Rev-erbα promoter 
activity decreased in the presence of EGR-1.  
Interestingly, Egr-1 is downstream of the MAPK signalling cascade initiated by 
the FGF21 binding to its receptor. In fact, Egr-1 expression is commonly used 
as an indicator of correct FGF21 signalling. This notion led us to propose a 
positive feedback mechanism in which FGF21 represses the repressor Rev-
erbα through the activation of Egr-1 (See Figure D2). In support of this idea, 
recent data indicate that a MEK-dependent transcriptional programme regulates 
the activation of EGR-1 during amino acid limitation (Shan et al. 2014).   
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Figure D 2 Proposed signalling pathways involved in FGF21 regulation during amino acid limitation 
The induction of ATF4 occurs very early in the AAR and decreases 
progressively. The results presented herein describe the mechanisms of Fgf21 
regulation after seven days of leucine deprivation. To improve knowledge of 
Fgf21 regulation, it would be interesting to analyse the time-course of the 
different factors involved. ATF4 could be the initial signal through which Fgf21 is 
boosted, and the repression of Rev-erbα could be a long-term mechanism to 
maintain the induction. 
To sum up, we propose a model whereby the induction of Fgf21 upon leucine 
deprivation is the consequence of the sum of two factors: binding of the 
activator ATF4 to the promoter and the absence of the repressor Rev-erbα. 
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THE ROLE OF FGF21 IN THE METABOLIC RESPONSE TO LEUCINE 
DEPRIVATION 
We have previously shown that leucine deprivation significantly increases 
FGF21 hepatic expression and serum protein levels (De Sousa-Coelho et al. 
2012), thereby pointing to a key role of this hormone in the amino acid 
starvation phenotype. In the current study, we demonstrate that weight loss, 
downregulation of key lipogenic genes in liver and WAT, and BAT activation in 
response to leucine deprivation are partly FGF21-dependent.  
We found that FGF21 serum levels positively correlated with the mRNA levels 
measured in liver. BAT mRNA levels remained unchanged whereas in eWAT, 
Fgf21 expression was repressed. These results are consistent with liver being 
the main source of FGF21, and they suggest that the effects of FGF21 on BAT 
and eWAT derive from the endocrine actions of liver-derived FGF21.  
We observed that FGF21 deficiency significantly attenuated weight loss under 
leucine deprivation. A leucine-deficient diet caused a reduction in food intake in 
wild-type mice and also in FGF21 null mice. This observation implies that 
FGF21 is, at least in part, responsible for weight loss in mice subjected to amino 
acid deprivation, independently of food intake. Consistent with our observation, 
previous studies have shown that FGF21-transgenic mice are resistant to diet-
induced obesity (DIO) and that FGF21 treatment triggers weight loss in 
genetically obese (Ob/Ob) mice (Kharitonenkov et al. 2005; Coskun et al. 
2008). The established reduction in food intake induced by the (-)leu diet was 
not changed by the absence of FGF21 or by disrupted leptin signalling (Ob/Ob 
mice). These observations indicate that neither FGF21 nor leptin are 
responsible for the food aversion produced by leucine deficiency.  
It has been shown that white adipocytes from FGF21 transgenic mice are 
substantially smaller than those from wild-type counterparts (Inagaki et al. 2007; 
Kharitonenkov et al. 2005). Here we demonstrate that the reduction in 
adipocyte volume and eWAT mass that occurs under leucine deprivation is 
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determined by the increased FGF21 expression and secretion that occur in 
response to this diet. 
We found that the levels of phosphorylated (P)-HSL were increased in eWAT 
upon (-)leu feeding, as had been described (Cheng et al. 2009).Therefore, 
activation of HSL, probably allowed increased lipolysis. Interestingly, our results 
show that lack of FGF21 significantly decreased P-HSL levels in the eWAT of 
(-)leu-fed mice. These findings thus points to a key role of FGF21 in leucine 
deprivation-induced lipolysis. 
The analysis of blood biochemical parameters, however, did not show 
significant changes in NEFA levels, possibly because of increased fatty acid 
utilisation by other tissues. We assume that glucagon signalling increases under 
leucine deprivation as indicated by the increased PKA-dependent HSL Ser660 
phosphorylation in WAT. In addition, a reduction in insulin levels under leucine 
deprivation was observed in wild-type but not in knockout mice. These changes 
were well correlated with the differences observed in body weight and fat mass.  
Adiponectin has recently been shown to mediate part of the metabolic actions 
of FGF21 (Holland et al. 2013; Lin et al. 2013). In contrast to the effects of 
pharmacological administration of adiponectin, we found that adiponectin 
concentration in serum was not changed by a (-)leu diet, despite the increased 
FGF21 concentration. This observation rules out adiponectin as a mediator of 
FGF21 actions upon leucine deprivation.  
We also examined whether the impaired reduction in body weight observed in 
FGF21-KO mice under leucine deprivation was related not only to lipolysis in 
WAT, but also to other factors that influence adipose tissue mass, such as 
lipogenesis. We observed a significant reduction in FASN protein and mRNA 
levels in eWAT upon (-)leu feeding. This reduction was totally blocked in 
FGF21-KO mice. Srebp1c and Acc1 mRNA levels presented the same pattern, 
although with distinct statistical significance. The same pattern was observed in 
3T3L1 cells treated with recombinant FGF21, thereby suggesting a direct effect 
of FGF21 on adipose tissue.  
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The endocrine effect of FGF21 on WAT under leucine deprivation that we 
observed here differs from the recently described autocrine effect of this 
hormone on this tissue in a fed state, in which FGF21 induces lipogenesis 
through the regulation of PPARγ activity (Dutchak et al. 2012). The decreased 
Fgf21 expression in WAT under leucine deprivation also contrasts with its 
observed induction after one day of fasting (Muise et al. 2008). FGF21 
administration to DIO mice leads to a dramatic decrease in the WAT Fgf21 
transcript. However, controversially, it induces an increase in the expression of 
adipogenic genes (Coskun et al. 2008). It seems, therefore, that the response 
to increased levels of FGF21 is determined by the origin of this hormone and 
also other factors, which may reflect the metabolic state and the energy 
requirements of the organism. 
Regarding the autocrine effects of FGF21 on liver, this protein has already been 
described to inhibit lipid synthesis (Xu et al. 2009). In this regard, the reduction 
of hepatic triglyceride levels is associated with FGF21 inhibition of Srebpc1c 
and the expression of an extended array of genes involved in fatty acid and 
triglyceride synthesis (Zhang et al. 2011). Accordingly, in the livers of FGF21-
KO mice, we did not observed the expected reduction in the mRNA levels of 
Srebp1c, Fasn and Acc1 in response to (-)leu diet. The analysis of SREBP1C, 
FASN and ACC1 protein abundance corroborated the abovementioned 
observations in mRNA levels. As a result, lipid accumulation was decreased by 
leucine deprivation in wild type mice but not in the FGF21-KO mice. 
The absence of Fgf21 itself reduced the hepatic expression of genes involved in 
fatty acid uptake (Cd36 and Fabp4) and oxidation (Acadm, Acadl, Cpt1a) in 
animals on both diets. This observation underlines the constitutive role of Fgf21 
in the lipid homeostasis in liver.  
In the liver from FGF21-KO mice, the induction of Asns expression, for which 
the gene product catalyses the glutamine and ATP-dependent conversion of 
aspartic acid to asparagine, suggests that FGF21 is not involved in the 
regulation of amino acid metabolism under amino acid starvation. We have also 
observed that contrary to the induction of ERK1/2 phosphorylation in the liver 
and WAT of mice acutely treated with FGF21 (Fisher et al. 2011), the FGF21-
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dependent phenotype under leucine deprivation is unexpectedly not related to 
the MAPK-ERK1/2 signalling pathway both in liver or WAT. 
Keeping with FGF21 signalling, the expression of Fgfr1 and Klb in eWAT 
tended to increase during leucine deficiency in wild type mice and was 
statistically higher in FGF21-KO animals. However, these findings were not true 
in BAT, thereby suggesting that the effects of FGF21 on eWAT upon leucine 
deprivation are modulated by both the increase in circulating FGF21 and the 
upregulation of the receptor complex. The significant increase in Fgfr1 and Klb 
mRNA levels in leucine-deprived FGF21-KO mice could be a compensatory 
mechanism in response to the lack of FGF21 when this hormone is required.  
BAT is a major site of adaptive thermogenesis, and it is used to preserve both 
thermal and caloric homeostasis, in response to environmental temperature or 
diet (Tseng et al. 2010). FGF21-KO mice under leucine deprivation exhibited 
decreased induction of genes defining BAT identity (i.e. Ucp1 and Dio2), while 
the FGF21 transcriptional regulators Pgc1α and Pparγ were induced in the 
same manner in both wild-type and FGF21-KO mice. Increased Ucp1 
expression may be regulated by the SNS through the activation of β-adrenergic 
receptors. We found that the mRNA expression of Adrb3 was induced by 
leucine deprivation in BAT, although there were no significant changes between 
genotypes. The β3-adrenergenic receptor stimulates p38 mitogen-activated 
protein kinase (p38 MAPK), which is required for the βAR-dependent increase 
in Ucp1 expression in brown adipocytes (Cao et al. 2001). Nevertheless, p38 
phosphorylation levels were not affected by leucine deprivation in wild-type 
mice or FGF21-KO mice when compared to controls. One of the best-known 
inducers of brown adipose tissue and its function is norepinephrine (Cannon & 
Nedergaard 2004), which has also been shown to be induced in (-)leu-deprived 
mice (Cheng et al. 2009). These findings raise the possibility that FGF21 
induces Ucp1 (and also Dio2) through an indirect mechanism involving the 
CNS. Of interest, it has recently been proposed that transgenic overexpression 
(Owen et al. 2014) and pharmacological administration (Douris et al. 2015) of 
FGF21 increase the sympathetic action. However, a more extensive analysis of 
other candidate factors should be performed, and further research will be 
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required to determine the exact mechanism by which FGF21 induces BAT 
activation. 
Feeding obese mice (Ob/Ob) with a (-)leu diet resulted in restrained effects on 
weight loss, Fgf21 induction in liver and Ucp1 induction in BAT. Of note, FGF21 
serum concentration was already elevated in the pair-fed control group, an 
observation that is consistent with obesity as an FGF21-resistant state (M. 
Fisher et al. 2010). Nevertheless, the serum FGF21 concentration was lower in 
leucine-deprived obese mice than in leucine-deprived lean counterparts. Proper 
Asns induction in obese mice discards trunked AAR as the mechanism 
underlying lower FGF21 serum concentration. Interestingly, it has been recently 
proposed that the c-Jun NH2-terminal kinase (JNK) pathway, which is involved 
in the development of obesity and insulin resistance, causes an increase in the 
expression of the repressor NCoR1 to inhibit Fgf21 expression. Therefore, 
increased JNK activity may impair Fgf21 induction in leucine-deprived obese 
mice. 
In summary, we found that FGF21 is an important factor, although not the only 
one, in mediating the changes in lipid metabolism observed upon leucine 
deprivation (Figure D3). We demonstrate that Fgf21-deficient mice under these 
circumstances show unrepressed lipogenesis in liver and WAT, decreased 
phosphorylation of HSL in WAT (thus indicating impaired lipolysis), and 
impaired induction of Ucp1 expression in BAT. Thus, our results support the 
notion that FGF21 plays a key role in the regulation of lipid metabolism during 
amino acid starvation. 
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Figure D 3 FGF21 mediates lipid metabolism in response to leucine deprivation in liver, WAT and BAT 
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THE ROLE OF FGF21 IN THE METABOLIC RESPONSE TO PROTEIN 
RESTRICTION 
Given the unfeasibility to translate single amino acid deprivation to humans, we 
focussed on low-protein diets (LPDs) as a more realistic approach. The aim of 
our study was to address whether LPDs cause similar metabolic effects to 
leucine deprivation. In addition, using the liver-specific Fgf21 KO mouse we 
determined the role of liver-derived FGF21 in the response to protein restriction. 
The LPD increased circulating FGF21 levels with an associated upregulated 
expression in liver. This KO model revealed that protein restriction almost 
exclusively affected the hepatic expression of FGF21 and that there was no 
compensatory response in other tissues, such as BAT or WAT. Analysis of 
serum human samples from the PREDIMED study extended the correlation 
between LPD and FGF21 to humans. 
Regarding the molecular basis of Fgf21 regulation during protein restriction, we 
have observed a clear induction of ATF4 protein levels in the liver of mice on 
the LPD. Our results support the notion that the GCN2-ATF4 pathway is the 
main mechanism underlying hepatic FGF21 overexpression upon protein 
restriction (Laeger et al. 2014).  
GCN2-independent mechanisms that induce hepatic FGF21 in response to 
methionine-restricted diets have recently been described (Wanders et al. 2016). 
This observation points to a different response programme in liver via the non-
canonical PERK/nuclear respiratory factor 2 (NRF2) pathway. This alternative 
pathway may effectively sense and translate the metabolic responses to 
methionine restriction in the absence of GCN2. In parallel, it has also been 
demonstrated that the absence of GCN2 during long-term dietary protein 
restriction do not completely blunt Fgf21 induction (Laeger et al. 2014). In 
conclusion, the impact of alternative pathways on stimulating FGF21 expression 
under a LPD, whether they involve ATF4 or not, should be addressed in greater 
depth.  
The ATF4-mediated upregulation of Fgf21 in liver was partially responsible for 
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the weight loss observed in mice fed a LPD, since the LFgf21KO mice were 
partially protected from this loss. The observed reduction in food intake in 
protein-restricted mice contrasts with studies on rats, which reported no 
changes (Ozaki et al. 2015) or increased consumption (Laeger et al. 2014) 
were registered. However, the decrease was consistent with the reduced food 
intake produced by a leucine-deficient diet. Minor changes in diet composition 
affecting amino acid bioavailability may explain these discrepancies. Moreover, 
although FGF21 has the potential to modulate food preferences (Talukdar et al. 
2016; von Holstein-Rathlou et al. 2016), in our mouse model it did not 
contribute to the food aversion caused by the LPD. 
When analysing the weight loss data, a global negative tendency was observed 
across tissues of mice on the LPD. However, only in heart and scWAT the 
weight loss was clearly dependent of FGF21.  
Focusing on the effects of FGF21 on scWAT and given the capacity of FGF21 
to produce the browning of white fat depots (Fisher et al. 2012), we examined 
the activation of the thermogenic programme in this tissue.  Accordingly, scWAT 
browning caused by the LPD did not occur in mice lacking hepatic Fgf21.  As 
UCP1 activity is related to EE, the blunted induction of Ucp1 in the LPD-fed 
LFgf21KO mice, may contribute to the reduction in weight loss observed in this 
mouse model under these circumstances.  
Contrary to data indicating an increase in Ucp1 expression in BAT of protein- 
restricted obese rats (Ozaki et al. 2015) and leucine-deprived mice (De Sousa-
Coelho et al. 2013), we did not observe significant changes in Ucp1 expression 
in BAT of protein-restricted mice. Nevertheless, the induction of the 
thermogenic programme in scWAT may be sufficient to affect body weight.  
An increasing body of evidence supports the capacity of FGF21 to modulate 
CNS signalling pathways that regulate a broad range of physiological functions. 
Processes such as female reproduction (Owen et al. 2013), sugar and alcohol 
preferences (Talukdar et al. 2016), gluconeogenesis in liver (Patel et al. 2015), 
circadian behaviour (Bookout et al. 2013) and the sympathetic outflow (Douris 
et al. 2015; Owen et al. 2014) have been described to be modulated by the 
Discussion
135
action of FGF21 in various regions of the brain. To further define the 
mechanisms activating Ucp1 expression in scWAT under protein restriction we 
analysed the plasma concentration of several candidate factors related to 
FGF21 and thermogenesis. We found that, among analysed factors, only 
variation in free T3 was clearly dependent on FGF21, whereas ACTH and 
noradrenaline increased in response to protein restriction in both genotypes.  
Although leucine deprivation increases free T3 levels (Cheng et al. 2009), we 
have observed a significant decrease in animals on the LPD, which is 
consistent with the effect of pharmacological administration of FGF21 on free 
T3 levels (Coskun et al. 2008). This result reinforces the idea of a mutual 
regulatory dependency (Domouzoglou et al. 2014) and suggests a negative 
feedback loop between FGF21 and the thyroid system. However, it discards T3 
as a mediator of the effects of FGF21 on thermogenesis. 
Increased levels of both FGF21 and noradrenaline are widely reported to 
induce UCP1 expression (Tseng et al. 2010; Fisher et al. 2012). The 
administration of the β-blocker propranolol to protein-restricted mice allowed us 
to distinguish between the roles of FGF21 and noradrenaline. While Ucp1 
expression was upregulated independently of adrenergic signalling, Dio2 and 
Pparγ expression was blunted by propranolol treatment. These results point to 
the induction of Ucp1 as a direct effect of liver-delivered FGF21 on scWAT and 
discard a CNS-mediated effect. Interestingly, our results agree with reported 
data indicating that adrenergic receptor blockade prevents the actions of central 
administered FGF21 but not those of peripheral administration (Owen et al. 
2014). It has been proposed that FGF21 exerts a dual effect on thermogenesis 
by both increasing sympathetic outflow and acting directly on adipocytes 
(Douris et al. 2015). Although we cannot totally discard an effect of FGF21 on 
sympathetic outflow upon protein restriction, the increase in noradrenaline 
levels caused by the LPD appeared to be independent of FGF21 levels. In this 
regard, although our results do not directly link FGF21 to adrenergic signalling, 
both signals appear to participate in the activation of the thermogenic 
programme in scWAT. 
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Consequently, the effects of the LPD on Ucp1 expression are explained by a 
direct effect of FGF21 on scWAT. In addition, our mouse model let us to 
propose that, under a LPD, the endocrine effects of liver-derived FGF21 on 
scWAT are predominant, consequently discarding any autocrine effect.  
Finally, since FGF21 is proposed as a candidate for the treatment of diabetes 
due to its beneficial effects on glucose metabolism, we analysed the role of this 
hormone in the glucose tolerance during protein restriction. The GTT showed 
that FGF21 is involved in the improved glucose tolerance observed in LPD-fed 
mice. However, the insulin response was not statistically improved, and Glut1 
mRNA levels in fat depots did not change in these animals. To further 
understand the metabolic changes regarding improved glucose tolerance, 
parameters such as fasted insulin levels or insulin signalling should be 
determined. Moreover, Glut1 mRNA levels in skeletal muscle would be also 
valuable information. 
BAT and BeAT have a powerful machinery for the oxidation of metabolic 
substrates, and correspondingly, robust enzymatic machinery for lipid and 
glucose uptake (Cannon & Nedergaard 2004). Due to this role of BAT/BeAT in 
the regulation of circulating lipids and glucose, browning of scWAT during 
protein restriction is probably responsible for the improved glucose tolerance  
To sum up, our results, together with the abovementioned published data 
(Ozaki et al. 2015; Laeger et al. 2014), provide a consistent evidence that 
protein restriction brings about weight loss and an increase in EE. In addition, 
the LPD improves glucose tolerance. All these observations are tightly linked to 
the increase in serum concentrations of FGF21 in rodents on a LPD. Our 
findings show that the effects of a LPD depend, at least in part, on the 
circulating levels of FGF21 and consequently on the liver production of this 
growth factor. The LFgf21KO mice revealed the relevance of FGF21 in the 
response to a LPD. 
Given the parallelism between the results of our study in humans and those in 
mice, we postulate that modulation of dietary protein content can bring about 
changes in the circulating levels of FGF21 in mice and humans. Furthermore, 
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we propose that in mice this nutritional intervention modulates FGF21 activity in 
the target tissues, especially scWAT. The present work describes the molecular 
mechanisms through which a LPD—via FGF21— contributes to restoring 
lipid/glucose homeostasis. The last question would be to define a nutritional 
recommendation based on a reduction in protein intake as a non-invasive 
approach to induce the hepatic expression of FGF21. 
Figure D 4 FGF21 mediates browning of scWAT and improves glucose tolerance in response to protein 
restriction 
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GLOBAL DISCUSSION 
Given the multiple beneficial metabolic effects of FGF21, this growth factor 
emerges as an attractive drug candidate for the treatment of metabolic 
conditions such as cardiovascular disease, obesity and type 2 diabetes. 
Knowledge of the molecular basis regulating a drug candidate like FGF21 is 
relevant for the design of therapeutic strategies. In this study, we sought to 
further our understanding of Fgf21 regulation upon amino acid deficiency by 
adding the repressor Rev-erbα to Fgf21 regulating factors. On the basis of our 
findings we propose that an increase in ATF4 and decrease in Rev-erbα act 
additively to boost Fgf21 expression during amino acid deficiency. However, 
how Rev-erbα is tethered to the Fgf21 promoter is not clear, and further studies 
will be devoted to this point. This question is especially relevant because 
targeting the binding of Rev-erbα to the tethering factor would more specifically 
modulate Fgf21 expression than generically targeting Rev-erbα, which would 
affect the entire clock machinery. 
Here we also demonstrate that the weight loss, downregulation of key lipogenic 
genes in liver and WAT, and BAT activation in response to leucine deprivation, 
are partly FGF21-dependent. Our results show that FGF21 serum levels 
positively correlate with the mRNA levels measured in liver but not in BAT or 
WAT, where they were not affected or even downregulated in response to 
leucine deprivation. All these results demonstrate that FGF21 mediates the 
response of the lipid metabolism to amino acid starvation. 
In the context of a dietary intervention approach and in order to translate our 
findings to humans, we analysed the role of FGF21 in response to protein 
restriction instead of to the deficiency of a single amino acid. 
Our results demonstrate that the effects of a LPD on body weight, browning of 
scWAT, and glucose tolerance depend, at least in part, on the circulating levels 
of FGF21 and consequently on the liver production of this growth factor. The 
LFgf21KO mice revealed the relevance of FGF21 in the response to a LPD, but 
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also in the metabolic and transcriptional pathways activated or repressed by 
protein restriction. 
We expected to find similar phenotypes between leucine deprivation and 
protein restriction. Indeed, we observed similarities regarding the induction of 
FGF21 and its contribution to weight loss. However, the LPD did not reproduce 
the robust induction of Ucp1 observed during leucine deprivation in mouse BAT. 
In addition, preliminary studies discarded changes in lipogenic genes in liver 
and eWAT and led us to focus on the metabolic effects observed on scWAT. 
These discrepancies not only underlie the different roles of each single amino 
acid in the metabolic response but also the important differences between 
protein restriction and amino acid deprivation. Taking into account these 
considerations, the contribution of each amino acid to the modulation of FGF21 
and the way in which a deficiency in specific types of dietary protein alters 
FGF21 expression gain relevance. In this regard, future studies should 
addressed these questions.  
During leucine deprivation, the FGF21 concentration in serum was higher than 
during protein restriction. Circulating FGF21 levels may partly explain the 
different phenotypes observed in leucine-deprived and protein-restricted mice. 
The concentration of peripheral FGF21 may be critical to ensure its capacity to 
cross the blood-brain barrier and thus, for its CNS-mediated effects. This 
observation would explain, for example, the induction of Ucp1 during leucine 
deprivation through increased sympathetic outflow to BAT. Circulating FGF21 
levels reached under protein restriction would not be higher enough to allow this 
hormone to cross the blood-brain barrier. Consequently, it would not be able to 
exert its actions on the CNS to increase Ucp1 expression in BAT. Along the 
same lines of this hypothesis, it has been proposed that differences between 
the effects of endogenous FGF21 and pharmacological treatment are due to the 
higher levels reached by the latter. Furthermore, our results demonstrate that 
precise mechanisms regulate Fgf21 expression during fasting, amino acid 
deprivation, or both, resulting in variations in FGF21 serum concentrations. This 
observation supports the notion that a fine-tuning of FGF21 serum 
concentrations is critical to determine its actions. 
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As previously mentioned, amino acid deficiency and protein restriction 
increased Ucp1 expression and EE. It may seem contradictory that under 
nutrient deficiency the organism would channel energy into thermogenesis. In 
this regard, we have questioned the purpose of this process. On the one hand, 
the uncoupled oxidation in BAT (or BeAT) may provide the metabolic precursors 
needed to adapt to a new metabolic state. On the other hand, the cold seasons 
usually coincide with a decrease in food availability, which can cause nutritional 
deficiencies in some amino acids. The induction of the thermogenic programme 
in response to amino acid restriction could be the result of an evolutionary 
adaptation, preparing the organism for the cold to come.  
Undoubtedly, a diet that naturally increases the secretion of a candidate factor 
for the treatment of the metabolic syndrome is very attractive and establishes 
the modulation of dietary protein content as an inexpensive and viable 
approach. However, some limitations may lower the potential of this strategy. 
Our results in Ob/Ob mice suggest that the physiological increase of FGF21 in a 
context of obesity, which has been described as an FGF21-resistant state (F. 
M. Fisher et al. 2010), may not be sufficient to produce the expected benefits.
The increase in the sensitivity of the target tissues should be a goal in parallel
to the increase in circulating FGF21 levels. In this regard, some published data
and unpublished results from our group show that bioactive dietary compounds
such as polyphenols, improve the FGF21 signalling. Therefore, LPD rich in
polyphenols, could satisfy both conditions, namely increased circulating FGF21
levels and enhanced target tissues sensitivity.
Studies performed in humans provide contradictory results regarding the 
correlation between plasma levels of FGF21, BMI, and insulin resistance 
(Zhang et al. 2008; Chavez et al. 2009; Chen et al. 2008). Also, the FGF21-
resistant state described in mice is not well established in humans, and the 
beneficial effects of FGF21 induction have yet to be demonstrated in the latter. 
Further studies will be needed to evaluate the effects of a LPD / FGF21 
induction on the metabolic profile of obese and insulin-resistant subjects. Also, 
potential long-term undesired effects such as impact on muscle mass or bone 
density require attention.  
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There is an array of possibilities to extend the strategy to increase the 
endogenous production of FGF21 as an alternative to exogenous 
administration. In this context, several scenarios that alter aminoacidemia also 
lead to an increase in FGF21 expression. The absence of slc6a19 (neutral 
amino acid transporter) causes a lack of systemic neutral amino acids, resulting 
in an increase in FGF21 transcription (Jiang et al. 2015).  Treatment with the 
antileukemic agent asparaginase depletes circulating asparagine and glutamine 
levels, thereby promoting FGF21 expression (Wilson et al. 2015), and the 
skeletal muscle-specific knockout mice for glucocorticoid receptor (GR) show 
reduced alanine flux from skeletal muscle during fasting, resulting in an 
increase in FGF21 plasma levels (Shimizu et al. 2015). Hence, it is likely that 
many other contexts that lead to a reduction in amino acid availability also 
trigger FGF21 expression. In this regard, we propose the following as 
examples: reducing amino acid absorption by inhibiting amino acid transporters 
in the intestinal tract, increasing amino acid catabolism, and partially blocking 
tRNAs to initiate the AAR. Furthermore, in addition to amino acids, other 
nutritional impacts can modulate FGF21 expression (Pérez-Martí et al. 2016).  
In summary, the results from the current study, together with a growing number 
of publications, highlight the role of FGF21 in metabolic adaptation to a wide 
variety of stress conditions, including amino acid starvation and protein 
restriction. Our findings provide new insight into the modulation of dietary 
protein as a strategy to induce elevated serum concentrations of this 
therapeutic candidate. 
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CONCLUSIONS	  

THE	   ROLE	   OF	   REV-­‐ERBα 	   IN	   THE	   INDUCTION	   OF	   FGF21	   UPON	  
LEUCINE	  DEPRIVATION
• Decreased Rev-erbα expression and activity enhances FGF21
expression during leucine deprivation.
• EGR-1 represses the promoter activity of Rev-erbα.
THE	  ROLE	  OF	  FGF21	   IN	  THE	  METABOLIC	  RESPONSE	  TO	   LEUCINE	  
DEPRIVATION
• FGF21 partly mediates the weight loss under leucine deprivation.
• FGF21 mediates increased lipolysis, decreased expression of
lipogenic genes and reduction of adipocytes size in eWAT upon
leucine deprivation.
• FGF21 mediates diminished expression of lipogenic genes and
reduction in lipid content in liver upon leucine deprivation.
• FGF21 mediates upregulation of thermogenesis machinery in BAT
upon leucine deprivation.
• The FGF21-dependent effects are not regulated through the
MAPK ERK1/2 pathway during leucine deprivation.
• Obese mice (ob/ob) are partially resistant to leucine deprivation
effects concerning weight loss, FGF21 circulating levels and Ucp1
expression in BAT.
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THE	  ROLE	  OF	  FGF21	   IN	  THE	  METABOLIC	  RESPONSE	  TO	  PROTEIN	  
RESTRICTION
• Protein restriction increases ATF4 protein levels and FGF21
expression in liver that couples with increased circulating FGF21.
• In humans, dietary protein intake inversely correlates with plasma
FGF21 concentration.
• Liver-derived FGF21 induces browning of scWAT where Ucp1
expression is upregulated independently of the adrenergic
signalling.
• Hepatic FGF21 mediates the improved glucose tolerance under
protein restriction.
Conclusions
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ANNEXES	  

ANNEX1:	  Diets	  composition	  

Control diet Low protein diet 
g (%) Kcal(%) g(%) Kcal(%) 
Protein 20 21 5 5 
Carbohydrate 66 68 81 83 
Fat 5 12 5 12 
Total 100 100 
Kcal/g 3,90 
Ingredient g Kcal g Kcal 
Casein 200 800 50 200 
DL-Methionine 3 12 1 4 
Corn Starch 150 600 252 1008 
Maltodextrin 10 0 0 50 200 
Sucrose 500 2000 500 2000 
Cellullose, BW200 50 0 50 0 
Corn Oil 50 450 50 450 
Mineral Mix S10001 35 0 35 0 
Vitamin Mix V10001 10 40 10 40 
Choline Bitartate 2 0 2 0 
FD&Y Yellow Dye #5 0 0 0,05 0 
Total 1000 3902 1000,05 3902 
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Control diet Leucine deficient diet 
g (%) Kcal(%) g(%) Kcal(%) 
Protein 17 18 16 16 
Carbohydrate 69 71 70 72 
Fat 5 12 5 12 
Total 100 100 
Kcal/g 3,90 3,90 
Ingredient g(%) Kcal(%) g(%) Kcal(%) 
L-Arginine 10 40 10 40 
L-Histidine-HCl-H2O 6 24 6 24 
L-Isoleucine 8 32 8 32 
L-Leucine 12 48 0 0 
L-Lysine-HCl-H2O 14 56 14 56 
L-Methionine 6 24 6 24 
L-Phenylalanine 8 32 8 32 
L-Threonine 8 32 8 32 
L-Tryptophan 2 8 2 8 
L-Valine 8 32 8 32 
L-Alanine 10 40 10 40 
L-Asparagine-H2O 5 20 5 20 
L-Aspartate 10 40 10 40 
L-Cysteine 4 16 4 16 
L-Glutamic Acid 30 120 30 120 
L-Glutamine 5 20 5 20 
Glycine 10 40 10 40 
L-Proline 5 20 5 20 
L-Serine 5 20 5 20 
L-Tyrosine 4 16 4 16 
Total L-Amino Acids 170 0 158 0 
Corn Starch 550,5 2202 562,5 2250 
Maltodextrin 10 125 500 125 500 
Cellulose 50 0 50 0 
Corn Oil 50 450 50 450 
Mineral Mix S10001 35 0 35 0 
Sodium Bicarbonate 7,5 0 7,5 0 
Vitamin Mix V10001 10 40 10 40 
Choline Bitrartrate 2 0 2 0 
Red Dye, FD&C#40 0 0 0,025 0 
Blue Dye, FD&C#1 0,05 0 0 0 
Yellow Dye, FD&C#5 0 0 0,025 0 
Total 1000,05 3872 1000,05 3872 
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ANNEX	  2:	  Promoters	  sequences	  

MOUSE	  FGF21	  PROMOTER	  
GGGCCCAGCTGTTACTTTTTAGATTGGTAAATACAGCAAATAACTTTTTTTCTG
GCCAGAAGGAGGAAAGAGAGTGTTTTCAACATTCTTTTTAGACAGGCCTCTGAA
GTGAGGCTGGAGACAAAGGTTCTCCCACGGTTCCTTCCGGAGCCCATTAATTAA
TCGCATGGAGTCGGGGCCTGAAGCCTCACCTTGACACCTTAAAAGACTCAGAAA
TTCCACTTGGCTAGCCCAAGATGAGATCATTTCTTCACACTGCAGAGTTCCAGG
GCCACATCAGTTCTAAAGGTCCACTCCCCAGCCTCCTCCCCTTAGATGCTCCTT
GGGACTTAGGGGTCAGTGCTCCAGTCTCACTCCCAAGAGTCCTTGCTCAGGGTT
CCTCCTAGAAATCCAAACTCGGCCCCAGCGCCTTTGACTGCAGGAAACAACCCA
GCTCTTCCCCTTCACCGAGCCTAATCCTCCCACCCCCCAAAGCATCTGGAGAGC
ACCTGTGCAGGACGCTGTCTGGTGAAAGAAGCACTAGGATTGCATCAGGGAGGA
CAGCAGCTGAGCACAAGGCCCGAATGCTAAGCAGGGGTTGGTGAGGGTGACTGG
CCTGTGGCCAGCTGGGAGACTTCCACCTGCTGGGCTGAGGACTCCTCTTACACA
CTGCTGATACAGCTCTCCTGATGAAAGAAAGCCTCAGACACGCCCCCCCCCCAA
AGCACCTTGAAGCTTAAAATTCCAAAAGGATGAACCACACCAGCTCAGTTGCTT
ACACAGAAAGTCTGAAGCCCCAGGTTCCTTCTTAGTACCCAAGAGCCAGACCCT
AGCCTCCTCCCTCAGACCCAAGAGCTAGATCCCAGCCTCCTCCCTCAGACCCAA
GAGCCAGACCCTAGCCTCCTCCCTCAGATCCAGGAATACAGACCCCAGCCACCT
CCCTCAGACCCAGAACTGCAGAGCCCAGCCACCTTCAGACCCAGGAGTGTAGAC
TTCAGTCTCCTACCTCAGACCCAGAACTGCAGACCCCAGCTACCTTCAGACCCA
GGAGTGTAGACCCCAGCCTCCTCCTTCAGACTCAGGAGTGTAGACCCCAGCCTC
CTCCCTCAGACTCAGGAGTGCAGACCCTAGCCTCCTCCCTCAGACTCAGGAGTG
CAGACCCCAGCCTCCTCCTTCAGACTCAGGAGTGCAGACAAGTCCCCTTCCTTA
GACCCAAGGCCCCAAACCCCATCTTTCCTCCCCTCAGATACTAAGGTGAAGATC
CCAACCTCCTCCAGAGTCCAACCCTCCTCCCTCAGACCAAGGAGCACAGACCCC
AGCCTCCTCCTCCAGATTTAGGAGTGCAGACCCGCCCCCCAGCACTCTTCCCCC
CCAAACCCAGGGGGCCCATGCCTAGCCCTTTTCATTCAGACCCCTGTTGGAAAG
ACCCCCCCATTGCATCATCCGTCCAGGCCGCCCTGGCCACGGTGGAATTCAGGT
TCCTGCCAAGTGTGTCAAATATCACGCGTCAGGAGTGGGGAGGGCACGTGGGCG
GGCCTGTCTGGGTATAAATTCTGGTATTTCTGCGTTCACCAGACAGCCTTAGTG
TCTTCTCAGCTGGGGATTCAACACAGGAGAAACAGCCATTCACTTTGCCTGAGC
CCCAGTCTGAACCTGACCCATCCCTGCTGGGCACCGGAGTCAGAACACAATTCC
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AGCTGCCTTGGCTCCTCAGCCGCTCGCTTGCCAGGGGCTCTCCCGAACGGAGCG
CAGCCCTGATGGAATGGATGAGATCTAGAGTTGGGACCCTGGGACTGTGGGTCC 
AARE1àATTGCATCA 
AARE2àATTGCATCA 
Fw primerà AGTCCCCGGGATTAATTAATCGCATGGAGT 
Rv primerà GCAATCTCGAGGCTGTCTGGTGAACGCAGA 
ATGà Translation start site 
AGAà Transcription start site 
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HUMAN	  FGF21	  PROMOTER	  
CCTACCCTTGCACCCTTAGGGGCTCCAGGAAATTAGCCAACCTGTCTTCCCTCTGGGTG
CCCACTCCAGGGCCTGGCTTGGCTGCCAACTCCAGTCAGGGACTTTCAGCCACCCCTCC
CCCCAGGTTATTTCAGGAGCACCTGCCTGGGCCTGGGATGGCTTCTCTGGTGAAAGAAA
CACCAGGATTGCATCAGGGAGGAGGAGGCTGGGATGTCCAGGGTCTGAGCATCTGAGCA
GGGACAGATGAGGTTGAGGTTGGCCCACGGCCAGGTGAGAGGCTTCCAAGGCAGGATAC
TTGTGTCTCAGATGCGGTCGCTTCTTTCATACAGCAATTGCCGCCTTGCTGAGGATCAA
GGAACCTCAGTGTCAGATCACGCCCTCCCCCCAAACTTAGAAATTCAGATGGGGCGCAG
AAATTTCTCTTGTTCTGCGTGATCTGCATAGATGGTCCAAGAGGTGGTTTTTCCAGGAG
CCCAGCACCCCTCCTCCCTCCGACTCAGGTGCTTGAGACCCCAGATCCTTCTCTCTGAG
ACTCAGGAATGTGGGCCCCCAGCCCCTTTCACCTGGGTCCCAGCTAACCCGATCCTCCC
CTCCCTCATCCCCTAGACCCAGGAGTCTGGCCCTCCATTGAAAGGACCCCAGGTTACAT
CATCCATTCAGGCTGCCCTTGCCACGATGGAATTCTGTAGCTCCTGCCAAATGGGTCAA
ATATCATGGTTCAGGCGCAGGGAGGGTGATTGGGCGGGCCTGTCTGGGTATAAATTCTG
GAGCTTCTGCATCTATCCCAAAAAACAAGGGTGTTCTGTCAGCTGAGGATCCAGCCGAA
AGAGGAGCCAGGCACTCAGGCCACCTGAGTCTACTCACCTGGACAACTGGAATCTGGCA
CCAATTCTAAACCACTCAGCTTCTCCGAGCTCACACCCCGGAGATCACCTGAGGACCCG
AGCCATTGATGGACTCGGACGAGACCGGGTTCGAGCACTCAGGACTGTGGGTTTCTGTG
CTGGCTGGTCTTCTGCTGGGAGCCTGCCAGGCACACCCCATCCCTGACTCCAGTCCTCT
CCTGCAATTCGGGGGCCAAGTCCGGCAGCGGTACCTCTACACAGATGATGCCCAGCAGA
CAGAAGCCCACCTGGAGATCAGGGAGGATGGGACGGTGGGGGGCGCTGCTGACCAGAGC
CCCGAAAGTGAGTGTGGGCCAGAGCCTGGGTCTGAGGGAGGAGGGGCTGTGGGTCTGGA
TTCCTGGGTCTGAGGGAGGAGGGGCTGGGGGCCTTGGCCCCTGGGTCTGAGGGAGGAGG
GGCTGGGGATCTGGACTCCTGGGTCTGAGGGAGGAGGGGCTGGGGATCTGGGCCCCTGG
GTCTGAGGGAGGAGGGGCTGGGTCTGGACCCCTGGGTCTGAGGGAGGAGGGGCTGGG 
AARE1àATTGCATCA 
AARE2àGTTACATCA 
Fw primer: GGTACCAGCCAACCTGTCTTCCCTCT 
Rv primer: CTCTGGCCCACACTCACTTT 
GAGCTCàSacI restriction site
ATGà Translation start site 
CTGà Transcription start site 
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MOUSE	  REV-­‐ERB	  ALPHA	  PROMOTER	  
TCGGGGAGTTGAGGGGTGGGAGTTAAATGATCCTCATGTTCTCCCTAAACTGTGGGCTT
CTTCTGCTATCATGAAGCCCTGCAGAGAGCAGACCCCCCTCTCTCTATGAGGACCTCAG
AGCACTTTCCCTTTGTTCTCCTTTTTATTTCCCAGACAAAGGGAAATGACTCACCCCAA
AGTCACTTGAGTGGGCAGTGTGGTGTCATATAAGCAAACAGGGAGTCCCTAGGGATATC
CCCGTGCTATGCCAGTCCTACCCGTGGGGGCTGGGGTTAGGGTGAAGAAGAGAAAGGGG
TTTTATTTACACTGCTTGTCGCCCACCTTGTCACCATAGCAAAAGATGCTTAAGTTCTT
GATTTAAGGGAAATCTCTCCTCCCAGCTTGTCTTTCTCCCCCTAGTCACCACTAACCTC
AGGGTGAGGTCAGTTCTCCAATCACGTGAAGCTCTCACGTTTGCTAGGTTTGCAGAAAG
GGCCTTTTAGCTTTGATCTTCCACGGAGCAGTAAAGCTTGCCAGGCCCTCCCCAGGAAT
TCACATGCCCTTGCCATACAAGGCTTTCCAAACACGCCACCCTGACTCTTCAGAAAACC
CCACCCCAGTCCACTTTCAGCTCCTCCCCGCTGCCAGCAAGCACTTTTGCAAAGCAGAA
AAGGAATAGGCACACTCCACCTACATTGTCAGTAGACTACAAATCCCAACAATCCTGGC
GGTGCGCAGGCGCACAGATCTCAACGTGCCGGCTGCTGGAAAAGTGTGTCACTGGGGCA
CGAGGCGCTCCCTGGAATCACATGGTACCTGCTCCAGTGCCGCGTGCGGCCCGGGAACC
CTGGGCTGCTGGCGCCTGCGCAGAGCCCTCTGTCCCAGGGAAAGGCTCGGGCAAAAGGC
GGTTGAGATTGGCAGAGTGAAATATTACTGCTGAGGAAACGTAGCAGGGCACACGTCTC
TCTTTGCGTCCTGGTGCCTCATTTCTCCATCACCTACTTACTTCCTGGTTGCAGCTTCT
CTTCCTTTGGGACTTTTGCACCCGGAGCTCCAGATTCATTACCCTGCTTCACTGCGGAG
CCTTCAGGAGTGGCATCCGGTGCACTGCAGAGACCCGACTCTCCTTGCTACCTTATAGC
CAGAACTGCTGCAGGCTGATTCTTCACACACACACTCTCTGCTCTTCCCATGCAAATCA
GATCTCAGGTGCCTCAGCGTCCTACCCTTCTGGAGGGCTGCAGTATAGCCACCCCAAGA
CCTTACTGCTCAGTGCCTGGAATCCTGATTGCGAACTGCGGGGCTCACTCGTCTCCCTC
AGCCATTGCCCAGGGGGCGAGAGAGGCCATCACAACCTCCAGTTTGTGTCAAGGTCCAG
TTTGAATGACCGCTTTCAGCTGGTGAAGACATGACGACCCTGGACTCCAATAACAACAC
AGGTACTGAGATTCTTATCTTTGCTCTGTCACTGTCTCCATTTCCATCCAAGGCTTATG
AGAGGAACTTTGTAAGGGATTGGGGATTCCCTCTGGC 
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GTGCGCAGGCGC Conserved EGR-1response element conserved in 
mice and human.  
ACT à Transcription start site 
ATG à Translation sart site 
Fw primer 5’-AAACGCGTAATCTCTCCTCCCAGCTTGT-3’ 
Rv primer 5’-AACTCGAGGTCTTCACCAGCTGAAAGCG-3’ 
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Abstract: Obesity is a worldwide health problem mainly 
due to its associated comorbidities. Fibroblast growth 
factor 21 (FGF21) is a peptide hormone involved in meta-
bolic homeostasis in healthy individuals and considered 
a promising therapeutic candidate for the treatment of 
obesity. FGF21 is predominantly produced by the liver 
but also by other tissues, such as white adipose tissue 
(WAT), brown adipose tissue (BAT), skeletal muscle, and 
pancreas in response to different stimuli such as cold 
and different nutritional challenges that include fast-
ing, high-fat diets (HFDs), ketogenic diets, some amino 
acid-deficient diets, low protein diets, high carbohy-
drate diets or specific dietary bioactive compounds. Its 
target tissues are essentially WAT, BAT, skeletal muscle, 
heart and brain. The effects of FGF21 in extra hepatic tis-
sues occur through the fibroblast growth factor receptor 
(FGFR)-1c together with the co-receptor β-klotho (KLB). 
Mechanistically, FGF21 interacts directly with the extra-
cellular domain of the membrane bound cofactor KLB 
in the FGF21- KLB-FGFR complex to activate FGFR sub-
strate 2α and ERK1/2 phosphorylation. Mice lacking KLB 
are resistant to both acute and chronic effects of FGF21. 
Moreover, the acute insulin sensitizing effects of FGF21 
are also absent in mice with specific deletion of adipose 
KLB or FGFR1. Most of the data show that pharmaco-
logical administration of FGF21 has metabolic beneficial 
effects. The objective of this review is to compile existing 
information about the mechanisms that could allow the 
control of endogenous FGF21 levels in order to obtain 
the beneficial metabolic effects of FGF21 by inducing 
its production instead of doing it by pharmacological 
administration.
Keywords: beta-klotho; diet; energy metabolism; fibro-
blast growth factor 21; obesity.
Introduction
Fibroblast growth factor 21 (FGF21) increases energy 
expenditure. It thus has beneficial effects on glucose/lipid 
homeostasis and on body weight control and emerges as 
a novel therapeutic agent for the treatment of metabolic 
diseases such as obesity, type 2 diabetes and metabolic 
syndrome. In rodent and primate models of the aforemen-
tioned conditions, FGF21 has the capacity to restore gly-
cemia and lipid profile, and to improve insulin resistance 
[1, 2].
It is widely accepted that FGF21 participates in meta-
bolic homeostasis in health but its action takes on greater 
relevance in diseases.
To date, the pharmacological use of FGF21 is limited 
due to its half-life of around 1–2 h. In order to improve 
the pharmacokinetics, selectivity, and potency of FGF21, 
several laboratories have focused on designing FGF21 
analogs. Two such analogs (LY2405319 and PF05231023) 
are currently being tested in clinical trials and have yielded 
similar results: benign toxicology, decreased plasma TGs 
and low-density lipoprotein cholesterol, increased high-
density lipoprotein cholesterol, modest weight loss, ele-
vated adiponectin, reduced insulin levels, and elevated 
plasma ketones. Surprisingly, no glucose-lowering effect 
was registered in any trial. This is a major setback as 
both compounds were assessed mainly as anti-diabetic 
drugs. However, the results of these two trials highlight 
the capacity of FGF21 to ameliorate lipid and cholesterol 
metabolism [3–5].
Nutritional signals play an important role in con-
trolling gene expression in mammals. Macronutrients 
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[carbohydrates, fatty acids (FAs), proteins], micronutri-
ents (minerals and vitamins), and some bioactive dietary 
compounds have the capacity to regulate gene expres-
sion and thus metabolic homeostasis. In this context, 
it has been described that endogenous FGF21 levels are 
regulated by various nutritional challenges such as high-
fat diets (HFDs), low-protein diets (LPDs), amino acid-
deficient diets, fasting, and polyphenols [6, 7] (Figure 1). 
However, the levels of this molecule are also determined 
by metabolic stress, including obesity, type 2 diabetes 
(T2DM), and non-alcoholic fatty liver disease (NAFLD) 
[8]. In this regard, this review summarizes how various 
nutrient stimuli and diet components regulate the 
expression of FGF21, and it also seeks to shed light on 
the molecular mechanisms and the clinical implications 
of the crosstalk between diet composition FGF21 levels 
and signaling.
FGF21 signal transduction
FGF21, together with FGF15/19 and FGF23, is an atypical 
member of the fibroblast growth factor (FGF) family. With 
endocrine, paracrine and autocrine properties, FGF21 
lacks the heparin domain present in the rest of the family 
members, thus allowing it to be secreted. Defined as a 
hepatokine, myokine, and adipokine, FGF21 is expressed 
in several tissues, including the liver, pancreas, thymus, 
heart, testis, skeletal muscle, white adipose tissue (WAT), 
brown adipose tissue (BAT), heart, and brain. It also exerts 
action on multiple target tissues, ranging from peripheral 
to central [9].
FGF21 acts as a hormone-like peptide and its signal-
ing pathway requires FGF21 binding to a fibroblast growth 
factor receptor (FGFR). FGFRs are tyrosine kinase recep-
tors, and seven isoforms have been described (1b, 1c, 2b, 
2c, 3b, 3c and 4). FGFR1c has been defined as the main 
mediator of FGF21 response in vivo [10] through an obli-
gate dimerization with the co-receptor β-klotho (KLB) [11]. 
The co-expression of these two receptors determines the 
sensitivity of a tissue or organ to FGF21 signaling.
Regarding the signal transduction pathway, the 
binding of FGF21 to the FGFR-KLB dimer stimulates the 
phosphorylation of FGFR substrate 2α (FRS2α) and the 
activation of extracellular signal-regulated kinase 1/2 
(ERK1/2) and Akt [12].
Figure 1: FGF21 expression is regulated by diet and its effects are widely distributed.
Endogenous levels of FGF21 are regulated by different macronutrients and bioactive dietary compounds. Acting as a hormone, FGF21 
impacts on several tissues where regulates mainly lipid and glucose metabolism.
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FGF21 as a hepatokine, myokine, adipokine 
and other kines
Liver production and secretion
The main source of FGF21 is the liver, where its expres-
sion is induced in response to stress. FGF21 was ini-
tially described as a fasting-adaptation hormone, as its 
hepatic production coupled to plasma levels is dramati-
cally increased during prolonged fasting [13, 14]. It is now 
known that hepatic FGF21 expression is also induced in 
other liver-stress circumstances such as in obesity, spe-
cific nutritional conditions, liver injury, viral infection, 
chemical insult, hepatosteatosis, steatohepatitis, NAFLD, 
cirrhosis, and liver cancer [8, 15–18].
Hepatic overexpression of FGF21 triggers ketogenesis, 
gluconeogenesis, and FA oxidation (FAO) and suppresses 
lipogenesis in the liver [15, 19]. However, the autocrine 
effects of FGF21 on this organ are still under debate. FGFR4 
is the predominant isoform in the liver, but the FGFR4-KLB 
complex cannot activate the FGF21 transduction pathway 
[10]. In contrast, hepatic FGFR1 levels are low, and it is 
unclear whether they are enough to ensure FGF21 signal-
ing. Later studies reported contradictory results regarding 
the role of FGF21 in ketogenesis, thereby suggesting that 
the physiological effects of this molecule may differ from 
the pharmacological ones.
As a hepatokine, FGF21 affects WAT and BAT, tissues 
in which it regulates lipid metabolism – mainly by induc-
ing lipolysis and browning and by increasing thermogenic 
capacity [20, 21]. It also exerts action in the brain, where 
it is able to reduce physical activity, induce torpor, and 
regulate circadian behavior [22, 23]. In conclusion, all 
data indicate that FGF21 is produced and secreted by the 
liver when the function of this organ is compromised by 
stress and that it is responsible for restoring and maintain-
ing metabolic homeostasis. Hepatic FGF21 expression is 
highly sensitive to nutritional status, and the molecular 
mechanisms that modulate its expression in the liver will 
be reviewed in the following chapter.
White adipose tissue: autocrine and paracrine effects
Adipose tissue is the main target tissue of FGF21 and the 
major mediator of its beneficial effects. While the physi-
ological effects of FGF21 during fasting remain elusive, 
most data on its signaling in WAT derive from studies in 
which it was pharmacologically administered or over-
expressed in obese mice. Nevertheless, FGF21 shows 
paradoxical actions on WAT depending on its source. 
Fgf21-over expressing mice show induced lipolysis [13, 
24]. In contrast, Fgf21-knockout mice present enhanced 
lipolysis in late fasting [21]. In addition, while FGF21 sup-
presses lipolysis in mouse and human adipocytes [25], it 
is induced by peroxisome proliferator activating receptor 
g (PPARg) in WAT upon feeding, thus stimulating adipo-
genesis [26, 27].
Regarding glucose metabolism, FGF21 induces 
glucose uptake in 3T3L1 adipocytes by increasing glucose 
transporter 1 (GLUT1) independently of insulin action [2, 
28]. Moreover, later studies showed increased glucose 
uptake in both WAT and BAT of lean mice infused with 
FGF21 and fed a chow diet [29].
In summary, in WAT, FGF21 induces genes involved 
in glucose uptake, lipogenesis and lipolysis, depending 
on the metabolic state of the adipocytes. These appar-
ently contradictory effects may be due to compensatory 
effects of genetic modifications in mice, different nutri-
tional status and different FGF21 concentrations reached 
between pharmacological administration and physiologi-
cal secretion.
WAT is not only a FGF21 target tissue but also a media-
tor of the effects of this growth factor. In this regard, the 
glucose- and insulin-sensitizing effects of FGF21 require 
the production and secretion of adiponectin from WAT. 
Accordingly, FGF21 stimulates this mechanism in rodents, 
and adiponectin-knockout mice fail to reproduce the sen-
sitizing effects of FGF21 [30]. Similarly, FGF21 also reduces 
the levels of the sphingolipid ceramide. Sphingolipid 
ceramides have been associated with insulin resistance 
caused by lipotoxicity. By inducing adiponectin secretion, 
FGF21 diminishes the accumulation of ceramides in obese 
animals [31]. Overall, despite some contradictory effects of 
FGF21 in adipose fat depots, adipose tissue is considered 
indispensable for the physiological and pharmacological 
effects of FGF21.
Finally, FGF21 induces the expression of uncoupling 
protein 1 (Ucp1), thus producing the so-called browning 
process of WAT in an autocrine, paracrine or endocrine 
fashion [20, 32]. Browning occurs in multilocular beige 
adipocytes in specific susceptible WAT depots, such as 
inguinal and perirenal tissue, through an increase in 
the expression of genes involved in thermogenesis and 
confers a brown fat-like phenotype to white adipocytes.
Brown adipose tissue: FGF21 induces thermogenic 
capacity
BAT is a FGF21 target tissue since it expresses FGFR1 and 
KLB; however, it is also a source of FGF21. In BAT, FGF21 
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stimulates glucose uptake and thermogenesis through the 
induction of UCP1 in the interscapular depot in an auto-
crine and paracrine fashion [33]. Upon cold exposure, 
FGF21 expression is increased in BAT and other cold-
sensitive fat depots in the β-adrenergic/ATF2-dependent 
pathway [32–34]. In this regard, Fgf21-deficient mice 
respond poorly to cold exposure and show greater shiver-
ing [32]. The mechanisms underlying the action of FGF21 
on BAT/WAT are still not well understood. Part of the 
FGF21-induced activation of the thermogenic program is 
driven by PGC1a, as FGF21 increases the protein levels of 
this molecule. Similarly, Pgc1a-knockout mice show an 
impaired response to FGF21 [32].
Furthermore, hepatic FGF21-mediated thermogenesis 
has also been described in response to maternal milk con-
sumption in neonatal pups [35], and also in situations of 
metabolic stress, for example upon amino acid restriction 
[20]. These observations suggest that the hepatic FGF21-
mediated increase in thermogenic capacity is an adaptive 
response to metabolic stress.
It has been proposed that the effect of FGF21 on 
energy expenditure and weight loss may be due to an 
increased thermogenic capacity of BAT and WAT (brown-
ing). However, recent experiments in Ucp1-null mice and 
interscapular BAT-excised mice show that when FGF21 is 
administered pharmacologically, UCP1 is not required for 
the improvement of the glucose, cholesterol, and free FA 
profile. Nonetheless, the increment in metabolic rate asso-
ciated with the administration of FGF21 is diminished in 
these mice [36–38]. These data suggest that the metabolic 
benefits of FGF21 are partly UCP1-independent.
Skeletal muscle: FGF21 is produced in response to 
mitochondrial dysfunction
FGF21 expression in muscle was first described in Akt1 
transgenic mice in which the mRNA and serum levels 
of FGF21 were induced [39]. In normal conditions, basal 
expression of FGF21 in skeletal muscle is low but its 
expression is increased by insulin [39, 40], exercise [41], 
mitochondrial myopathies [42], impaired mitochondrial 
FAO [43], muscle-specific autophagy deficiency [44] and 
transgenic overexpression of Akt1, perilipin-5 [45] or Ucp1 
[46] in skeletal muscle. The induction of FGF21 in muscle
due to a metabolic dysfunction is driven by the tran-
scription factor ATF4, which is activated by endoplasmic
reticulum (ER) stress. The AMPK and PI3K/Akt1 signaling
pathways are also able to increase FGF21 expression [43].
The impact of FGF21 on skeletal muscle is not clear, as 
the expression levels of KLB do not seem to be sufficient 
to respond to FGF21. Several studies suggest that FGF21 
administration can improve glucose uptake in vitro [47, 
48], and a model of impaired mitochondrial FAO has 
recently shown the same in vivo [43].
In contrast, the role of FGF21 as a myokine is more 
evident. In the abovementioned conditions where 
FGF21 is overexpressed in muscle, the plasma levels of 
this growth factor also increase. The metabolic effects 
of this increase include the reduction of fat content in 
liver, increased FAO, resistance to a HFD and brown-
ing of WAT. These results show that FGF21 can act as a 
myokine when secreted in response to muscle stress and 
that it exerts its effects on metabolism in an endocrine 
fashion.
Heart: FGF21 exerts cardioprotective actions
Initially, the heart was discarded as a target tissue or 
source of FGF21 due to the low levels of FGF21 and KLB 
mRNA detected in this organ. However, later studies 
showed that FGF21 is expressed and secreted by cardiac 
cells in response to various stress conditions, including 
obesity, type 1 diabetes, fasting, ER stress, inflamma-
tion, infarct or hypertrophy, and some cardiovascular 
diseases [49, 50]. In the heart, FGFR1 and KLB have 
been detected in cardiac cells, where FGF21 exerts pro-
tective effects in an autocrine and endocrine fashion. 
The mRNA expression of FGF21 in these cells is driven 
by the transcriptional activation of Sirtuin1 – peroxi-
some proliferator-activated receptor a (Sirt1-PPARa) 
[50]; however, it can also be regulated by ATF4, espe-
cially when FGF21 induction is caused by ER or oxida-
tive stress [49, 51].
It is now well established that FGF21 plays a key role 
in cardiac remodeling and pathophysiology. FGF21 pro-
tects cardiomyocytes from hypertrophy through a mecha-
nism that involves the activation of the cAMP responsive 
element binding protein (CREB), the induction of PGC1a 
expression, and the reduction of the NF-kB pro-inflam-
matory pathway [50]. Cardiac FGF21 also induces the 
expression of anti-oxidant genes such as Ucp3 and 
superoxide dismutase (Sod2), thus preventing the pro-
duction of reactive oxygen species (ROS) in cardiac cells 
and oxidative stress in the heart [52]. In an autocrine 
fashion, FGF21 modulates cardiac lipid homeostasis [49] 
and protects against diabetes-induced cardiomyopathy 
by activating the ERK-p38MAPK-AMPK pathway [50]. 
Finally, as an endocrine peptide, FGF21 can also inhibit 
cardiomyocyte apoptosis, thus reducing damage to the 
heart [53, 54].
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Central nervous system: target tissue of FGF21
FGF21 has the potential to act in the central nervous 
system (CNS) since FGFRs are widely expressed in this 
tissue and KLB is specifically expressed in the suprachias-
matic nucleus, the dorsal vagal complex of the hindbrain, 
the area postrema, the nucleus tractus solitari, the nodose 
ganglia, and the paraventricular nucleus [22, 55, 56]. 
Immunoblotting experiments have revealed that FGF21 
is expressed in several regions of the brain, such as the 
substantia nigra, striatum, hippocampus, and cortex [57]; 
however, this growth factor also crosses the blood brain 
barrier and is present in the cerebrospinal fluid in a linear 
relationship with serum levels [58]. FGF21 modulates cir-
cadian rhythm and fertility [22, 59], but current data point 
to the CNS as a mediator of the effects of FGF21 on energy 
expenditure and browning [60]. However, in all cases, the 
presence of KLB appears to be required for FGF21 to exert 
its effects. This observation thus indicates that this growth 
factor is an endocrine signal. Regarding the effects of 
FGF21 on energy expenditure and browning, experiments 
with diet-induced obese (DIO) mice show that the lack of 
KLB in the CNS abrogates all the effects of FGF21 on body 
weight, insulin sensitivity, metabolic regulation in liver, 
WAT, and BAT. These data suggest that direct signaling in 
the CNS causes an increase in the sympathetic outflow.
In the hypothalamus, FGF21 affects the expression 
of corticotropin-releasing factor. Intracerebroventricular 
injection of FGF21 in Fgf21-KO mice restores the metabolic 
effects of FGF21 essentially through the corticotropin-
releasing hormone (CRH) and the activation of CREB, 
which finally enhances hepatic gluconeogenesis and 
sympathetic nerve activity in BAT [56, 61, 62]. According 
to that, lack of KLB in the brain blunts these effects [56, 
60, 61]. Finally, treatment with the b-blocker propranolol 
diminishes the effects of FGF21 when it is centrally admin-
istered but not when delivered peripherally [60].
Given the wide range of biological processes regu-
lated by the CNS and the capacity of FGF21 to act in the 
brain, it is likely that future studies will reveal new actions 
of FGF21 signaling through the CNS.
Pancreas: FGF21 preserves b-cell function
FGF21 is highly expressed in the pancreas and has pro-
tective effects against cerulein-induced pancreatitis [63]. 
Supporting data show that FGF21-deficient mice are 
more susceptible to damage, and FGF21-overexpressing 
mice are partly protected. In addition, FGF21 may be 
involved in enhancing islet engraftment [64] and in the 
preservation of b-cell function and survival [65]. Another 
point is that KLB expression is critical for these beneficial 
effects, but the expression of KLB is reduced when islets 
are treated with high glucose concentrations [66]. In the 
pancreas, FGF21 increases insulin content and glucose-
dependent secretion and inhibits glucagon release in iso-
lated islets [65].
Other effects of FGF21
In addition, and consistent with its metabolic benefits, 
FGF21 transgenic overexpression extends lifespan in 
mice. The authors of that study proposed that inhibition of 
the GH/IGF-1 signaling pathway would explain life exten-
sion in Fgf21 transgenic mice. Furthermore, microarray 
analysis showed that FGF21 modulates gene expression in 
the liver in a similar manner to caloric restriction (which 
is known to extend lifespan in mammals). These data 
suggest that FGF21 extends lifespan by acting as a selec-
tive caloric restriction mimetic in the liver [67].
Interestingly, FGF21 appears to be not only a meta-
bolic regulator but also a nutrient intake and taste regu-
lator. Both pharmacologic administration and hepatic 
secretion of FGF21 produce a satiety signal that sup-
presses the intake of “sweets” [68, 69]. In addition, two 
genome-wide meta-analyses associated genetic variations 
in a locus including Fgf21 with significant differences in 
macronutrient intake [6, 70].
While FGF21 boasts numerous beneficial effects, 
a major adverse effect is a decrease in bone mass. Both 
genetic overexpression of Fgf21 and pharmacological 
administration of this molecule lead to the inhibition of 
osteoblastogenesis and the stimulation of adipogenesis. 
In contrast, the absence of Fgf21 leads to a high bone mass 
phenotype. The mechanism underlying bone mass loss 
is the potentiation of PPARg activity [71]. Although this 
non-desirable effect has been described only in rodents, it 
has to be taken into account when considering FGF21 as a 
potential drug candidate.
FGF21 expression is regulated by nutrition
Fasting and feeding
FGF21 is expressed and produced by multiple tissues. 
However, under normal physiological conditions, all 
circulating protein appears to derive from the liver [72]. 
FGF21 was initially described as a protein induced in the 
liver to control metabolic adaptation to long periods of 
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starvation. This mRNA induction goes through the PPARa 
[13, 73, 74] and CREBH [75, 76]. Later, several studies 
showed that FGF21 expression is regulated not only by 
fasting but also by other nutritional states [77]. In addi-
tion to PPARa and CREBH FGF21 expression responds 
to the retinoic acid (RA) receptor b (RARb) [78], the RA 
receptor-related orphan receptor a (RORa) [79], the thyroid 
hormone receptor b (TRb) [80], the activating transcrip-
tion factor-4 (ATF4) [81], the farnesoid X receptor (FXR) 
[82], and the carbohydrate responsive element binding 
protein (ChREBP) [83]. The following chapter will sum-
marize the effects of various macronutrients and bioactive 
dietary components on FGF21 expression, the metabolic 
consequences and the putative signaling transduction 
pathways involved.
Carbohydrates upregulate FGF21 expression
Hepatic FGF21 is induced by prolonged fasting and also 
by refeeding with a high carbohydrate diet (HCD) (mixed 
sugar and starch) [84]. Rats starved for 24  h and refed 
with a HCD for 12  h show an increase in hepatic mRNA 
and serum levels of FGF21 and metabolic adaptations in 
the liver and WAT. Specifically in liver, there is an induc-
tion of lipogenesis, glucose uptake and metabolism, and a 
reduction of FA uptake and FAO. Similarly, in WAT, refeed-
ing with a HCD induces lipogenesis, glucose uptake and 
metabolism, and lipolysis [84]. These results support the 
hypothesis that FGF21 is produced to compensate any 
imbalanced nutritional states.
Hepatic FGF21 mRNA expression and plasma levels 
are also induced in male C57BL/6 mice fed a HC diet con-
taining 77% of energy as dextrose, 0.5% as fat and 22.5% 
as protein [85]. These results agree with previous studies 
performed in isolated rat hepatocytes cultured with high 
glucose [86]. Under this dextrose-rich diet, the liver induc-
tion of FGF21 increases de novo lipogenesis, probably as 
a result of excess carbohydrate intake. In contrast, the 
same diet supplemented with exogenous lipids [a soybean 
oil-based emulsion that is rich in C-18:1 and C-18:2 (n–6) 
unsaturated FAs] reduces FGF21 mRNA levels and de novo 
lipogenesis.
In rodents and humans, glucose is not the only mol-
ecule able to induce FGF21 expression in vitro. The human 
promoter of FGF21 responds to xylitol [77] and fructose [87] 
through the transcription factor ChREBP, which binds to a 
carbohydrate response element (ChoRE) present in human 
and mouse promoters [77, 83]. These data again reveal the 
independent mechanisms that regulate the expression of 
FGF21 downstream of fasting and feeding signals. In vivo, 
both in humans and rodents, fructose ingestion, but not 
glucose, leads to an increase of FGF21 serum levels, which 
peak 2 h after an acute load [87]. In this case, the remain-
ing question is how and why FGF21, which is considered a 
metabolic positive hormone, is induced by a metabolically 
pernicious sugar such as fructose.
Finally, it has also been demonstrated that FGF21 
expression is regulated by dietary fiber. The intake of 
such fiber facilitates weight loss and improves lipid and 
glucose profiles. Sugarcane fiber (SCF: 85% insoluble 
fiber, 70% particles  < 1 mM) administered to mice fed a 
HFD for 12 weeks enhances insulin sensitivity, diminishes 
fasting plasma glucose and TGs, and attenuates weight 
[88]. Without altering caloric intake, SCF regulates leptin 
and glucagon-like peptide 1 (GLP-1) in these mice. In the 
liver, SCF decreases TGs, cholesterol content, and FGF21 
expression, but induces mRNA levels of KLB, FGFR1, 
FGFR3 and PPARa, thus enhancing FGF21 signaling and 
ameliorating the obesity observed in the FGF21-resistant 
state. In parallel SCF also increases AMPK signaling [88].
High-fat diets induce FGF21 resistance
The notion of crosstalk between HFDs and FGF21 expres-
sion is controversial probably because of the variety of FAs 
included in diets. For example, mice fed a corn-oil based 
HFD (cHFD) for 5 weeks express more FGF21 in liver than 
those fed a HFD in which corn-oil is replaced by a fish-
derived long-chain polyunsaturated n-3 FA (PUFA) [89]. 
Moreover, another study reported that mice fed a HFD 
for 16 weeks show no differences in FGF21 mRNA levels 
versus those fed a low-fat diet [85].
In HepG2 cells, oleate, linoleate and trans-10, cis-12 
conjugated linoleic acid (t-10, c-12-CLA) induce FGF21 
expression and secretion while palmitate has no effect 
[90, 91]. Lipid infusion in humans increases the circu-
lating levels of FGF21 [90]. Similarly, in neonatal mice, 
hepatic FGF21 expression is induced at the initiation of 
suckling, mainly due to the high FA content of milk [35]. 
In this case, the FGF21 secreted induces the thermogenic 
program in BAT.
In the abovementioned situations, mRNA induction 
occurs through the activation of PPARa and causes an 
increase in serum levels of FGF21.
In addition to long-chain FAs, butyrate and α-lipoic 
acid also modulate FGF21 expression in the liver. The 
former is produced mainly by bacterial fermentation of 
dietary fiber in the large intestine, and its effect on FGF21 
expression seems to be due to its capacity to inhibit 
histone deacetylase-3 (HDAC3) [92]. Another short FA, 
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α-lipoic acid, is also involved in the regulation of FGF21. 
α-lipoic acid can be obtained from the diet (leafy green 
vegetables and red meats), and its dietary supplementa-
tion induces hepatic and plasma levels of FGF21 in vivo 
and in vitro [93, 94]. The effect of α-lipoic acid on FGF21 
expression depends on a CREBH-dependent mechanism 
that includes the induction of its expression and an 
increase in its binding to the FGF21 promoter [95].
Finally, several models of obesity in rodents, primates 
and humans showed that FGF21 levels are higher than 
in normal weight littermates [17, 96, 97]. In this context, 
obesity can be defined as an “FGF21-resistant state” [98]. 
The hepatic induction of FGF21 mRNA in DIO mice posi-
tively correlates with an attenuated responsiveness in 
liver and WAT as a result of a reduction in FGFR1, FGFR4 
and KLB levels.
Amino acid-deficient and low-protein diets increase 
energy expenditure
Several studies have described that hepatic FGF21 is reg-
ulated by protein intake. In general, LPDs or diets defi-
cient in a specific amino acid (i.e. leucine or methionine) 
cause an increase in the hepatic expression and serum 
levels of FGF21. In this regard, diets with a relatively low 
content of essential amino acids, such as many vegan 
diets, are known to be protective against cancer, auto-
immunity, obesity, and diabetes. These benefits could be 
partly due to increased circulating levels of FGF21 [99]. 
Several studies have demonstrated that FGF21 is the link 
between imbalanced amino acid intake and adaptive 
metabolic response and that it serves to restore metabolic 
homeostasis.
In liver – but not in WAT or BAT–, FGF21 is induced 
by leucine deprivation. In wild-type mice, the metabolic 
response to leucine deprivation includes dramatic changes 
in lipid metabolism. In liver, such deprivation inhibits 
FA synthase (FAS) activity, decreases the expression of 
lipogenic genes, and increases the mobilization of lipid 
stores. In WAT, it decreases FAS activity and the expres-
sion of lipogenic genes and increases the expression of 
FAO genes. Finally, there is an induction of UCP1 expres-
sion in BAT [20, 100, 101]. In contrast, in Fgf21-deficient 
mice this metabolic response to leucine is impaired, thus 
indicating that FGF21 is a key hormone in the regulation of 
lipid metabolism during leucine deprivation [20, 81].
In the same way, methionine-deprived mice show a 
comparable phenotype to that of leucine deprivation. The 
metabolic response to methionine deficiency includes 
resistance to diet-induced obesity, improved glucose 
homeostasis, increased FA activation and oxidation in 
liver, increased lipolysis in WAT, and increased Ucp1 
expression in BAT [102–104]. All these effects are coupled 
to an increase in FGF21 levels.
The metabolic response to protein restriction is 
similar to that observed under leucine or methionine 
restriction [7]. Serum levels of FGF21 increase in both 
rodents and humans upon exposure to LPDs, regardless 
of overall caloric intake [105, 106]. Protein restriction is 
accompanied by weight loss and an increase in both food 
intake and energy expenditure. Remarkably, neither food 
intake nor energy expenditure of Fgf21-deficient mice 
are altered by the administration of LPDs [7]. Moreover, 
ketogenic diets (KDs), which are widely known to induce 
FGF21 expression, are usually low in carbohydrates and 
proteins but rich in fat. The protein content of KDs under-
lies the increased levels of circulating FGF21, since protein 
supplementation but not carbohydrate supplementation 
blunts the induction [107]. This effect could also explain 
the induction of FGF21 observed in HCDs, which are char-
acterized by a low protein content.
Protein undernutrition caused by LPDs or imbalanced 
diets (which are common in mammals confronted with 
deficient sources of certain amino acids like legumes, 
grains or corn) strongly affects aminoacidemia. Addition-
ally, pathological situations caused by various forms of 
stress, such as trauma, thermal burning, sepsis and fever, 
can lead to a negative nitrogen balance. In this context, 
several scenarios that alter aminoacidemia also lead to 
an increase in FGF21 expression. The absence of slc6a19 
(neutral amino acid transporter) causes a lack of systemic 
neutral amino acids, resulting in an increase in FGF21 
transcription [108]. The treatment with the antileukemic 
agent asparaginase depletes circulating asparagine and 
glutamine levels, promoting FGF21 expression [109], and 
the skeletal muscle-specific knockout mice for glucocorti-
coid receptor (GR) show reduced alanine flux from skeletal 
muscle during fasting, resulting in an increase in FGF21 
plasma levels [110]. Hence, it is likely that many other situ-
ations that reduce amino acid availability also lead to an 
induction of FGF21 expression.
GCN2, a kinase that acts as a sensor of amino acid 
supply [111], and PPARa are indispensable for the induc-
tion of FGF21 in response to protein restriction. In this 
regard, the respective knockout mice present blunted 
induction of FGF21 when fed a LPD. Nevertheless, it is 
worth mentioning that in both Ppara-KO and Gcn2-KO 
mice, the LPD still induces FGF21 expression [7]. This 
observation suggests that additional signaling pathways 
are involved in triggering the increase in FGF21 expression 
in response to protein restriction.
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To date, there is no evidence of PPARa activation in 
response to a LPD, thus suggesting that PPARa plays a 
role in the constitutive expression of FGF21. In contrast, 
the LPD increases GCN2-dependent phosphorylation of 
eIF2a, resulting in greater ATF4 protein levels [100, 112]. 
Therefore, the GCN2/eIF2a/ATF4 cascade emerges as the 
main signaling pathway in the induction of FGF21 by 
protein restriction. ATF4 directly or indirectly induces the 
transcription of a subset of specific target genes, includ-
ing FGF21, to modulate many cellular processes to adapt 
to amino acid deficiency [81, 113, 114]. The 5′ regulatory 
region of the human FGF21 gene contains two evolutionar-
ily conserved functional ATF4-binding sequences (AARE), 
which are responsible for ATF4-dependent transcriptional 
activation in response to ER stress or amino acid restric-
tion [81, 115].
Hepatic mTORC1 activity is also related to FGF21 
expression. The mTOR signaling pathway monitors amino 
acid sufficiency and promotes protein translation and cell 
growth, among other processes [116]. In this case, L-Tsc1 
KO mice, which present mTORC1 hyperactivity in the liver, 
show increased expression of FGF21 and depleted levels 
of glutamine [117]. Moreover, when these animals are 
treated with rapamycin (mTORC1 inhibitor) or glutamine, 
the increase in FGF21 is blunted. Finally, in human 
hepatic tumors, mTORC1 activation also correlates with 
FGF21 levels [117]. It has been proposed that the mecha-
nism underling the increase in FGF21 expression occurs 
through PGC1a; however, additional mechanisms could 
be involved and it is feasible that depleted glutamine 
levels trigger an amino acid response (AAR).
In summary, amino acid-deficient diets diminish 
aminoacidemia and trigger AAR, thereby resulting in ele-
vated FGF21 levels. The contribution of each single amino 
acid to the modulation of FGF21 and how a deficiency in 
specific types of dietary protein alters FGF21 expression 
require further study.
Bioactive dietary compounds affect FGF21 expression 
and signaling
Polyphenols are the most abundant phytochemicals in 
nature. These bioactive compounds are synthesized as 
secondary metabolites by plants and are thus abundant 
in fruits, vegetables, legumes, cocoa and some beverages, 
such as tea, coffee and wine. Polyphenols comprise a large 
heterogeneous group of chemical structures, all with a 
phenolic ring with one or more hydroxyl groups, and they 
are classified mainly into two families, namely flavonoids 
and non-flavonoids, and also into many subfamilies. 
Flavonoids are the most abundant polyphenols and con-
sequently those most greatly ingested in human diets.
Due to the diversity of polyphenols, their absorption 
in the body is dose- and type-dependent and their effects 
are related to their bioavailability and pharmacokinet-
ics. It is estimated that most of the polyphenols ingested 
go directly to the colon and only between 5 and 10% are 
absorbed in small intestine. The effects of polyphenols 
in the colon have been related to a prebiotic capacity, 
as they are believed to induce the growth and activity of 
some bacteria, such as Bifidobacterium, Enterococcus 
and Prevotella. Furthermore, once absorbed, polyphenols 
enter portal circulation and are metabolized in the liver. 
Finally, the conjugate metabolites reach the bloodstream 
and the target tissues [118, 119].
Various epidemiological studies have reported that 
the regular consumption of polyphenols has beneficial 
effects in obesity, insulin resistance, cardiovascular dis-
eases, and cancer. Several lines of evidence support the 
notion that polyphenol-rich diets play a key role in regu-
lating lipid and glucose metabolism and are thus pivotal 
in the prevention and treatment of pathologies related to 
energy homeostasis [120–123].
It has been described that resveratrol has a protective 
effect on cardiovascular risk associated to ROS overpro-
duction but also on the prevention of hepatic steatosis 
and the improvement of insulin resistance [124]. Green tea 
polyphenols, mainly epigallocatechin-3-gallate (EGCG), 
reduce the LDL and increase HDL levels in humans and 
improve insulin sensitivity in genetic models of insulin 
resistance, thus exerting a beneficial effect on body weight 
and lipid profile [125, 126]. Isoflavones and polyphenol-
rich grape extract can partially prevent hepatic steatosis 
associated with obesity by restoring the correct secretion 
of adipokines – mainly leptin and adiponectin, by up-
regulating FAO, and by down-regulating lipogenesis in 
adipose tissue [127, 128].
For many years, the health benefits of polyphenols 
were attributed to their anti-oxidant capacity as free 
radical scavengers. It has recently been described that 
polyphenols activate cell-signaling pathways that are not 
related to ROS production but rather those involved in 
metabolic regulation. It is remarkable that most of these 
pathways are downstream of FGF21. It has been reported 
that, in vitro, polyphenols downregulate SREBP-1c and its 
main target genes in lipogenesis, namely FAS and acetyl-
CoA carboxylase (ACC) [129]. Stilbens, mainly resveratrol, 
exert their effects by promoting the phosphorylation and 
activation of the AMP-activated protein kinase (AMPK) and 
the activity of SIRT and PGC1a, thus inducing FA catabo-
lism through the AMPK/SIRT1/PGC1a axis [130,  131]. On 
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the other hand, an anthocyanin-rich juice extract up-regu-
lates PPARa activity in mice on a HFD and down-regulates 
lipogenic gene expression in liver by promoting FA con-
sumption. Coffee polyphenols and resveratrol also induce 
FAO in rats through PPARa and PGC1a-dependent mecha-
nisms [132]. Chalcones and flavokawain cardamonin type 
B inhibit lipid accumulation and adipocyte differentiation 
by increasing the phosphorylation of the ERK in the early 
phase of adipogenesis [133].
In summary, polyphenols exert beneficial metabolic 
effects especially in obese and in insulin-resistant animal 
models, and FGF21 restores homeostasis in scenarios of 
metabolic stress. The crosstalk between the two signals 
remains unclear, but a positive correlation between the 
beneficial effects of polyphenol-rich fruit extracts and 
FGF21 activity has been described in various rodent 
models of diet-induced obesity. In some cases, the effects 
of polyphenols were due to an induction of FGF21 levels 
in liver [134, 135] but also to an enhancement of FGF21 
signaling by increasing the expression of FGF21 receptors 
and KLB, [136, 137]. Moreover, flavokawain B and carda-
monin also modulate the secretion of FGF21 in mature 
adipocytes [133].
FGF21 in humans
After the identification of rodent FGF21 as an endocrine 
regulator induced downstream of PPARa and its agonists 
by both fasting and a KD [13, 73], it was shown that fasting 
FGF21 levels are significantly increased in patients with 
T2DM without a correlation with BMI, thereby pointing 
to a potential role of FGF21 in the pathogenesis of insulin 
resistance and T2DM [138].
Later, in contrast to previously published data, it was 
described that serum FGF21 levels in overweight and in 
obese subjects are significantly higher than in lean indi-
viduals and that they correlate positively with adiposity 
and the metabolic syndrome [17, 139]. Also, an increase 
in plasma levels of FGF21 in hepatic- and muscle-insulin 
resistant states and a correlation with BMI have been 
reported [140].
Accordingly, a study performed in 2010 again showed 
a positive correlation between FGF21 expression and 
BMI; however, the authors did not find that fasting and 
refeeding or 12  days of a KD regulated the hormone in 
humans [8]. Moreover, FGF21 concentrations are revers-
ibly increased and are related to leptin and free FAs in 
obese children. However, the results of that study do not 
support a significant relationship between FGF21, insulin 
resistance, and features of metabolic syndrome or NAFLD 
in this age group [141]. The same pattern of FGF21 expres-
sion was described in obese adolescents with T2DM com-
pared with obese adolescents without. As in rodents, this 
increment in FGF21 levels in obesity and T2DM points to a 
FGF21-resistant state and an impaired capacity of FGF21 
to improve insulin sensitivity [142]. No significant asso-
ciation between FGF21 and growth or IGF-1 was found in 
either cross-sectional or longitudinal analyses; these find-
ings do not support a relationship between FGF21 and 
growth in obese children [143].
In contrast, in the pubertal transition, it was found 
that FGF21 concentrations do not differ by obesity status 
or by sex. An inverse association between FGF21 and 
bone mineral content (BMC) among non-obese individu-
als and an inverse association between FGF21 and lean 
mass among females were observed, which were both 
independent of fat mass. FGF21 was inversely associated 
with HOMA-IR in males but not in females. The existence 
of relationships between FGF21, musculoskeletal para-
meters, and insulin resistance raises the possibility of 
crosstalk between these systems. These data suggest that 
circulating FGF21 differs in its association with bone, lean 
mass and insulin resistance depending on the sex and 
weight of the individual [144].
Globally, several studies have proposed FGF21 as a 
biomarker for metabolic pathologies such as cardiovascu-
lar diseases, NAFLD, and mitochondrial disease [8, 145]. 
Serum FGF21 concentrations are significantly elevated 
in patients with mitochondrial disease. This prospective 
study established serum FGF21 levels as a sensitive bio-
marker of mitochondrial disease and demonstrated that 
they are the best predictor of this disorder when compared 
to serum levels of other classical indicators [146]. In the 
same way, a cross-sectional study with a large well-char-
acterized sample (913 subjects) assessed the interaction 
between clinical parameters (renal function, metabolic, 
hepatic and vascular risk markers), as well as growth 
hormone (GH) status, with FGF21 levels. Those authors 
concluded that FGF21 serum concentrations are associ-
ated with several aspects of the metabolic syndrome, 
hepatocellular function, as well as with GH status [147].
In a healthy population, there is also an age-related 
increase in serum FGF21 levels. This observation high-
lights a potential age effect in response to metabolic 
demands during the lifespan. FGF21 levels increase with 
age independently of body composition. At lower levels 
of FGF21, bone mineral density (BMD), but not other 
body composition parameters, attenuates the association 
between FGF21 levels and age, thereby suggesting that the 
metabolic demands of the skeleton serve to link FGF21 
and energy metabolism [148].
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Regarding the nutritional regulation of FGF21 in 
humans, the data are less clear than in rodents. Increased 
levels of FGF21 in human serum after extreme fasting 
(7 days) and PPARa activation have been described in 
healthy non-diabetic individuals but with a wide inter-
individual variation. The induction of ketogenesis inde-
pendently of FGF21 levels suggests that the physiological 
role of FGF21 in humans differs from that in mice [149]. 
Although FGF21 is elevated in response to pharmacologi-
cal activation of PPARa and PPARd, the absence of varia-
tion in human plasma during fasting and refeeding and 
the decrease after a 3-month KD confirm that FGF21 does 
not play a major role in regulating fasting response or 
ketosis in humans [150].
Unlike mice, which showed an increase in circulating 
FGF21 after only 6  h of fasting, human subjects did not 
have a notable surge in FGF21 until 7–10 days of fasting. 
Moreover, FGF21 induction was associated with decreased 
thermogenesis and adiponectin, an observation that con-
trasts with previous reports based on supraphysiological 
dosing. In addition, FGF21 levels increased after ketone 
induction, thereby demonstrating that endogenous 
FGF21 does not drive starvation-mediated ketogenesis in 
humans. Instead, a longitudinal analysis of biologically 
relevant variables identified serum transaminase markers 
of tissue breakdown as predictors of FGF21. These data 
establish FGF21 as a fasting-induced hormone in humans 
and indicate that it contributes to the late stages of adap-
tation to starvation, when it may regulate the utilization of 
fuel derived from tissue breakdown [151].
A large number of studies have shown that dietary 
protein content markedly influences food intake and 
metabolism. In this context, in humans, circulating 
FGF21 levels increase dramatically after 28 days on a LPD, 
thereby suggesting that FGF21 is a signal of protein restric-
tion and providing an explanation of the effect of dietary 
protein deficiency on metabolism [7].
As mentioned earlier, FGF21 levels increase rapidly 
following fructose ingestion and return to baseline within 
5 h. Moreover, both baseline and fructose-stimulated 
FGF21 levels are 2–3 fold higher in subjects with meta-
bolic syndrome compared to those in healthy subjects. In 
contrast, FGF21 does not increase in the first 2 h after the 
ingestion of a glucose load, although a modest increase is 
observed after 3–4 h. These data suggest that FGF21 plays 
a key role in fructose metabolism in humans [87].
Other nutritional challenges that affect FGF21 levels 
are fish oil supplements and betaine. The inclusion of the 
former in a diet for 3 months markedly reduces the circu-
lating levels of FGF21 and other biomarkers, combined 
with decreases in serum lipids, glucose, liver enzymes, 
and other NAFLD risk factors. These results suggest that 
fish oil might contribute to reversing FGF21 resistance 
[152]. Regarding betaine, it is known that plasma betaine 
levels are reduced in insulin-resistant humans and that 
they correlate closely with insulin sensitivity. In this 
context, in addition to the beneficial metabolic effects of 
betaine, supplementation with this compound robustly 
increases hepatic and circulating FGF21 levels in mice. On 
the basis of these observations, betaine supplementation 
merits further investigation for the treatment or preven-
tion of T2DM in humans [153].
Circulating levels of FGF21 can also be boosted by 
exercise. Increased levels of the protein were observed 
in the serum of healthy male volunteers performing 
a treadmill run at 50 or 80% VO2max. These results 
suggest that FGF21 is also associated with exercise-
induced lipolysis [41].
Finally, in healthy human volunteers, the injection of 
natural glucagon increased plasma FGF21 within hours, 
showing for the first time that glucagon regulates glucose, 
energy, and lipid metabolism, at least in part via FGF21-
dependent pathways [154].
Expert opinion
FGF21 is a peptide hormone involved in metabolic homeo-
stasis and considered a promising therapeutic candidate 
for the treatment of obesity and associated comorbidities 
such insulin resistance, T2DM, and cardiovascular dis-
eases. Although the effects of FGF21 in humans seems to 
be weaker than in mice and interindividual variability in 
the levels of this growth factor are observed, it is obvious 
that FGF21 exerts beneficial effects on metabolic homeo-
stasis in both species. To date, the therapies related to 
FGF21 overexpression have involved pharmacological 
administration; however, this approach has considerable 
limitations due to the kinetics and bioavailability of the 
compound. Recently, several studies have demonstrated 
that specific macronutrients and bioactive dietary com-
pounds can modulate endogenous FGF21 expression and 
signaling, thereby opening up the possibility to induce 
FGF21 production or increase activity through dietary 
intervention. The most feasible approaches to define a 
nutritional intervention able to induce FGF21 activity and 
reduce obesity and associated-comorbidities are prob-
ably through protein restriction and polyphenol-enriched 
diets. However, more research is needed in order to estab-
lish the role of FGF21 as the link between the dietary com-
ponents. It is also important to highlight that all these 
nutritional interventions must be done in compliance 
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with a balanced diet in order to prevent the loss of muscle 
mass or BMD and essential nutrient deficiencies.
Outlook
To design therapeutic approaches based on a nutritional 
intervention it is essential to determine the molecular 
mechanisms through which macronutrients, micronutri-
ents, and bioactive dietary compounds affect FGF21 expres-
sion and signaling. It is likely that the  metabolic effects 
of certain diets such as vegan or the beneficial effects of 
established healthy diets, such as the Mediterranean diet, 
occur at least in part through FGF21. Further studies in 
humans will be required to define the effect of a nutritional 
profile on FGF21 levels and signaling in healthy, obese and 
T2DM patients. Also it will be important to define if there 
are any differential effects between the pharmacological 
administration of FGF21 and its endogenous overproduc-
tion. Moreover, obesity that is one of the possible diseases 
treatable with FGF21 is also a FGF21-resistant state. In 
this context it will be strictly necessary to study the way 
to overcome this resistance, thus increasing the levels of 
the FGF21 receptors in its target tissues. Some studies have 
revealed that some nutritional interventions are able to 
induce the expression of FGFR and KLB.
In summary, FGF21 is a promising therapeutic can-
didate against metabolic pathologies such as obesity or 
T2DM and its expression and signaling are highly regu-
lated by different nutritional states. The remaining ques-
tion is how we can increase the responsiveness to FGF21 in 
obese or T2DM patient just through a dietary intervention.
Highlights
In animal models has been is well described that:
 – The liver is the main organ in contributing to serum 
levels of FGF21.
 – The transcription factors network responsible for the 
control of FGF21 gene expression is highly compli-
cated. Both, positive and negative factors have been 
described.
 – The expression of hepatic FGF21 responds to several 
stimuli, mainly metabolic stress signals.
 – The hepatic expression of FGF21 can be modified by 
dietary components. Mainly high fat diet, high carbo-
hydrate diet, low protein diet or amino acid restricted 
diets.
In order to confirm FGF21 as a therapeutic candidate 
against metabolic pathologies such as obesity or T2DM:
 – The role of FGF21 as the link between the dietary 
components and its metabolic effects has to be set 
precisely.
 – The effect of dietary bioactive compounds on the 
expression of hepatic FGF21 needs further studies.
 – The mechanisms responsible for the establishment of 
the FGF21-resistant state have to be proven.
 – The effect of different dietary interventions on the 
expression of FGF21 receptors in target tissues needs 
future evaluation.
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tissue (WAT), brown adipose tissue (BAT), skeletal muscle, 
and pancreas ( 3–6 ). FGF21 expression in liver is under 
tight control by peroxisome proliferator-activated recep-
tor (PPAR)  ! ( 7–10 ). It is induced in the liver during fast-
ing and its expression induces a metabolic state that 
mimics long-term fasting. Thus, FGF21 is critical for the 
induction of hepatic fat oxidation, ketogenesis, and gluco-
neogenesis, which are metabolic processes critical for the 
adaptive metabolic response to starvation ( 11 ).  Fgf21 is 
also a target of the liver X receptor that represses its induc-
tion during fasting ( 12, 13 ). Signifi cantly, FGF21 extends 
life span in transgenic mice to a similar extent as dietary 
restriction ( 14 ). 
 A dietary amino acid imbalance alters metabolic path-
ways beyond protein homeostasis. GCN2-dependent inhi-
bition of fatty acid synthase (FASN) activity, expression of 
lipogenic genes in liver, and increased mobilization of 
lipid stores occur in response to leucine deprivation in 
mice ( 15 ). In addition, the following have been observed: 
increased expression of  " -oxidation genes, decreased ex-
pression of lipogenic genes and activation of FASN in 
WAT, and increased expression of uncoupling protein 1 
( Ucp1 ) in BAT ( 16, 17 ). 
 Abstract  Lipogenic gene expression in liver is repressed in 
mice upon leucine deprivation. The hormone fi broblast 
growth factor 21 (FGF21), which is critical to the adaptive 
metabolic response to starvation, is also induced under 
amino acid deprivation. Upon leucine deprivation, we found 
that FGF21 is needed to repress expression of lipogenic 
genes in liver and white adipose tissue, and stimulate phos-
phorylation of hormone-sensitive lipase in white adipose tis-
sue. The increased expression of  Ucp1 in brown adipose 
tissue under these circumstances is also impaired in FGF21-
defi cient mice.  Our results demonstrate the important 
role of FGF21 in the regulation of lipid metabolism dur-
ing amino acid starvation. —De Sousa-Coelho, A. L., J. Relat, 
E. Hondares, A. Pérez-Martí, F. Ribas, F. Villarroya, P. F.
Marrero, and D. Haro.  FGF21 mediates the lipid metabo-
lism response to amino acid starvation.  J. Lipid Res. 2013.
54:  1786–1797. 
 Supplementary key words brown adipose tissue • fi broblast growth 
factor 21 • leucine deprivation • liver • white adipose tissue 
 Amino acid starvation initiates a signal transduction cas-
cade, starting with the activation of the general control 
nonderepressible 2 (GCN2) kinase, phosphorylation of 
eukaryotic initiation factor 2 (eIF2), and increased synthe-
sis of activating transcription factor 4 (ATF4) ( 1 ). We have 
recently found that fi broblast growth factor 21 ( Fgf21 ) is a 
target gene for ATF4. Consequently, FGF21 is induced by 
amino acid deprivation both in mouse liver and HepG2 
cells as part of the transcriptional program initiated by in-
creased levels of ATF4 ( 2 ). 
 FGF21 is a member of the FGF family with endocrine 
properties. It is predominantly produced by the liver, but 
is also produced by other tissues such as white adipose 
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incubator, and cultures were replenished with fresh MEM me-
dium and serum for approximately 16 h prior to initiating all 
treatments to ensure that the cells were in the basal (“fed”) state. 
Amino acid deprivation was induced by transfer of cells to cul-
ture medium containing 2 mM histidinol (HisOH) for 8 h, which 
blocks charging of histidine onto the corresponding tRNA and 
thus mimics histidine deprivation and triggers activation of the 
AAR cascade ( 19 ). For mitogen-activated protein/ERK kinase 
(MEK) inhibition, the direct upstream kinases of ERK1/2, cells 
were treated with 30  % M PD98059 (PD98) for approximately 16 h 
before harvesting. HisOH (H6647) and PD98059 (P215) were pur-
chased from Sigma-Aldrich (St. Louis, MO). Primary BAT adipo-
cytes were obtained and maintained as previously described ( 20 ). 
Mouse 3T3-L1 adipocytes were cultured and differentiated as de-
scribed previously ( 21 ). 
 Serum measurements.  Serum was obtained by centrifugation 
of clotted blood and stored at  # 80°C. A mouse FGF21 enzyme-
linked immunosorbent assay (ELISA) kit was obtained from Mil-
lipore for the quantifi cation of FGF21 in mouse serum. The assay 
was conducted according to the manufacturer’s protocol. Briefl y, 
a calibration curve was constructed by plotting the difference in 
absorbance values at 450 and 590 nm versus the FGF21 concen-
trations of the calibrators, and concentrations of unknown sam-
ples (performed in duplicate) were determined using this 
calibration curve ( 22 ). The Veterinary Service of Clinical Bio-
chemistry at the Universitat Autònoma de Barcelona determined 
blood biochemical parameters. 
 RNA isolation and relative quantitative RT-PCR.  Total RNA 
was extracted from the frozen tissues [liver, epididymal white adi-
pose tissue (eWAT), and BAT] or cells (3T3L1 and primary 
brown adipocytes) using TRI reagent solution (Ambion) fol-
lowed by DNase I treatment (Ambion) to eliminate genomic 
DNA contamination. To measure the relative mRNA levels, quan-
titative (q)RT-PCR was performed using TaqMan reagents. cDNA 
was synthesized from 1  % g of total RNA by MLV reverse tran-
scriptase (Invitrogen) with random hexamers (Roche Diagnos-
tics) according to the manufacturer’s instructions. TaqMan Gene 
Expression Master Mix and TaqMan Gene Expression assays 
(Invitrogen/Applied Biosystems) were used for the PCR step. 
Amplifi cation and detection were performed using the Step-One 
Plus Real-Time PCR System. Each mRNA from a single sample 
was measured in duplicate, using 18S rRNA as an internal con-
trol. Results were obtained by the comparative threshold cycle 
(Ct) method and expressed as fold of the experimental control. 
 Protein extract preparation.  Whole-cell lysates from HepG2 cells 
were isolated using NP40 lysis buffer [50 mM Tris-HCl (pH 8), 
150 mM NaCl, 1% Nonidet P-40]. To obtain liver nuclear ex-
tracts, frozen liver was triturated within a mortar in liquid nitro-
gen and immediately homogenized with a Dounce homogenizer 
in 1 ml of HB buffer [15 mM Tris-HCl (pH 8), 15 mM NaCl, 
60 mM KCl, 0.5 mM EDTA], and centrifuged at 800  g for 5 min. The 
resulting pellet was resuspended in 100  % l of HB buffer supple-
mented with 0.05% Triton X-100 (Sigma), and centrifuged for 
10 min at 1,000  g . Nuclear pellets were washed with 1 ml of HB buf-
fer supplemented with 0.05% Triton X-100 and 1 ml of HB buf-
fer. Nuclei were incubated at 4°C for 30 min in 50  % l of HB buffer 
containing 360 mM KCl and centrifuged for 5 min at 10,000  g . 
The supernatant corresponding to the nuclear extract was col-
lected, frozen, and stored at  # 80°C. To obtain liver, WAT, and 
BAT total extracts, tissues were homogenized in RIPA buffer and 
centrifuged at 12,000  g for 15 min at 4°C. The supernatant was 
collected and frozen at  # 80°C until analysis. Protein concentra-
tion was assayed using Bio-Rad reagent. All of the buffers were 
 The coincidence between the metabolic response to es-
sential amino acid deprivation and to FGF21, the induc-
tion of  Fgf21 under amino acid deprivation ( 2 ), together 
with the repression of the transcription and maturation of 
sterol regulatory element binding protein 1c (SREBP1c) 
induced by FGF21 in HepG2 cells ( 18 ), led us to consider 
that FGF21 could be an important mediator between 
amino acid deprivation and lipid metabolism in liver, 
WAT, and BAT. 
 To investigate this hypothesis, we examined the re-
sponse of FGF21-defi cient mice to deprivation of the es-
sential amino acid leucine. As expected, we found a huge 
increase in  Fgf21 expression in the liver of wild-type (WT) 
animals, along with a repression of lipogenic genes after 7 
days of leucine deprivation. In this condition, FGF21-defi -
cient mice developed liver steatosis caused by unrepressed 
expression of lipogenic genes. In WAT, the expression of 
lipogenic genes was also repressed and the phosphoryla-
tion of hormone-sensitive lipase (HSL) was increased un-
der leucine deprivation. The absence of leucine also 
induced an increase in the expression of  Ucp1 and type 2 
deiodinase ( Dio2 ) in BAT. We found that all these effects 
in WAT and BAT were also impaired in FGF21-defi cient 
mice. Here, we show the involvement of FGF21 in the reg-
ulation of lipid metabolism during amino acid starvation, 
thus reinforcing its important role as an endocrine factor 
in coordinating energy homeostasis under a variety of nu-
tritional conditions. 
 MATERIALS AND METHODS 
 Animals and diets 
 Male WT and  Fgf21 -null mice (B6N; 129 S5-Fgf21tm1Lex/
Mmucd), obtained from the Mutant Mouse Regional Resource 
Center, were housed in a temperature-controlled room (22 ± 
1°C) on a 12/12 h light/dark cycle and were provided free access 
to commercial rodent chow and tap water prior to the experi-
ments. Control (nutritionally complete amino acid) and leucine-
defi cient [( # )leu] diets were obtained from Research Diets, Inc. 
(New Brunswick, NJ). All diets were isocaloric and composition-
ally the same in terms of carbohydrate and lipid components. At 
the beginning of the feeding experiment, 12–15 week old male 
mice were fi rst acclimated to the control diet for 7 days, and then 
randomly assigned to either the control diet group, with contin-
ued free access to the nutritionally complete diet, or the ( # )leu 
diet group, with free access to the diet devoid of the essential 
amino acid leucine for 7 days. Food intake and body weight were 
recorded at least every 2 days. Animals were anesthetized by iso-
fl urane inhalation, and blood was collected from the heart for 
the assay described below. After euthanization, tissues were iso-
lated and immediately snap-frozen and stored at  # 80°C for fu-
ture analysis. The Animal Ethics Committee of the University of 
Barcelona approved these experiments. 
 Cell culture and treatment conditions 
 HepG2 cells were cultured in Eagle’s Minimal Essential Me-
dium (MEM) (GIBCO, Invitrogen) supplemented to contain 1× 
nonessential amino acids, 4 mM glutamine, 100  % g/ml strepto-
mycin sulfate, 100 units/ml penicillin G, and 10% (v/v) fetal bo-
vine serum. Cells were maintained at 37°C in a 5% CO 2 /95% air 
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 Lipolysis assay.  Lipolysis assay was performed after 24 h 
treatment with FGF21 using the Free Glycerol Determination Kit 
(Sigma). 
 Data analysis/statistics.  All data are expressed as means ± 
SEM. Signifi cant differences were assessed by a two-tailed Stu-
dent’s  t -test.  P < 0.05 was considered statistically signifi cant.  a ,  P < 
0.05 versus control (Ctl) WT mice (or DMSO-treated HepG2 
cells);  b ,  P < 0.05 versus Ctl  Fgf21 -knockout (KO) mice;  c ,  P < 0.05 
versus ( # )leu WT (or HisOH-treated HepG2 cells) (n = 6 per 
group of mice, or at least three independent experiments with 
HepG2 cells). 
 RESULTS 
 FGF21 gene expression is induced by leucine deprivation 
specifi cally in liver but not in BAT or WAT 
 According to our previously reported results ( 2 ), mice 
maintained on a ( # )leu diet show a dramatic increase in 
FGF21 circulating levels ( Fig. 1A ). To check the origin of 
this circulating FGF21 we analyzed  Fgf21 gene expression 
in several tissues. Consistent with the liver as the main site 
of FGF21 production and release into the blood,  Fgf21 
mRNA levels in liver paralleled those in serum, whereas 
mRNA levels were unchanged in BAT and, unexpectedly, 
signifi cantly decreased in eWAT in WT mice maintained 
on a ( # )leu diet ( Fig. 1B ). As expected,  Fgf21 mRNA lev-
els were undetectable in any analyzed tissue in the  Fgf21 -KO 
mice. In accordance with previous reports ( 23 ), the circu-
lating levels of FGF21 in KO mice were below the thresh-
old for correct quantifi cation . 
 FGF21 defi ciency signifi cantly attenuates weight loss 
under leucine deprivation 
 When fed a leucine-deprived diet, mice undergo rapid 
weight loss ( 16 ). The goal of the present study is to investi-
gate whether this phenomenon is FGF21 dependent. For 
this purpose, WT and  Fgf21 -KO mice were fed a control or 
( # )leu diet for 7 days. Together with total body weight 
supplemented with a mixture of protease inhibitors (Sigma-Al-
drich), 0.1 mM phenylmethylsulfonyl fl uoride (PMSF), and a 
phosphatase inhibitor cocktail (IPC3, Sigma-Aldrich). 
 Immunoblotting.  Total and nuclear proteins were resolved 
by SDS-polyacrylamide gel electrophoresis and transferred onto 
a Hybond-P PVDF membrane (Millipore). Membranes were 
blocked for 1 h at room temperature. The blots were then incu-
bated with primary antibody in blocking solution overnight at 
4°C. Antibodies were diluted according to the manufacturer’s 
instructions. The blots were washed three times and incubated 
with horseradish peroxidase-conjugated secondary antibody in 
blocking buffer for 2 h at room temperature. After three washes, 
the blots were developed using the EZ-ECL Chemiluminescence 
Detection Kit for HRP (Biological Industries). The quantifi ca-
tion of phosphorylation was performed by densitometry of phos-
phorylated protein normalized to total protein using Image J 
software. 
 Antibodies.  HSL (#4107), phospho HSL (#4126), ERK1/2 
(#4695), phospho-ERK1/2 (#4370), and phospho-p38 (#9211) 
antibodies were purchased from Cell Signaling Technology. 
ATF4 (sc-200), p38 ! / " (A-12, sc-7972), and SREBP1c (C-20, 
sc-36) antibodies were from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA); FASN (ab128870) antibody was from Abcam; 
acetyl-CoA carboxylase 1 (ACC1) (04-322) and phospho-ACC1 
(07-303) antibodies were from Millipore; actin antibody (A2066) 
was from Sigma-Aldrich; and tubulin antibody (#CP06) was from 
Calbiochem. 
 Histological examinations.  For the histological analysis, 
tissues (liver and eWAT) were fi xed in 10% formalin (Sigma-
Aldrich) and embedded in paraffi n. Then, 4  % m thick sections 
were cut and stained with hematoxylin and eosin (H and E). 
Images were acquired using a Leica CTR 4000 microscope. 
Quantitative data were obtained using the IMAT program de-
veloped in the Science and Technology Center of the Univer-
sity of Barcelona. The selection of the test objects was 
performed according to color and choosing the same limits 
for binari zation for all images. Adipocyte size and lipid accumula-
tion were measured using at least three different randomly cho-
sen fi elds of eWAT and liver sections, respectively, from each 
mouse. 
 Fig.  1. FGF21 is differently regulated by leucine deprivation in liver and adipose tissues. A: Serum FGF21 
protein concentrations were measured by ELISA. B:  Fgf21 mRNA in BAT, eWAT, and liver was measured by 
qRT-PCR. Error bars represent the mean ± SEM.  a ,  P < 0.05 versus Ctl WT. 
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suggested that FGF21 stimulates lipolysis in WAT during 
normal feeding, but inhibits it during fasting ( 25 ). There-
fore, to examine the role of FGF21 in lipolysis, we evalu-
ated the mRNA levels of adipose triglyceride lipase ( Atgl ), 
 Hsl , and perilipin 1 ( Plin1 ), and the levels of phosphory-
lated HSL. We did not fi nd any statistically signifi cant 
changes in  Atgl ,  Hsl , or  Plin1 mRNA levels upon leucine 
deprivation ( Fig. 3B ). Consistent with changes in body 
weight, lack of FGF21 signifi cantly decreased levels of 
phosphorylated HSL in WAT under leucine deprivation 
( Fig. 3C ), which suggests that lipolysis was impaired in 
these mice. Despite the evidence of increased lipolysis un-
der leucine deprivation, levels of free fatty acids in serum 
were not signifi cantly altered in the conditions analyzed 
( Table 1 ), suggesting increased fatty acid utilization by 
other tissues. 
 FGF21 defi ciency prevents changes in liver and WAT 
in leucine-deprived mice 
 A link between FGF21 and SREBP1c during lipogene-
sis in cultured hepatocytes has recently been proposed 
( 18 ). As lipogenic genes are downregulated in the liver 
of mice deprived of leucine ( 15 ), we speculated that 
FGF21 might regulate their expression. To investigate 
this possibility, we examined the expression of genes in-
volved in the regulation of lipid metabolism in the liver 
loss ( Figs. 2A, B ), mice fed a leucine-deprived diet un-
dergo a fat mass loss, both epididymal and subcutaneous 
( Fig. 2D ). We found that these effects were partially 
blunted in  Fgf21 -KO mice ( Figs. 2A, B, D ), while the reduc-
tion in food intake caused by leucine deprivation ( ! 30%) 
was unchanged between genotypes ( Fig. 2C ). 
 The reported observation that white adipocytes from 
FGF21 transgenic mice are substantially smaller than those 
from WT mice ( 8, 24 ) and that leucine deprivation de-
creased adipocyte volume ( 16 ), led us to examine whether 
this effect was FGF21 dependent. A histological analysis of 
eWAT ( Fig. 3A ) showed that leucine deprivation resulted 
in a reduction in adipocyte volume compared with mice 
fed a control diet. By contrast, the adipocyte volume was 
only slightly reduced in ( # )leu-fed  Fgf21 -KO mice and re-
mained unchanged in  Fgf21 -KO mice on the control diet 
( Fig. 3A ). We note that other groups reported increased 
( 25 ) or decreased ( 26 ) adipocyte size in  Fgf21 -KO mice on 
regular diets. We have no explanation for these discrepan-
cies beyond potential minor differences in the composi-
tion of the diet. 
 Increased phosphorylation of HSL under leucine 
deprivation is FGF21 dependent 
 It has been previously described that leucine depri-
vation increases lipolysis in WAT ( 16 ). It has also been 
 Fig.  2. FGF21 is required for ( # )leu diet effects on body weight without affecting food consumption. A: Body weight of mice fed with Ctl 
or ( # )leu diet. The weight on the fi rst day was considered 100%. B: Body weight change (%) after 7 days of feeding the Ctl or ( # )leu diet. 
C: Daily food intake. D: BAT, eWAT, and scWAT weight of mice fed with Ctl or ( # )leu diet related to 100 mg of body weight. E: Liver weight 
of mice fed with Ctl or ( # )leu diet related to 100 mg of body weight. Error bars represent the mean ± SEM.  a ,  P < 0.05 versus Ctl WT mice; 
 b ,  P < 0.05 versus Ctl FGF21-KO mice;  c ,  P < 0.05 versus ( # )leu WT mice (n = 6/group). 
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[cluster of differentiation 36 ( Cd36 ) and  fatty acid bind-
ing protein 4 ( Fabp4 )] or oxidation [carnitine palmitoyl-
transferase 1a  ( Cpt1a )] was decreased in the absence of 
 Fgf21 . The analysis of FASN, SREBP1c, and ACC1 protein 
abundance showed a good correlation with the gene ex-
pression data ( Fig. 4B ). By contrast ACC1 phosphoryla-
tion was decreased under leucine deprivation in both 
WT and  Fgf21 -KO mice. 
of WT and  Fgf21 -KO mice maintained either on the con-
trol or ( # )leu diet. As expected, levels of  Fasn ,  Srebp1c , 
and  Acc1 mRNA were signifi cantly decreased on the ( # )
leu diet. However, in mice lacking FGF21, the reduced 
expression of  Fasn was statistically signifi cantly increased, 
and, although not statistically signifi cant, showed a ten-
dency to increase in both  Srebp1c and  Acc1 ( Fig. 4A ). The 
expression of other genes involved in fatty acid uptake 
 Fig.  3. The ( # )leu diet effects on adipocyte size and lipid metabolism in WAT are FGF21 dependent. A: Representative H and E-stained 
eWAT sections from WT and FGF21-KO mice (×20 magnifi cation). Scale bar, 50  % M. Adipocyte size (right panel) was measured as de-
scribed in Materials and Methods, using at least three different randomly chosen fi elds of eWAT sections from each mouse. B:  Atgl , Hsl ,  and 
Plin1 gene expression was measured by qRT-PCR in mouse eWAT. C: Phosphorylated HSL (P-HSL) and total HSL (t-HSL) protein levels 
were measured in WT and FGF21-KO eWAT homogenates by Western blot analysis. The bottom panel shows quantifi cation by densitometry 
of phosphorylated HSL normalized to total HSL using Image J software. Error bars represent the mean ± SEM.  a ,  P < 0.05 versus Ctl WT 
mice;  b ,  P < 0.05 versus Ctl FGF21-KO mice;  c ,  P < 0.05 versus ( # )leu WT mice (n = 6/group). P-HSL, phosphorylated HSL. 
 TABLE 1. Serum measurements in mice maintained on different diets 
WT Ctl FGF21-KO Ctl WT leu( # ) FGF21-KO leu( # )
NEFA (nmol/l) 0.79 ± 0.11 1.05 ± 0.11 0.73 ± 0.09 0.82 ± 0.06
TG (mg/dl) 95.79 ± 7.18 153.73 ± 11.62 a 99.39 ± 15.36 186.08 ± 27.38 a , c 
Cholesterol (mg/dl) 101.13 ± 13,13 147.65 ± 4.21 a 96.40 ± 7.69 122.55 ± 3.08 b , c 
Glucose (mg/dl) 209.43 ± 10.45 212.90 ± 7.88 185.53 ± 14.87 187.02 ± 9.55
Glycerol (µmol/l) 393.50 ± 38.32 520.95 ± 23.10 a 313.93 ± 26.56 372.16 ± 19.99 b 
Insulin (µg/l) 1.26 ± 0.23 2.01 ± 0.52 0.41 ± 0.04 a 1.21 ± 0.20 c 
All data are expressed as means ± SEM. Signifi cant differences were assessed by a two-tailed Student’s  t -test. 
 P < 0.05 was considered statistically signifi cant. n = 6/group of mice. TG, triglycerides. 
 a P < 0.05 versus Ctl WT mice.
 b P < 0.05 versus Ctl FGF21-KO mice.
 c P < 0.05 versus ( # )leu WT mice.
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a decrease in the expression of  Fasn , Srebp1c , and  Acc1 and 
also of  Atgl and  Plin ( Fig. 5D ). 
 The FGF21-dependent phenotype during leucine 
deprivation is not related with the mitogen-activated 
protein kinase ERK1/2 signaling pathway 
 As described, mitogen-activated protein kinase (MAPK) 
ERK1/2 signaling is required for the amino acid starvation 
response ( 27, 28 ). Accordingly, histidinol treatment of 
HepG2 cells, which blocks charging of histidine onto the 
corresponding tRNA and thus mimics histidine depriva-
tion, induced the phosphorylation of ERK1/2 ( Fig. 6A ). 
In addition, increased  FGF21 and asparagine synthetase 
( ASNS ), mRNA levels ( Fig. 6C ), as well as increased ATF4 
protein levels in HisOH-treated cells ( Fig. 6B ) were re-
duced in the presence of the MEK inhibitor PD98. In these 
cells,  FASN expression is opposed to that of  FGF21 ( Fig. 6D ), 
mimicking what we observed in leucine-deprived WT (high 
FGF21) or  Fgf21 -null mice ( Fig. 4A ). 
 As it has been described that exogenous FGF21 is able 
to induce ERK1/2 phosphorylation in the liver and WAT 
 Although liver triglyceride levels, measured by extrac-
tion and posterior quantifi cation, did not refl ect the ex-
pression pattern of the lipid synthesis genes, H and E 
staining revealed it. This suggested a decreased lipid ac-
cumulation under leucine deprivation in WT animals that 
does not seem to occur in the  Fgf21 -KO mice ( Fig. 4C ). 
 As expected, gene expression analysis in eWAT revealed 
that the mRNA levels of the lipogenic genes  Fasn ,  Srebp1c , 
and  Acc1 were also lower in this tissue in mice maintained 
on the ( # )leu diet. These changes were blunted in the 
 Fgf21 -KO mice, particularly for  Fasn ( Fig. 5A ). The analysis 
of FASN protein abundance showed a good correlation 
with the gene expression data ( Fig. 5B ). 
 We have analyzed the expression of the FGF21-receptor 
complex  " -Klotho and fi broblast growth factor receptor 1 
(FGFR1) in WAT. There was a signifi cant increase in both 
 " -Klotho and  Fgfr1 mRNA levels induced by both  Fgf21 
knockout and leucine deprivation ( Figs. 5C ). 
 To further confi rm the results obtained in mice, we 
have analyzed the expression of lipogenic and lipolytic 
genes in 3T3L1 treated with FGF21. This treatment induced 
 Fig.  4. FGF21-KO liver has impaired lipid metabolism and lipid accumulation in response to leucine deprivation. A: Expression of genes 
related with lipid handling was measured by qRT-PCR in mouse liver. B: FASN , SREBP1c, phosphorylated ACC1 (P-ACC1), and total ACC1 
(t-ACC1) protein levels were detected by Western blot analysis in mouse liver. The bottom panel shows quantifi cation by densitometry of 
the immunoblotted proteins using Image J software. Error bars represent the mean ± SEM.  a ,  P < 0.05 versus Ctl WT mice;  b ,  P < 0.05 versus 
Ctl FGF21-KO mice;  c ,  P < 0.05 versus ( # )leu WT mice (n = 6/group). C: Histological appearance and hepatic lipid accumulation of H and 
E liver staining of WT and FGF21-KO mice maintained either on a Ctl or a ( # )leu diet. Representative H and E-stained hepatocytes are 
shown (×20 magnifi cation). Scale bar, 50  % M . Lipid accumulation (right panel) was measured as described in Materials and Methods, using 
at least three different randomly chosen fi elds of liver sections from each mouse. Acadm, medium-chain acyl-CoA dehydrogenase; Acadl, 
long-chain acyl-CoA dehydrogenase; Acox, acetyl-CoA oxidase; Lpl, lipoprotein lipase; Scd1, stearoyl-CoA desaturase 1. 
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BAT of WT mice . These changes were blocked in  Fgf21 -KO 
mice ( Fig. 7A ). Because UCP1 expression is related to en-
ergy expenditure, the absence of induction of  Ucp1 in 
 Fgf21 -KO mice under leucine deprivation may contribute 
to the decrease in weight loss observed under these cir-
cumstances. mRNA levels of  Pgc1 ! , which regulates the 
expression of UCP1 ( 32 ), were also increased. However, 
they did not differ between WT and  Fgf21 -KO mice under 
either control or ( # )leu diet conditions ( Fig. 7B ). The 
same pattern as for  Ppar " and  Pgc1 ! was observed for  Adrb3 
mRNA levels ( Fig. 7C ). We tested the possibility that the 
activation of p38 MAPK by the  " 3-adrenergic receptor 
( " 3AR) participated in the induction of the  Ucp1 gene in 
BAT under this situation. However, although p38 phos-
phorylation, but not PKA activity, is induced in primary 
brown adipocytes treated with recombinant FGF21 (data 
not shown), phosphorylated p38 levels remained un-
changed between diets and genotypes in BAT ( Fig. 7C ). 
 We have also analyzed the expression of lipogenic and 
lipolytic genes and glycerol release in primary brown adi-
pocytes treated with FGF21. This treatment decreased the 
expression of  Fasn and increased glycerol release with-
out signifi cant changes in the expression of  Atgl and  Plin 
of acutely treated mice ( 29 ); we checked ERK1/2 phos-
phorylation in leucine-deprived WT and FGF21-null mice. 
Effectively, ERK1/2 phosphorylation was induced in the 
liver of leucine-deprived mice, although there were no dif-
ferences between genotypes ( Fig. 6E ). Accordingly, the 
amino acid starvation response program was correctly ini-
tiated in  Fgf21 -KO mice, as shown by the increased levels 
of ATF4 protein and  Asns , a prototypical ATF4 target gene, 
mRNA levels ( Fig. 6F ). Moreover, despite the fact that 
FGF21 serum levels are highly increased in leucine-de-
prived mice ( Fig. 1A ), ERK1/2 phosphorylation is not 
modifi ed in WAT ( Fig. 6G ). 
 FGF21 defi ciency prevents increases in BAT 
activation in leucine-deprived mice 
 Thermogenesis in BAT is mediated by the upregulation 
of UCP1 ( 30 ). It has been proposed that the induction of 
FGF21 production by the liver mediates direct activation 
of brown fat thermogenesis during the fetal-to-neonatal 
transition ( 20 ). FGF21 also regulates PPAR $ coactivator 1 
(PGC1)  ! and browning of WAT in adaptive thermogen-
esis ( 31 ). Consistent with previous results ( 16 ), leucine de-
privation increased levels of  Ucp1 and  Dio2 mRNAs in the 
 Fig.  5. FGF21-KO eWAT has altered lipogenic pathway in response to leucine deprivation. A:  Fasn ,  Srebp1c , and  Acc1 gene expression was 
measured by qRT-PCR in mouse eWAT. B: FASN protein levels were detected by Western blot analysis in mouse liver. The bottom panel 
shows quantifi cation by densitometry of the immunoblotted proteins using Image J software. Error bars represent the mean ± SEM.  a ,  P < 
0.05 versus Ctl WT mice;  b ,  P < 0.05 versus Ctl FGF21-KO mice;  c ,  P < 0.05 versus ( # )leu WT mice (n = 6/group). C:  FgfR1 and  " -Klotho 
gene expression was measured by qRT-PCR in mouse eWAT. D: The expression of genes related with lipid metabolism pathways was mea-
sured by qRT-PCR in 3T3L1 adipocytes treated with recombinant FGF21 (100 nM) for 24 h. Error bars represent the mean ± SEM.  a ,  P < 
0.05 versus Ctl WT mice;  b ,  P < 0.05 versus Ctl FGF21-KO mice;  c ,  P < 0.05 versus ( # )leu WT mice (n = 6/group). 
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in liver but not in BAT or WAT where they were not 
affected or even downregulated. 
 We have seen that FGF21 defi ciency signifi cantly attenu-
ates weight loss under leucine deprivation; although the 
established reduction in food intake induced by a leucine-
deprived diet was not changed by the absence of FGF21. 
This means that FGF21 is in part responsible for the loss of 
weight under amino acid deprivation, independently of 
food intake . Consistent with our observation, previous 
studies have shown that FGF21 transgenic mice are resis-
tant to diet-induced obesity (DIO) and that FGF21 treat-
ment induced weight loss in genetically obese (ob/ob) 
mice ( 24, 33, 34 ). 
 It has been shown that white adipocytes from FGF21 
transgenic mice are substantially smaller than those from 
WT mice ( 8, 24 ). Here, we demonstrate that the reduction 
( Fig. 7E, F ). Accordingly, mRNA levels of  Hsl and  Atgl as 
well as HSL phosphorylation did not change in BAT of 
 Fgf21 -defi cient mice ( Fig. 7B, D ). 
 DISCUSSION 
 We have previously shown that leucine deprivation sig-
nifi cantly increased FGF21 hepatic expression and serum 
protein levels ( 2 ), suggesting an important role of this 
hormone in the amino acid starvation phenotype. In the 
current study, we demonstrate that in response to leucine 
deprivation, weight loss, downregulation of liver and WAT 
key lipogenic genes, as well as BAT activation are partly 
FGF21 dependent. Our results show that the FGF21 serum 
levels positively correlate with the mRNA levels measured 
 Fig.  6. Activation of the MEK/ERK pathway in the liver by leucine deprivation is independent of FGF21. HepG2 cells were incubated for 
8 h with HisOH (2 mM) and the MEK inihibitor PD98 (30  % M), when indicated. Phosphorylation of ERK1/2 (A) and ATF4 protein levels 
(B) were analyzed by Western blot in total and nuclear HepG2 extracts, respectively. mRNA levels for  FGF21 ,  ASNS (C), and  FASN (D) were
analyzed by qRT-PCR. E: Phosphorylated ERK1/2 (P-ERK1/2) and total ERK1/2 (t-ERK1/2) levels were measured in liver extracts of WT
and FGF21-KO mice by Western blot analysis. The right panel shows quantifi cation by densitometry of phosphorylated ERK1/2 normalized
to total ERK1/2 using Image J software. F:  Asns and  Atf4 mRNA levels and nuclear ATF4 protein levels (insert), were measured in FGF21-KO
mouse liver by qRT-PCR and Western blot, respectively. Actin was used as a loading control. A representative blot is shown. G: Phosphory-
lated and total ERK1/2 levels were measured in WT mouse eWAT homogenates by Western blot analysis. The right panel shows quantifi ca-
tion by densitometry of phosphorylated ERK1/2 normalized to total ERK1/2 using Image J software. Error bars represent the mean ± SEM.
 a ,  P < 0.05 versus Ctl WT mice;  b ,  P < 0.05 versus Ctl FGF21-KO mice;  c ,  P < 0.05 versus ( # )leu WT mice (n = 6/group).
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 Fig.  7. FGF21 is required for inducing BAT activation during amino acid deprivation. A:  Ucp1 and  Dio2 gene expression was measured by 
qRT-PCR in mouse BAT. B: The expression of genes related with lipid metabolism was measured by qRT-PCR in mouse BAT. C: Phosphory-
lated p38 MAPK (P-p38 MAPK ) and total p38 MAPK (t-p38 MAPK) levels were measured in WT and FGF21-KO mouse liver extracts by 
Western blot analysis. The right panel shows quantifi cation by densitometry of phosphorylated p38 MAPK normalized to total p38 MAPK 
using Image J software. D: Phosphorylated and total HSL protein levels were measured in WT and FGF21-KO eWAT homogenates by West-
ern blot analysis. The right panel shows quantifi cation by densitometry of phosphorylated HSL normalized to total HSL, using Image J 
software. A representative blot is shown. E:  Fasn, Srebp1c, Atgl and  Plin1 gene expression was measured by qRT-PCR in differentiated primary 
BAT treated with FGF21 (50nM) for 24h. F: Glycerol release in differentiated primary BAT treated with FGF21 (5nM and 50nM) for 24h. 
Error bars represent the mean ± standard error of the mean (SEM). Error bars represent the mean ± SEM. A representative blot is shown. 
 a ,  P < 0.05 versus Ctl WT mice;  b ,  P < 0.05 versus Ctl FGF21-KO mice;  c ,  P < 0.05 versus ( # )leu WT mice (n = 6/group). 
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its origin and other factors, which may refl ect the meta-
bolic state and the energy requirements of the organism. 
 An inhibitory action in the lipid synthesis had been al-
ready described for FGF21 ( 36 ). It was demonstrated that 
the reduction of hepatic triglyceride levels was associated 
with FGF21 inhibition of nuclear sterol regulatory element 
binding protein 1c ( Srebp1c ) and the expression of an ex-
tended array of genes involved in fatty acid and triglycer-
ide synthesis. Accordingly, in liver, we have seen that the 
expected reduction in the mRNA levels of  Srebp1c ,  Fasn , and 
 Acc1 by ( # )leu diet was not observed in  Fgf21 -KO mice. 
We have also seen a direct effect in lipogenic gene expres-
sion in both 3T3L1 cells and primary brown adipocytes 
treated with recombinant FGF21. 
 The induction, in liver from  Fgf21 -KO mice, of  Asns ex-
pression, for which the gene product catalyzes the glu-
tamine and ATP-dependent conversion of aspartic acid to 
asparagine, suggests that FGF21 is not involved in the con-
trol of amino acid metabolism under amino acid starva-
tion. We have also observed that contrary to the exogenous 
FGF21 induction of ERK1/2 phosphorylation in the liver 
and WAT of acutely treated mice ( 29 ), the FGF21-depen-
dent phenotype in leucine deprivation is unexpectedly 
not related with the MAPK ERK1/2 signaling pathway 
both in liver and WAT. 
 BAT is a major site of adaptive thermogenesis, and it is 
used to preserve both thermal and caloric homeostasis in re-
sponse to environmental temperature or diet ( 37 ).  Fgf21 -KO 
mice under leucine deprivation exhibited decreased induc-
tion of genes defi ning BAT identity (i.e.,  Ucp1 and  Dio2 ), 
while its transcriptional regulators  Pgc1 ! and  Ppar " were 
identically induced in both WT and  Fgf21 -KO mice. Increased 
 Ucp1 expression may be regulated by the sympathetic ner-
vous system through the activation of  " -adrenergic receptors. 
We found that the mRNA expression of  Adrb3 was induced 
by leucine deprivation in BAT, although there were no sig-
nifi cant changes between genotypes. The  " 3AR stimulates 
p38 MAPK, which is required for the  " AR-dependent in-
crease in  Ucp1 expression in brown adipocytes ( 38 ). Never-
theless, p38 phosphorylation levels were not affected by 
leucine deprivation compared with control, both in the WT 
in the adipocyte volume that occurs under leucine depri-
vation depends on the increased FGF21 expression and 
secretion that takes place under this diet. 
 We have found that the levels of phosphorylated (P)-
HSL were increased upon ( # )leu feeding in eWAT, as it 
was described in ( 16 ), so activation of the HSL protein 
probably allowed increased lipolysis. Interestingly, our re-
sults show that lack of FGF21 signifi cantly decreases phos-
phorylated HSL levels in the eWAT of ( # )leu-fed mice, 
suggesting an important role of FGF21 action on leucine 
deprivation-induced lipolysis. 
 The analysis of blood biochemical parameters, however, 
did not show signifi cant changes in NEFA levels, likely due 
to increased fatty acid utilization by other tissues. We as-
sume that there is an increased glucagon signaling under 
leucine deprivation, indicated by the increased PKA-de-
pendent HSL Ser660 phosphorylation in WAT. Addition-
ally, a reduction in insulin levels under leucine deprivation 
is observed in WT but not in KO mice; these changes are 
well correlated with the differences observed in body 
weight and fat mass. 
 We have also examined whether the impaired reduction 
in body weight observed in  Fgf21 -KO mice under leucine 
deprivation was not only related to lipolysis in WAT, but 
also to other factors that infl uence adipose tissue mass as 
lipogenesis. We have observed a signifi cant reduction in 
 Fasn mRNA levels in eWAT upon ( # )leu feeding that was 
totally blocked in  Fgf21 -KO mice.  Srebp1c and  Acc1 mRNA 
levels presented the same pattern, although with distinct 
statistical signifi cances. The endocrine effect of FGF21 on 
WAT under leucine deprivation that we observe here is 
different from the recently described autocrine effect on 
this tissue in a fed state, in which FGF21 induces lipogen-
esis through the regulation of PPAR $ activity ( 26 ). The 
decreased  Fgf21 expression in WAT under leucine depri-
vation also contrasts with its observed induction after one 
day of fasting ( 35 ). FGF21 administration to DIO mice 
leads to a dramatic decrease in the WAT  Fgf21 transcript. 
However, controversially, it induces an increase in the ex-
pression of adipogenic genes ( 33 ). It seems, therefore, 
that the response to increased levels of FGF21 depends on 
 Fig.  8. Working model of the FGF21 regulatory 
pathway under leucine deprivation. 
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and  Fgf21 -KO mice. One of the best-known inducers of BAT 
and its function is norepinephrine ( 39 ), which has also been 
shown to be induced in leucine-deprived mice ( 16 ). These 
fi ndings raise the possibility that FGF21 might induce  Ucp1 
(and also  Dio2 ) through an indirect mechanism involving 
the central nervous system. Of interest, it has been recently 
proposed that increased expression of FGF21 secreted from 
liver enters the brain and stimulates the hypothalamic-pitu-
itary-adrenal axis ( 40 ). However, a more extensive analysis of 
other candidate factors should be performed in the future, 
and further investigation will be required to determine the 
exact mechanism by which FGF21 induces BAT activation. 
 In summary, we found that FGF21 is an important fac-
tor, although not the only one, in mediating the changes 
in lipid metabolism observed upon leucine deprivation 
( Fig. 8 ). We have shown that  Fgf21 -defi cient mice under 
these circumstances showed unrepressed lipogenesis in 
liver and WAT, decreased phosphorylation of HSL in WAT 
indicating impaired lipolysis, and impaired induction of 
 Ucp1 expression in BAT. Thus, our results suggest that 
FGF21 plays an important role in the regulation of lipid 
metabolism during amino acid starvation. 
 While this work was under revision, a study was published 
( 41 ) that showed the Atf4-dependent induction of FGF21 in 
mice with autophagy defi ciency in skeletal muscle or liver. 
As a result of this induction, these mice are protected from 
diet-induced obesity and insulin resistance. In the supple-
mentary results of this paper, the authors confi rm that the 
ATF4-FGF21 axis also has a physiologically relevant role un-
der conditions of leucine deprivation. In agreement with 
our results, they also show how the effects of leucine depri-
vation on body weight, fat weight, and blood glucose are 
partially diminished in  Fgf21 -KO mice.  
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Scope: Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic candidate
for the treatment of obesity. Since FGF21 production is regulated by various nutritional factors,
we analyze the impact of low protein intake on circulating levels of this growth hormone in
mice and in a sub cohort of the PREDIMED (Prevencio´n con Dieta Mediterra´nea) trial. We also
describe the role of hepatic FGF21 in metabolic adaptation to a low-protein diet (LPD).
Methods and results: We fed control and liver-specific Fgf21 knockout (LFgf21KO) mice a
LPD. This diet increased FGF21 production by inducing its overexpression in liver, and this
correlated with a body weight decrease without changes in food intake. The LPD also caused
FGF21-dependent browning in subcutaneous white adipose tissue (scWAT), as indicated by
an increase in the expression of uncoupling protein 1 (UCP1). In a subgroup of 78 individuals
from the PREDIMED trial, we observed an inverse correlation between protein intake and
circulating FGF21 levels.
Conclusion: Our results reinforce the involvement of FGF21 in coordinating energy home-
ostasis under a range of nutritional conditions. Moreover, here we describe an approach to
increase the endogenous production of FGF21, which if demonstrated functional in humans,
could generate a treatment for obesity.
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1 Introduction
FGF21 (Fibroblast growth factor 21) is considered a promis-
ing therapeutic candidate for the treatment of obesity and
type-2 diabetes. Its administration to obese rodents andmon-
keys leads to decreased plasma concentrations of glucose,
insulin, triglycerides and cholesterol, as well as a reduction
in bodyweight through increased energy expenditure (EE) [1].
The injection of FGF21 in experimental animals induces in-
creased thermogenic capacity by stimulating the expression
of uncoupling protein 1 (UCP1) and type 2 iodothyronine
deiodinase protein 2 (DIO2) in brown adipose tissue (BAT),
and UCP1 in white adipose tissue (WAT), where it produces
the so-called browning process [2,3]. Althoughmost of the ef-
fects of FGF21 have been related to UCP1 expression, it has
also been reported that Ucp1-null mice respond positively
to the pharmacological administration of this growth factor
[4, 5].
FGF21 is a member of the FGF family, which is charac-
terized by endocrine properties. It is produced mainly by the
liver, but also by other tissues such as WAT, BAT, skeletal
muscle, and pancreas [6–9]. Expression of FGF21 in the liver
is induced by fasting, and its transcriptional activity is tightly
controlled by peroxisome proliferator-activated receptor al-
pha (PPAR-) [10–13]. The expression of this growth factor
in liver activates fatty acid oxidation (FAO), ketogenesis, and
gluconeogenesis in this organ, thereby triggering ametabolic
state that mimics long-term fasting [14].
In addition to fasting, FGF21 expression is also induced
in various tissues in response to a number of nutritional chal-
lenges and also to cold exposure. In this regard, FGF21 ex-
pression in BAT is produced in response to cold temperature
[9,15], although it is unclear whether BAT-derived FGF21 acts
as an endocrine factor or whether it is simply an autocrine
factor in the adipose tissue itself.
In mouse liver and HepG2 cells, FGF21 is induced by
leucine-deprivation as part of the transcriptional program
initiated by increased levels of activating transcription fac-
tor 4 (ATF4) [16]. The ATF4-dependent increase in FGF21
expression has been confirmed in mice with autophagy defi-
ciency in skeletal muscle and in liver [17]. Interestingly, these
mice are protected from diet-induced obesity (DIO) and in-
sulin resistance. The similarities in the metabolic responses
between the effects to leucine-deprivation [18] and to FGF21
overexpression allowed us to consider FGF21 as a key media-
tor between amino acid deprivation and lipid metabolism in
liver, WAT, and BAT. In this regard, results from the eval-
uation of the metabolic response of Fgf21-deficient mice to
a leucine-deficient diet previously led us to conclude that, as
expected, most of the effects caused by leucine deprivation
in liver, WAT, and BAT are impaired in the absence of this
growth factor [19].
Likewise, methionine-deprived mice show a phenotype
comparable to that of leucine-deprivation, including resis-
tance to a high-fat diet (HFD), improved glucose homeosta-
sis, increased fatty acid activation and FAO in liver, enhanced
lipolysis in WAT, and increased UCP1 expression in BAT
[20, 21]. Of note, the induction of hepatic FGF21 expression
under leucine- or methionine-restricted diets was found to
be accompanied by an increase in FGF21 protein levels in
serum.
In order to facilitate the translation of these findings to
humans, here we focussed on low-protein diets (LPD) instead
of amino acid-deficient diets. Protein restriction brings about
weight loss and an increase in both food intake and EE [22].
Moreover, a LPD induces thermogenic markers in BAT of
obese rats [23]. Moreover, serum concentrations of FGF21
in both rodents and humans increase upon exposure to an
LPD, regardless of total calorie intake. This observation thus
reveals that FGF21 is likely to be involved in the metabolic
response to protein-restricted diets [24].
Here we addressed whether a LPD exerts similar effects
on lipid metabolism to those of a leucine-deficient diet and
whether these effects are dependent on hepatic FGF21 pro-
duction. To this end, we examined the metabolic response of
wild-type and Fgf21 liver-specific knockout mice (LFgf21KO)
to a LPD (up to 5%of energy as protein). Adecreased indietary
protein content induced a huge increase in FGF21 serum
levels, significant weight loss, and an increase in the expres-
sion of UCP1 in the subcutaneousWAT (scWAT) of wild-type
mice. Remarkably, no effects were observed in Fgf21-deficient
mice, thereby indicating that the absence of FGF21 blunts or
completely blocks the response to a LPD in thismousemodel.
To corroborate these results in humans, we evaluated
whether protein intake is associated with circulating levels
of FGF21. We calculated protein intake through nutritional
questionnaires and determined the serum levels of FGF21
in 78 individuals randomly selected from two nodes of the
PREDIMED (Prevencio´n con Dieta Mediterra´nea) trial. As with
the animal model, an inverse correlation between circulating
FGF21 levels and protein intake was observed.
To summarize, here we define themolecularmechanisms
by which a LPD exerts itsmetabolic effects through the induc-
tion of hepatic FGF21 expression and browning of scWAT.
Furthermore, the data collected from humans raises the pos-
sibility of investigate the dietarymodulation of circulating lev-
els of FGF21 as an alternative approach to its pharmacological
administration. In this regard, we propose the modification
of protein intake to enhance FGF21 production.
2 Material and methods
2.1 Animals
To generate the LFgf21KO mice, Fgf21loxP mice
(Fgf21tm1.2Djm/J) that have Fgf21 flanked by two loxP
sites (Jackson Laboratory, USA) were crossed with Albumin-
cre (Tg(Alb1-cre)1Dlr/J) mice (kindly provided by Dr. A.
Zorzano). The latter express the CRE recombinase enzyme
under control of albumin promoter/enhancer elements,
thus allowing liver-specific gene deletions [25]. Fgf21LoxP
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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mice were used as controls. Animals were housed in a
temperature-controlled room (22 ± 1C) on a 12/12 h
light/dark cycle and were provided free access to commercial
rodent chow and tap water prior to the experiments.
2.1.1 Dietary intervention
The control diet (CD) (Ref. D10001) and LPD (Ref.
D12010401) were obtained from Research Diets, Inc. (USA).
Both diets were isocaloric. They had the following composi-
tion (in percentage ofmass): 20% protein, 66% carbohydrates
and 5% fat for the CD, and 5% protein, 81% carbohydrates
and 5% fat for the LPD (detailed composition shown in Sup-
porting Information Table 1). For the feeding experiment,
8-week-old male mice were first fed the CD for 7 days and
then randomly assigned to either the CD or LPD group with
free access to food and water for 7 days. Food intake and body
weight were recorded daily. Animals were then anesthetized
by isoflurane inhalation, and blood was collected by cardiac
puncture. After euthanizing the animals, tissues were iso-
lated and immediately snap-frozen and stored at −80C for
future analysis. The Animal Ethics Committee of the Univer-
sity of Barcelona approved these experiments (CEEA register:
48/15)
2.1.2 Human samples for plasma measurements
Weused plasma samples from 78men and women randomly
selected from the participants of the centers inHospital Clinic
(Barcelona) and Reus (Tarragona) of the PREDIMED trial
(www.predimed.es). This study was a 5-year randomized clin-
ical trial to compare the effects of either a Mediterranean diet
supplemented with extra virgin olive oil or nuts versus a low-
fat control diet. A total of 7447 asymptomatic men but at high
cardiovascular risk (aged 55–80 years) and women (aged 60–
80 years) were recruited. All participants had type 2 diabetes
or three or more cardiovascular risk factors. Details of the
recruitment method and study design have been described
elsewhere [26] and are also available at www.predimed.es. In
addition to the plasma samples, we also gathered informa-
tion from these 78 individuals, including a 137-item semi-
quantitative food frequency questionnaire (FFQ), and a gen-
eral questionnaire that provided data on lifestyle habits, con-
current diseases, anthropometry, and medication use. Total
energy intake and nutrient intake were calculated on the basis
of Spanish food composition tables [27]. The study protocol
was approved by the institutional review boards of the partic-
ipating centers (ISRCTN35739639).
2.1.3 Plasma measurements
Mouse plasma samples were obtained by centrifuging whole
blood collected in EDTA-treated tube. The plasma was stored
at−80C. FGF21 inmouse and human plasmawasmeasured
by means of a Human (ref. EZHFGF21-19K) and Mouse/Rat
(ref. EZRMFGF21-26K) FGF21 ELISA obtained from EMD
Millipore (Germany). The assay was conducted following the
manufacturer’s protocol. Briefly, a calibration curve was con-
structed by plotting the difference in absorbance values at 450
and 590 nm versus the FGF21 concentrations of the calibra-
tors, and concentrations of unknown samples (performed in
duplicate) were determined using this calibration curve. Free
fatty acids (non-esterified fatty acids, NEFA) were determined
in mice plasma by an enzymatic colorimetric assay. The Free
fatty acids, Half-micro test (ref. 11383175001) was obtained
from Sigma-Aldrich (USA). The measure was performed ac-
cording to the manufacturers’ instructions.
2.1.4 RNA isolation and relative quantitative RT-PCR
Total RNA was extracted from the frozen tissues [liver, epi-
didymal WAT (eWAT), BAT and inguinal scWAT] using TRI
reagent solution (ref. AM9738 Ambion, Thermo Fisher Sci-
entific, USA) followed by DNase I treatment (ref. AM1906,
Ambion, Thermo Fisher Scientific, USA) to eliminate ge-
nomic DNA contamination. To measure the relative mRNA
levels, quantitative (q)RT-PCR was performed using SYBR
Green or TaqMan reagents. cDNA was synthesized from 1
g of total RNA by MLV reverse transcriptase (ref. 28025021,
Invitrogen, ThermoFisher Scientific, USA)with randomhex-
amers (ref. 11034731001, Roche Diagnostics, Germany), fol-
lowing the manufacturer’s instructions. The TaqMan Gene
ExpressionMasterMix (ref. 4369514) and SYBR R© GreenPCR
Master Mix (ref. 4364344), supplied by Applied Biosystems
(ThermoFisher Scientific, USA), were used for the PCR step.
Amplification and detection were performed using the Step-
One Plus Real-Time PCR System (Applied Biosystems, Ther-
moFisher Scientific, USA). EachmRNA from a single sample
was measured in duplicate, using 18S, Beta-Actin, and 36b4
as housekeeping genes. The primer sequences are shown in
Supporting Information Table 2. Results were obtained by
the Relative Standard Curve Method and expressed as fold
increase versus the experimental control.
2.1.5 Protein extracts preparation
To obtain liver nuclear extracts, frozen liver was triturated
with a mortar in liquid nitrogen and immediately homoge-
nized with a Dounce in 1 mL of HB buffer [15 mM Tris-HCl
(pH 8), 15 mM NaCl, 60 mM KCl, 0.5 mM EDTA], and cen-
trifuged at 800 × g for 5 min. The resulting pellet was re-
suspended in 100 L of HB buffer supplemented with 0.05%
TritonX-100 (Sigma,USA) and centrifuged for 10min at 1000
× g. Nuclear pellets were washed with 1mL ofHB buffer sup-
plemented with 0.05% Triton X-100 and 1 mL of HB buffer.
Nuclei were incubated at 4C for 30 min in 50 L of HB
buffer containing 360 mM of KCl and then centrifuged for
5 min at 10 000 × g. The supernatants corresponding to the
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Figure 1. FGF21 is induced by an LPD
in liver but not in BAT or WAT, and
this induction correlates positively with
plasma concentration in mice. Plasma
protein concentration of FGF21 was
measured by ELISA (A). Fgf21 mRNA
levels in liver (B) and WAT and BAT (C)
were measured by qRT-PCR. Error bars
represent the mean ± SEM. **p<0.01
***p<0.001 versus Fgf21LoxP mice fed a
CD (n = 7–9/group).
nuclear extracts were collected, frozen, and stored at −80C.
Protein concentrationwas determined using the Bio-Rad Pro-
tein Assay Dye Reagent Concentrate (Ref. 5000006, Bio Rad,
USA). All buffers were supplemented with a mixture of pro-
tease inhibitors (Ref. P8340, Sigma-Aldrich, USA), 0.1 mM
of PMSF, and a phosphatase inhibitor cocktail 3 (Ref. P0044,
Sigma-Aldrich, USA).
2.1.6 Immunoblotting
Nuclear proteins were resolved by SDS-polyacrylamide gel
electrophoresis and transferred onto a Hybond-P PVDF
membrane (Millipore). Membranes were blocked (Tris-HCl
50 mM pH 8, 150 mM, 5% skimmed milk, 0.1% Tween) for
1 h at room temperature. The blots were then incubated with
ATF4 primary antibody (sc-200, Santa Cruz Biotechnology,
Inc., USA) in blocking solution (1:200). After an overnight
incubation at 4C, the blots were washed and incubated with
an anti-rabbit horseradish peroxidase-conjugated secondary
antibody (ref. NA934, Amersham, GE Healthcare, UK) in
blocking buffer for 2 h at room temperature. The blots were
developed using the EZ-ECL Chemiluminescence Detection
Kit for HRP (ref. 20-500-500, Biological Industries, Israel).
Quantification was performed using Image J software.
2.1.7 Data analysis/statistics
For human samples, baseline characteristics are presented
as means ± standard error of the mean (SEM) for contin-
uous variables, frequencies and percentages for categorical
variables across quartiles of protein intake at baseline. Dif-
ferences between quartiles were tested by a 1-factor ANOVA
test for continuous variables and by the chi-square test for
the categorical ones. We performed multiple linear regres-
sions to evaluate the relationship between protein intake
(exposure variable) and FGF21 hormone levels (dependent
variable). Protein intake was previously adjusted for calories
using the residual method. Regression analyses were unad-
justed (model 1) or adjusted by body mass index (BMI) and
total energy intake (model 2).
All statistical analyseswere conductedusingSAS software,
version 9.3 (SAS Institute, Inc., USA). All t tests were two-
sided and p values below 0.05 were considered statistically
significant.
3 Results and discussion
3.1 A LPD induces FGF21 gene expression in the
liver of control mice, but not in BAT or WAT
According to previously reported results, mice on an LPD
show a dramatic increase in serum levels of FGF21 [22–24]
(Fig. 1A). To check the origin of this FGF21, we analyzed
the Fgf21 mRNA levels in several tissues. The liver is the
main site of FGF21 production and release into the blood.
Accordingly, we observed a great induction of Fgf21 mRNA
synthesis in the liver of mice on the LPD (Fig. 1B). This
increase correlated positively with serum levels. In contrast,
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Fgf21 expression was unchanged in BAT, eWAT and scWAT
of control mice (Fgf21loxP) on the same diet (Fig. 1C).
To determine the specific role of hepatic FGF21 in the
metabolic response to a LPD, we fed LFgf21KO mice a LPD
diet. As expected, Fgf21 mRNA levels were undetectable in
the livers of these animals (Fig. 1B), while no statistically
significant changes were detected in BAT, eWAT, or scWAT
when compared to the same tissues in control mice (Fig. 1C).
This mouse model shows that protein restriction almost
exclusively affects the hepatic expression of FGF21 and that
there is no compensatory response in other tissues, such as
BAT or WAT.
We measured the circulating FFA levels as a possible sig-
naling factor for the induction of FGF21 in mice under a low
protein diet. The absence of statistically significant changes
in FFA (data not shown) allow us to rule out the PPAR-FA axis
in the signaling mechanism responsible for the induction of
the hepatic expression of FGF21 in these conditions.
3.2 A LPD increases ATF4 protein levels in mouse
liver
GCN2 is a kinase that acts as a sensor of amino acid sup-
ply [28]. When activated, GCN2 phosphorylates EIF2a, which
results in the slowing or stalling of the initiation step of
mRNA translation. Hence, phospho-EIF2a reduces general
protein synthesis rates. Paradoxically, in these circumstances
there is an increase in the translation of discrete mRNAs,
including ATF4 [29, 30]. A LPD increases GCN2-dependent
phosphorylation of eIF2a, resulting in greater levels of ATF4
protein [31, 32]. ATF4 is a transcriptional factor that directly
or indirectly induces a subset of specific genes to regulate
metabolic adaptation to amino acid restriction. The 5’ region
of Fgf21 contains two evolutionarily conserved functional
ATF4-binding sequences responsible for its ATF4-dependent
transcriptional activation [16, 33]. To determine the effect of
anLPDonATF4 expression,we analyzed liver protein extracts
of mice fed an LPD or a CD for 7 days. ATF4 expression was
induced in liver in response to the LPD, as revealed by West-
ern blot assays (Fig. 2A and B). These results are consistent
with previous published data reporting that ATF4 triggers
the expression of FGF21 and that Gcn2 -/- mice show a par-
tially blunted induction of FGF21 under protein restriction
[24]. On the basis of the aforementioned published data, our
results support the notion that the GCN2-ATF4 pathway is
likely to be the main mechanism underlying hepatic FGF21
overexpression upon protein restriction.
GCN2-independent mechanisms that induce hepatic
FGF21 in response to methionine-restricted diets have re-
cently been described [34]. This observation points to a
different response program in liver via a non-canonical
PERK/nuclear respiratory factor 2 (NRF2) pathway. This al-
ternative pathway could effectively sense and translate the
metabolic responses to methionine restriction in the absence
of GCN2. In parallel, the absence of GCN2 during long-term
Figure 2. An LPD increases ATF4 protein levels in liver. ATF4
protein levels were determined by Western blot analysis using
hepatic nuclear extracts obtained from Fgf21LoxP mice adminis-
tered a CD or LPD (A). The experiment was normalized by actin
protein levels as loading control and the intensity of the bands
were quantified by densitometry with the Image J software (B).
Error bars represent the mean ± SEM. **p<0.01 versus CD (n =
3/group).
dietary protein restriction has been reported to be compen-
sated upstream of ATF4 to induce FGF21 [35]. Globally, the
impact of alternative pathways to stimulate FGF21 expression
under a LPD, whether they involve ATF4 or not, should be
addressed in greater depth.
3.3 Fgf21 deficiency significantly attenuates weight
loss under an LPD
Mice fed an LPD presented rapid weight loss. Here we ad-
dressed whether this phenomenon is dependent on hepatic
FGF21. For this purpose, Fgf21LoxP mice and LFgf21KO mice
were fed a CD or LPD for 7 days.
Our data showed that weight loss was partially blunted
in LFgf21KO mice (Fig. 3A and B). However, the reduction
in food intake observed under an LPD, that can account for
some of the loss in body weight, was unchanged between
genotypes (Fig. 3C). It is remarkable that these results con-
tradicted previous publications describing either no change
or an increase in food intake in response to protein restriction
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 3. Hepatic FGF21 expression is required for the weight loss caused by LPD but does not affect food consumption. Body weight
progression of mice fed a CD or LPD expressed as percentage of the initial weight, which was considered 100% (A). Total body weight
change (g) after 7 days on a CD or LPD (B). Daily food intake (C). Error bars represent the mean ± SEM. **p<0.01 versus Fgf21LoxP mice fed
a CD, #p<0.05 versus LFgf21KO fed a CD; 0.07 represents p value versus LFgf21KO mice fed a CD (n = 7–9/group).
[24]. Nonetheless, the present results are consistent with the
decreased food intake described in mice fed leucine-deficient
diets [19]. Minor changes in diet composition affecting amino
acid bioavailability may explain these discrepancies. More-
over, although FGF21 has the potential to modulate food
preferences [36, 37]. In our mouse model this FGF21 did not
contribute to the food aversion caused by the LPD.
To determine the importance of each tissue in overall
weight loss, we calculated the change in weight of individ-
ual tissues. All tissues analyzed tended to weigh less in mice
on the LPD, reaching statistical significance in heart, liver,
scWAT and p = 0.06 in eWAT (Fig. 4). Regarding the role
of FGF21, our results show that the weight loss observed in
scWAT and heart was dependent on hepatic FGF21 expres-
sion, as weight loss was blunted in LFgf21KOmice under the
same diet. The effect of the LPD on liver tissue weight was
partially abolished by hepatic Fgf21 deficiency (Fig. 4).
Taken together, FGF21 produced by the liver is, at least in
part, responsible for the body weight loss experienced by the
mice on the LPD.Our results point to scWAT as one of the tar-
get tissues of hepatic FGF21 regarding the weight loss effect.
Since hepatic FGF21 exerts its effects mainly in WAT and
BAT through regulating lipid metabolism, the following ex-
periments are focused on describing the role of LPD-induced
FGF21 on the metabolic response of adipose depots.
3.4 LPD induces metabolic changes in response to
FGF21 in scWAT, but not in eWAT or BAT
Thermogenesis in BAT is mediated by the upregulation of
UCP1 [38]. It has been proposed that the induction of FGF21
production by the liver mediates direct activation of brown
fat thermogenesis during the fetal-to-neonatal transition [39].
FGF21 also regulates peroxisome proliferator-activated re-
ceptor gamma coactivator 1-alpha (PGC1a) and browning of
WAT in adaptive thermogenesis [40].
Contrary to what happens under leucine deprivation [19],
no statistically significant induction of Ucp1 or Dio2 mRNA
levels were observed in BAT or eWAT of control mice under
the LPD (Fig. 5A and B). In contrast, the analysis of gene
expression in scWAT revealed that the LPD induced the ex-
pression ofUcp1, Pgc1a, Cidea and PR domain containing 16
(Prdm16), reaching a statistically significant value for Ucp1
and Pgc1a (Fig. 6). This expression pattern was not detected
in the LFgf21KO mice (Fig. 6), thereby indicating the role
Figure 4. Hepatic FGF21 is required for the
weight loss caused by an LPD. The weight
of heart, liver, eWAT, scWAT, BAT, and gas-
trocnemius in mice fed a CD or LPD is
presented as the mg of tissue per 100 mg
of total body weight. Error bars represent
the mean ± SEM. *p<0.05, ***p<0.001
versus Fgf21LoxP mice fed a CD; #p<0.05,
##p<0.01 versus LFgf21KO mice fed a CD;
0.06 represents the p value with respect to
Fgf21LoxP mice fed a CD (n = 7–9/group).
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Figure 5. A LPD does not alter thermogenic genes in BAT or
eWAT. Ucp1 and Dio2 expression was measured by qRT-PCR in
mouse BAT and eWAT. Error bars represent the mean ± SEM.
*p<0.05 versus Fgf21LoxP mice fed a CD (n = 7–9/group).
of FGF21 in the metabolic adaptation of scWAT to protein
restriction.
As UCP1 activity is related to EE, the blunted induction
of UCP1 in the LFgf21KO mice under LPD may contribute
to the lower weight loss observed in this mouse model under
these circumstances. In conclusion, hepatic FGF21 induces
the browning of scWAT and increases the thermogenic ca-
pacity of mice on an LPD.
3.5 FGF21 plasma levels correlate negatively with
protein intake in humans
To translate our results to humans, we evaluated the relation-
ship between protein intake and circulating levels of FGF21
in 78 individuals randomly selected from the PREDIMED
trial. Baseline data for these subjects are shown in Table 1.
Protein intake was obtained from FFQs and was expressed
as grams of protein per day (g/day). We used baseline sam-
ples (T = 0). Results from the multiple linear regression
analyses showed a significant inverse relationship between
plasma FGF21 concentrations and dietary intake of protein.
At baseline, FGF21 levels decreased by 3.39 pg/mL for each
gram of protein ingested (Table 2). The participants with a
high intake of protein showed statistically significant lower
values of circulating FGF21.
We also performed regression analyses using quartiles of
protein intake and obtained similar results. After adjustment
for BMI and total energy intake, FGF21 decreased (−30.7
pg/mL) when moving from the lower to higher quartiles (p
= 0.015)(Fig. 7).
Similarly to the data frommice, these results indicate that
the serumconcentrations of FGF21 are inversely proportional
to dietary protein intake.
4 Concluding remarks
Here we addressed the role of hepatic FGF21 in themetabolic
changes triggered by an LPD. Our results demonstrate that
the effects of anLPDdepend, at least in part, on the circulating
levels of FGF21 and consequently on the liver production of
Figure 6. Hepatic FGF21 is required
for inducing thermogenic gene expres-
sion during an LPD. Ucp1, Dio2, Pgc1a,
Pparg, Prmd16, and Cidea expression
was measured by qRT-PCR in mouse
scWAT. Error bars represent the mean
± SEM. *p<0.05 versus Fgf21LoxP mice
fed a CD (n = 7–9/group).
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Table 1. Baseline characteristics of participants from the PREDIMED cohort included in this study, divided into quartiles of energy-adjusted
protein intake at baselinea)
Quartiles of energy-adjusted protein intake p valueb)
Q1 Q2 Q3 Q4
No subjects (78) 19 20 20 19
Age (years) 67.1 ± 5.9 65.7 ± 4.8 67.0 ± 6.4 65.3 ± 4.0 0.30
Sex (women) 6 (31) 10 (50) 9 (45) 15 (79) 0.03
Body mass index (kg/m2) 28.1 ± 3.2 30.0 ± 3.4 27.7 ± 2.7 30.8 ± 2.9 0.006
Energy intake (kcal/day) 2370 ± 350 2192 ± 603 2227 ± 433 2390 ± 571 0.51
Protein intake (g/day) 80 ± 6 90 ± 2 97 ± 3 110 ± 5 <0.0001
FGF21 (pg/mL) 289 ± 116 276 ± 143 256 ± 117 190 ± 115 0.07
a)Categorical variables: subjects (percentage), continuous variables: mean ± SD
b)One-way ANOVA tests (continuous variables) or chi-squared tests (categorical variables).
Table 2. Multivariable regression analyseswith FGF21 (pg/mL) as
dependent variable and energy-adjusted protein intake
at baseline (g/day) as independent variable
a) p value 95% CI
Protein intake
(continuous
variable)
Model 1b) −3.42 0.006 −5.83, −1.02
Model 2c) −3.39 0.007 −5.86, −0.92
Quartiles of
protein
intake
Model 1b) −31.5 0.01 −56.5, −6.5
Model 2c) −30.8 0.02 −56.5, −5.0
CI: Confidence interval.
a)Parameter estimates.
b)Unadjusted.
c)Adjusted for body mass index (BMI) and total energy intake.
Figure 7. Circulating FGF21 levels correlate negatively with pro-
tein intake. Plasma FGF21 concentration divided into quartiles of
protein intake adjusted for the calorie intake of 78 participants
in the PREDIMED trial. Error bars represent the mean ± SEM.
*p<0,05 from first quartile; #p<0,05 from the second quartile.
this growth factor. The LFgf21KO mice revealed the
relevance of FGF21 in the response to an LPD, but also
in the metabolic and transcriptional pathways activated or
repressed by protein restriction.
Given the parallelism between the results of our study in
humans and those in mice, we postulate that dietary protein
content is crucial for the modulation of circulating FGF21
levels and thus for the activity of this hormone in target tissues
in mice and that it could also be in humans. We propose to
investigate a dietary intervention consisting of a reduction
in protein intake as a non-invasive approach to induce the
hepatic expression of FGF21. We also describe the molecular
mechanisms through which a LPD—via FGF21—could be
beneficial to restore lipid/glucose homeostasis.
Studies performed in humans provide contradictory re-
sults regarding the correlation between plasma levels of
FGF21, BMI, and insulin resistance [41–43]. Also, the FGF21-
resistant state described inmice [44] is not well established in
humans and the beneficial effects of FGF21 induction have
yet to be demonstrated in the latter.
Our findings provide new insight into the modulation of
dietary protein as a strategy to induce elevated serum concen-
trations of FGF21. Further studies will be needed to evaluate
the effects of an LPD / FGF21 induction on the metabolic
profile of obese and insulin-resistant subjects.
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In mice, a low protein diet
induces a huge increase in liver
FGF21 expression and serum
levels, which correlates with
enhanced ATF4 protein levels.
Also, this diet caused an
FGF21-dependent browning of
subcutaneous white adipose
tissue. The observation of an
inverse relationship between
serum levels of FGF21 and
dietary protein content also in
humans suggests that the
induction of hepatic FGF21
expression by a low protein diet
could offer an effective treatment
for obesity and type 2 diabetes.
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ANNEX 6: Abbreviations 

(-)leu Leucine deficient 
AAR Amino Acid Response 
AARE Amino Acid Response Element 
ACACA Acetyl-CoA Carboxylase Alpha (Aso ACC1) 
ACADM Acyl-CoA dehydrogenase, C-4 to C-12 straight chain 
(Medium-Chain Acyl-CoA Dehydrogenase - MCAD) 
ACC1 Acetyl-CoA carboxylase 1 
ACOX Acyl-CoA Oxidase 
ACTH Adenocorticotropic Hormone 
ADRB3 Adrenoceptor Beta 3 
AKT1 RAC-alpha serine/threonine-protein kinase 1 
ALAS-1 Delta-Aminolevulinate Synthase 1 
ANOVA ANalysis Of VAriance 
ANP Atrial Natriuretic  Peptide 
ASNS Asparagine Synthetase 
ATF3 Activating Transcription Factor 3 
ATF4 Activating Transcription Factor 4 
ATGL Adipose triglyceride lipase (Also PNLPA2 - Patatin Like 
Phospholipase Domain Containing 2) 
AUC Aerea Under the Curve 
BAT Brown Adipose Tissue 
BeAT Beige Adipose Tissue 
BLAST Basic Local Aligment Search Tool 
BMI Body Mass Index 
bp base pairs 
C/EBP CCAAT/enhancer-binding protein 
CARE C/ebp-Atf Response Element 
CD Control Diet 
ChIP Chromatin Immunoprecipitation 
CHOP CCAAT-enhancer-binding protein Homologous Protein 
ChREBP Carbohydrate-Responsive Element-Binding Protein 
CIDEA Cell Death-Inducing DFFA-Like Effector A 
CNS Central Nervous System 
CPT1A Carnitine Palmitoyltransferase 1A 
CREB cAMP-responsive element binding protein 
CREBH cAMP-responsive element binding protein, hepatocyte 
specific (Also CREB3L3 cAMP responsive element binding 
protein 3-like 3) 
CRH Corticotropin-Releasing Hormone 
Ctl Control 
DIO Diet Induced Obesity 
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DIO2 Type II Iodothyronine Deiodinase 
DMEM Dubecco’a Modified Eagle’s Medium 
DMT2 Diabetes Mellitus Type 2 
dNTPs Deoxynucleotides 
dsDNA double stranded DNA 
EE Energy Expenditure 
EGR1 Early growth response protein 1 
eiF2 Eukaryotic Initiation Factor 2 
ELISA Enzyme-Linked ImmunoSorbent Assay 
ER Endoplasmic Reticulum 
ERK1/2 Extracellular Signal-Regulated 
eWAT epididymal White Adipose Tissue 
FA Fatty Acid 
FABP4  Fatty Acid Binding Protein 4 
FAO Fatty Acid Oxidation 
FASN Fatty Acid Synthase 
FBS Fetal Bovine Serum 
FFA Free Fatty Acids 
FFQ Food Frequency Questionnaire 
FGF Fibroblast Growth Factor 
FGFR Fibroblast Growth Factor Receptor 
FOXO1 Forkhead box O1 
FRS2 Fibroblast growth factor receptor substrate 2 
FXR Farnesoid X Receptor 
GCN2 General Control Nonderepressible 2) 
gDNA genomic DNA 
GH Growth Hormone 
GLUT1 Glucose Transporter 1  
GLUT4 Glucose Transporter 4 
GR Glucocorticoid Receptor 
GTT Glucose Tolerance Test 
H&E Hematoxylin and Eosin 
HDAC3 Histone deacetylase 3 
HFD High Fat Diet 
hisOH Histidinol 
HNF6 Hepatocyte Nuclear Factor 6 
HRP Horseradish Peroxidase 
HSL Hormone Sensitive Lipase 
iBAT interscapular Brown Adipose Tissue 
Ig Immunoglobulin 
IGF-1 Insulin Growth Factor 1 
IP Immunoprecipitation 
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ip intraperitoneal 
ITT Insulin Tolerance Test 
JNK cJun NH-terminal Kinase 
KLB Beta-Klotho 
KO Knockout 
LPD Low protein Diet 
LPL Lipoprotein Lipase 
LXR Liver X Receptor 
MAPK Mitogen-Activated Protein Kinase 
MEM Minimum Essential Medium 
mTOR mammalian Target Of Rapamycin 
MW Multiwell 
NA Noradrenaline 
NAFLD Non Alcoholic Fatty Liver Disease 
NCoR Nuclear Receptor CoRepressor  
NEFAs Non Esterified Fatty Acids 
NFY Nuclear Transcription Factor Y 
NR1D1 Nuclear Receptor Subfamily 1 Group D Member 1 (Also 
Rev-Erb alpha) 
NRF-1 Nuclear Respiratory Factor 1 
PBS Phosphate-Buffered Saline 
PCR Polymerase Chain Reaction 
PERK Protein kinase RNA-like Endoplasmic Reticulum kinase 
PGC-1 Peroxisome proliferator-activated receptor gamma coactivator 
1 
PI3K Phosphatidylinositide 3-kinases 
PKA Protein Kinase A 
PKR Protein Kinase R 
PLIN1 Perilipin 1 
PPAR Peroxisome Proliferator-Activated Receptor 
PPARE PPAR Response Element 
PRDM16 PR domain containing 16 
PREDIMED Primary Prevention of Cardiovascular Disease with a 
Mediterranean Diet 
Prop Propranolol 
Q1 First Quartile 
Q2 Second Quartile 
Q3 Third Quartile 
Q4 Fourth Quartile 
qPCR quantitative Polymerase Chain Reaction 
RAR Retinoic Acid Receptor 
ROR RAR-related orphan receptor 
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RORE ROR/REV-ERB-response element 
RT Reverse Transcription 
RT Real Temperature ( 25ºC) 
scWAT Subcutaneous White Adipose Tissue 
SEM Standard Error of the Mean 
SIRT1 Sirtuin1 
SNAT2 Sodium-dependent neutral amino acid transporter-2 
SNS Sympathetic Nervous System 
SOD2 Superoxide Dismutase 2 
SP1 Specific Protein 1 
SREBP1 Sterol Regulatory Element-Binding Protein 1 
supBAT supraclavicular Brown Adipose Tissue 
TBS Tris-Buffered Saline 
TGF Transforming Growth Factor 
TGs Triglyceride’s 
TRPM8 Transient Receptor Potential Melastin 8 
TRVP-4 Transient Receptor Potential Vainilloid 4 
UCP1 Uncoupling Protein 1 
UCP3 Uncoupling Protein 3 
VNP Ventricular Natriuretic Peptide 
WB Western Blot 
ZT Zeitgeber Time 
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